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Abstract
Drug resistance is a major problem in quickly evolving diseases, including
the human immunodeficiency (HIV) and hepatitis C viral (HCV) infections. The
viral proteases (HIV protease and HCV NS3/4A protease) are primary drug tar-
gets. At the molecular level, drug resistance reflects a subtle change in the bal-
ance of molecular recognition; the drug resistant protease variants are no longer
effectively inhibited by the competitive drug molecules but can process the natu-
ral substrates with enough efficiency for viral survival. Therefore, the inhibitors
that better mimic the natural substrate binding features should result in more ro-
bust inhibitors with flat drug resistance profiles. The native substrates adopt a
consensus volume when bound to the enzyme, the substrate envelope. The most
severe resistance mutations occur at protease residues that are contacted by the
inhibitors outside the substrate envelope. To guide the design of robust inhibitors,
we investigate the shared and varied properties of substrates with the protein dy-
namics taken into account to define the dynamic substrate envelope of both viral
proteases. The NS3/4A dynamic substrate envelope is compared with inhibitors
to detect the structural and dynamic basis of resistance mutation patterns. Com-
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parative analyses of substrates and inhibitors result in a solid list of structural and
dynamic features of substrates that are not shared by inhibitors. This study can
help guiding the development of novel inhibitors by paying attention to the subtle
differences between the binding properties of substrates versus inhibitors.
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Chapter I
Introduction
1.1 Human Immunodeficiency Virus
Human Immunodeficiency Virus (HIV) is a lentivirus of the Retroviridae fam-
ily that infects vital cells in the human immune system including CD4+ T cells,
macrophages, and dendritic cells. HIV infection causes the acquired immunode-
ficiency syndrome (AIDS). Without effective treatment, the infection can result in
the collapse of the immune system. UNAIDS reports, globally, 34 million people
were living with HIV at the end of 2011 with 2.5 million new infections and 1.7
million people died from AIDS-related causes. [1] Two types of HIV and sev-
eral groups within each type exist in the genus of lentivirus with distinct patterns
of spread and progression to AIDS. [2] HIV Type 1 (HIV-1) is responsible for
the AIDS pandemic. As the worldwide epidemic finishes its third decade, a cure
for HIV-1 still eludes the biomedical community. In the absence of a cure for
1
2HIV-1 pathogenesis, suppressing viral replication and maintaining it at low to un-
detectable levels have become critical goals in the field of HIV-1 research. To this
end, highly active antiretroviral therapy (HAART) has become a successful strat-
egy in providing long, quality life for infected individuals [3, 4] and is the global
standard of care for AIDS treatment. There are many steps in the viral life cycle
for potential pharmacological intervention. The US Food and Drug Administra-
tion (FDA) has approved more than 30 drugs that target various stages of viral
replication cycle including fusion and entry, reverse transcription, integration and
proteolytic processing of viral polyproteins. Maturation requires a viral protease
to process the virally encoded polyproteins to yield infectious virions. Due to this
essential function in viral maturation, HIV-1 protease is an antiviral drug target.
1.2 Structure and Function of HIV-1 Protease
HIV-1 protease is an aspartyl protease that processes the viral polyproteins,
allowing the virus to mature and become infectious. The enzyme is a symmetrical
homodimer of 99 amino acids each (Figure 1.1). Substrate binding disrupts this
symmetry, allowing the recognition of asymmetric substrates by this otherwise
symmetric protease. Each monomer contains a flap comprising two anti-parallel
β-strands connected by a β-turn and situated on top of the catalytic site. The
conformation of the highly flexible flap region differs significantly in the apo and
substrate-bound forms. The dimer is stabilized by four antiparallel β-strands, two
from each subunit, which form an interdigitated β-sheet. Each subunit also con-
3tributes a catalytic aspartate residue, located at the dimer interface. The catalytic
triad in the active site (Asp25-Thr26-Gly27) is responsible for the substrate hy-
drolysis.
In total, twelve proteolytic reactions are required to process Gag, Gag-Pro-
Pol, and Nef. These reactions occur late in the viral life cycle, during virion
assembly and maturation at the cell surface. The cleavage is a highly regulated
and ordered stepwise process. The scissile bond between Nucleocapsid (NC) and
p2 (MA-CA-p2↓NC-p1-p6) is cleaved first, followed by the hydrolysis of Matrix
(MA) and Capsid-p2 (CA-p2)(MA↓CA-p2). Subsequently, p6 is separated from
NC-p1 (NC-p1↓p6). Finally, the spacer peptides p1 and p2 are removed from
NC (NC↓p1) and Ca-p2 (CA↓p2), respectively. NC-p1 is the rate-limiting cleave
reaction. [5]
Temporal regulation is achieved with a unique intrinsic proteolytic rate at each
site and is critical for precise processing underlying the importance of substrate
specificity. Although hydrophobic residues are favored at P1/P1′ positions, the
cleavage sites are non-homologous in sequence and asymmetric in size and charge
(Table 1.1). This asymmetry prompts the question as to how a symmetric protease
could recognize and cleave an asymmetric substrate. The amino acid sequence
by itself is not the specificity determinant for substrate recognition. On the other
hand, the symmetry observed in the apo enzyme juxtaposed with the asymmetric
nature of the substrates [6] and all these asymmetric substrates have similar bind-
ing modes in an extended conformation. [7] Structural studies have shown that the
various cleavage site peptides adopt a conserved shape when bound to HIV-1 pro-
4tease. [7] This conserved shape was initially characterized by visualizing the van
der Waals volume shared by four of the six substrates, which was later on referred
to the substrate envelope (Figure 1.2). The substrate envelope was hypothesized
as the recognition motif for HIV-1 protease.
5Figure 1.1: HIV-1 and HCV NS3/4A protease structures. (A) HIV-1 protease
has two monomers (blue and gray) and displayed here bound to a decameric pep-
tide (magenta) corresponding to the matrix-capsid cleavage site on Gag bound
to the active site. (PDB ID: 1KJ4) (B) The full-length HCV NS3/4A has two
domains: helicase (light pink) and protease (teal). NS4A, the cofactor for the
protease, is shown in blue. C-terminal 6 residues of the helicase domain, the self-
cleavage product, is observed at the binding site of the protease domain. (PDB
ID: 1CU1)
6Figure 1.1
7Table 1.1: Cleavage site sequences for HIV-1 and HCV NS3/4A pro-
teases
HIV-1 Protease Substrates
Substratea P4 P3 P2 P1 * P1′ P2′ P3′ P4′
Matrix-Capsid S Q N F * P I V Q
Capsid-p2 A R V L * A E A M
p2-Nucleocapsid A T I M * M Q R G
Nucleocapsid-p1 R Q A N * F L G K
p1-p6 P G N F * L Q S K
Nucleocapsid-Transframe R Q A N * F L R E
Transframe-p6pol D L A F * L Q G K
p6pol-Protease S F N F * P Q I T
Autoproteolysis Q I T L * W Q R P
PR-Rev. Transcriptase T L N F * P I S P
Rev. Transcriptase-RNase H A E T F * Y V D G
RNase H-Integrase R R I L * F L D G
HCV NS3/4A Protease Substrates
Substratea P6 P5 P4 P3 P2 P1 * P1′ P2′ P3′ P4′
3-4A D L E V V T * S T W V
4A-4B D E M E E C * S Q W L
4B-5A E C T T P C * S G S W
5A-5B E D V V C C * S M S Y
Amino acids are colored according to their physicochemical properties.
RK (purple), DE (red), ILVA (yellow), H (light blue), CM (green)
FYW (dark blue), NQST (pink), PG (gray).
a Protease cleaves the scissile bond P1/P1′.
b Host cellular proteins.
8Figure 1.2: The substrate envelope hypothesis. (A) HIV-1 protease substrate
and inhibitor envelopes are colored blue and red, respectively. The two envelopes
were superimposed to highlight the regions where inhibitors protrude beyond the
substrate to make more extensive contacts with some protease residues. These
protease residues corresponded to the previously known sites of drug resistance.
Figure modified from King et. al., 2004. [8] (B) HCV NS3/4A protease substrate
envelope (blue) and a small-molecule inhibitor of NS3/4A protease, Danoprevir,
are shown in comparison along with the binding site residues. Figure modified
from Romano et. al., 2010. [9]
9Figure 1.2
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1.3 HIV-1 Protease Inhibitors as Antivirals
HIV-1 protease is a major drug target because of its key function in viral as-
sembly and maturation. [10] FDA has so far approved nine protease inhibitors
(PIs) for clinical use: Saquinavir (SQV) [11], Indinavir (IDV) [12], Ritonavir
(RTV) [13], Nelfinavir (NFV) [14], Amprenavir (APV) [15], Lopinavir (LPV)
[16], Atazanavir (ATV) [17], Tipranavir (TPV) [18], and Darunavir (DRV) [19–
21] (Figure 1.3). All these PIs are competitive active site inhibitors and, except
for TPV, they are all peptidomimetics. They bind to the protease with the flaps of
the enzyme tightly closed over the active site, thus mimicking the transition state
between substrate binding and cleavage reaction and thereby effectively inacti-
vating the enzyme. PIs generally have large, hydrophobic moieties that interact
with the mainly hydrophobic S2-S2′ pockets in the active site. Although they are
chemically different relatively low molecular weight compounds, their three di-
mensional shape and electrostatic character are fairly similar. Majority of these
PIs occupy a similar volume, the inhibitor envelope, mostly contacting the same
residues at the active site (Figure 1.2). [8]
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Figure 1.3: FDA-approved HIV-1 Protease Inhibitors. They are all chemi-
cally different; yet share a fairly similar three-dimensional shape and electrostatic
character.
12
Figure 1.3
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1.4 Viral Resistance to HIV-1 Protease Inhibitors
The quality and life expectancy of HIV infected patients has improved since
the introduction of HAART. However, high frequency of random nucleotide mis-
incorporation by the error-prone reverse transcriptase (about three mutations per
virion per round of replication) and a huge reservoir of replicating virus (1010 in-
fected cells in an average patient) diversify the viral population. [22] The selective
pressure of therapy, especially combined with low drug adherence due to toxicity
and high pill burden, facilitates the emergence of drug resistance variants. [23]
PIs are essential components of HAART. [24, 25] Consequently, drug resistance
to PIs has become a major issue in the failure of HAART. [23]
Structural studies showed that drug resistance occurs where the inhibitor atoms
protrude beyond the substrate envelope and contact protease residues. [8] Thus,
mutations at these sites would specifically impact inhibitor binding while sub-
strate recognition and cleavage remains relatively unaffected. The fact that most
drug resistance mutation sites do not contact the substrates led to the substrate en-
velope hypothesis: Inhibitors that fit well within the substrate envelope would be
less susceptible to drug resistance, because a mutation that affects inhibitor bind-
ing would simultaneously impact the recognition and processing of the majority
of the substrates. [8]
More than half of the residues within the protease mutate in different combina-
tions and lead to drug resistance. [26,27] Following the accumulation of resistance
mutations within the protease, mutations also develop within the substrate cleav-
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age sites, including NC-p1 and p1-p6, altering the susceptibility to various PIs.
[28–32] Primary PI mutations, especially in the active site, reduce both protease
catalytic efficiency and viral replicative capacity. [33–36] Nevertheless, evolution
of mutations within the cleavage sites leads to improved viral fitness compared to
the viral variants carrying protease resistance mutations only. [28,30,37,38] Sub-
strates exhibit subtle differences in their binding modes. Some substrates protrude
beyond the substrate envelope at regions where they contact the sites of drug resis-
tance in the protease. The primary mutation sites, contacted by a substrate outside
the substrate envelope, can lead to impaired recognition and cleavage of that sub-
strate. [32, 39, 40] Therefore, that particular substrate would be more susceptible
to the drug resistance mutations in the protease. [40] In conclusion, co-evolved
mutations within the cleavage sites play an important role in the development of
resistance and affect virological response during therapy. The substrate envelope
hypothesis not only explains specificity of the substrates but also the development
of resistance to various PIs and substrate co-evolution. [8, 39, 40]
1.5 Substrate Envelope in Drug Design
The substrate envelope hypothesis provides a framework to designing robust
HIV-1 PIs that avoid resistance. A survey of five approved drugs indicates that
the volume of the inhibitors outside the substrate envelope correlates with the loss
of affinity to mutant proteases. [41] Meanwhile, DRV, the most potent of the cur-
rently prescribed inhibitors, fits well within the substrate envelope although not
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designed using the substrate envelope as a constraint. [42, 43] The ability of the
substrate envelope to correlate with resistance mutations prompted the use of sub-
strate envelope constraints in the design of new inhibitors. [44–48] According to
the substrate envelope hypothesis, the optimum strategy to minimize resistance
is to design inhibitors that fit within the substrate envelope. To test the substrate
envelope hypothesis, various groups took different approaches and designed new
HIV-1 PIs on the hydroxyethylamine scaffold. Two computational methods incor-
porated structural constraints of the substrate envelope as an a priori considera-
tion during the design stage of the inhibitors while the third method employed a
structure activity relationship (SAR) that does not include the substrate envelope
constraint explicitly. The first computational design, based on optimized docking,
resulted in two good candidates exhibiting flat affinity profiles against multi-drug
resistant mutants, although the binding affinity of these candidates were in the nM
range. [48] The second computational design systematically explored the combi-
natorial space for three constituent R groups on the same scaffold in two rounds
of design, synthesis, testing, and retrospective structural analysis. The second
round resulted in low nanomolar-picomolar range compounds, the majority of
which have flatter resistance profiles against resistant variants. [45] As a negative
control, the inhibitors designed with the SAR approach resulted in picomolar in-
hibitors, however they were significantly less potent against the resistant variants.
These studies validated the use of the substrate envelope as a constraint during
the development of HIV-1 PIs with low susceptibility to resistance and yielded
several leads for potential new drugs. [46]
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1.6 Generality of the Substrate Envelope Hypothesis
Application of the substrate envelope hypothesis to other quickly evolving tar-
gets is beginning to emerge. In a recent study, applicability of the substrate enve-
lope hypothesis has been tested for five prospective drug targets from a diverse set
of diseases: Abl kinase, chitinase, thymidylate synthase, dihydrofolate reductase,
and neuraminidase. [49] The volume of inhibitors protruding beyond the native
substrate envelope correlated with average mutation sensitivity. This suggests
that inhibitor design would benefit from a similar reverse engineering strategy for
these enzymes. The substrate envelope has also been applied in the development
of tenofovir, a reverse transcriptase inhibitor. [50] Similar to the case of HIV-1
protease, the drugs AZT and 3TC protrude beyond the consensus volume, cre-
ating an opportunity for the reverse transcriptase to develop resistant mutations.
The newly designed inhibitor, lacking such protrusions, is expected to evade re-
sistance mutations as an improvement over its predecessors. Thus, the substrate
envelope hypothesis appears to be a valid general strategy for avoiding drug re-
sistance. Recently, high resolution crystal structures showed that the substrate
cleavage products of Hepatitis C viral protease NS3/4A adopt a consensus vol-
ume at the binding site and the most severe resistance mutations correspond to the
sites that are contacted by inhibitors outside the substrate envelope. [9] NS3/4A
emerges as a good candidate to target with the substrate envelope approach.
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1.7 Another Quickly Evolving Virus: Hepatitis C
Hepatitis C is an infectious liver disease with significant global impact, which
is caused by an RNA virus of Flaviviridae family. The Hepatitis C virus (HCV)
infection can lead to liver cirrhosis and hepatocellular sarcoma and is the most
common reason for liver transplants in the United States. The World Health Or-
ganization estimates 150 million people worldwide are infected with HCV and
3-4 million new infections coming up every year with more than 350,000 cases
of death from HCV-related liver diseases. [51] HCV is genetically highly diverse.
So far, six major HCV genotypes and several subtypes within each genotype have
been identified. [52] The high viral replication rate combined with the error-prone
RNA-dependent RNA polymerase causes large inter-patient genetic diversity as
well as viral diversity within a single infected individual. [53, 54]
The genetic heterogeneity of the virus across and within patients has greatly
challenged the development of robust direct-acting antiviral agents (DAAs) that
retain efficacy against multiple genotypes and drug-resistant variants of these
genotypes since the discovery of HCV in 1989 as the cause of the Hepatitis
C. [55, 56] Until 2011, the standard of care for HCV was weekly injections of
pegylated interferon α combined with ribavirin (Peg-IFN/RBV), which can re-
sult in undetectable levels of HCV in 70-80% of people with genotypes 2 and 3
but only 40-50% of people with genotype 1. [51] Genotype 1, the most difficult
genotype to treat, is also the most common form of HCV in the US accounting
for about 75-80% of the cases. [57, 58] In addition, the severe side effect pro-
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file of this combination therapy amplifies the need to develop more effective and
better-tolerated DAAs.
1.8 NS3/4A Protease as an Antiviral Target
Among the drug targets in HCV is the non-structural protein 3 (NS3), which is
a 631 amino acid bifunctional protein, with a serine protease domain located in the
N-terminal one-third and an NTPase/RNA helicase domain in the C-terminal two-
third. The reason for the protease and helicase domains to be physically linked
is not fully known. Although their interplay has been reported [59–62], both do-
mains fold independently and are active in the absence of the other [59, 61–64].
The most efficient proteolytic activity of NS3 requires a cofactor NS4A, a 54-
amino acid peptide that is tightly associated with the protease. [51] The HCV
genome encodes a single polyprotein of ≈3000 acids, which is processed by a
series of host and viral proteases into at least 10 structural and nonstructural pro-
teins. The viral NS3/4A hydrolyzes the polyprotein precursor at four known cleav-
age sites (3-4A, 4A-4B, 4B-5A, 5A-5B) yielding non-structural proteins essential
for viral maturation. The first proteolytic event occurs at 3-4A junction in cis
as a unimolecular reaction, while processing of the remaining junctions 4A-4B,
4B-5A, and 5A-5B occurs bimolecularly in trans. [65] These cleavage sites are
non-homologous except for an Asp/Glu at P6, Cys/Thr at P1 and Ser/Ala at P1′
(Table 1.1). NS3/4A also confounds the innate immune response to viral infection
by cleaving the human cellular targets TRIF and MAVS and to block toll-like re-
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ceptor 3 signaling and RIG-I signaling, respectively. [66–69] Cleavage of another
cellular target, TC-PTP, at two separate sites enhances EGF signaling and basal
Akt activity. [70] Very recently, DDB1, a core subunit of the Cul4-based ubiquitin
ligase complex, was reported to play a critical role in HCV replication and get
cleaved by NS3/4A. [71] Thus, in addition to blocking the viral maturation, ef-
fective inhibition of the proteolytic activity of the NS3/4A may also exert indirect
antiviral effects, further interfering with viral replication.
NS3/4A adopts a chymotrypsin-like fold with two β-barrel domains (Fig-
ure 1.1). The catalytic triad is formed by His-57, Asp-81 and Ser-139 and is
located in a cleft separating the two domains. The structure is stabilized by a
Zn+2 ion that is coordinated by Cys-97, Cys-99, Cys-145, and His-149. NS4A
aids in the proper folding of NS3; the central 11 amino acids of NS4A inserts as
a β-strand to the N-terminal β-barrel of NS3. The binding site of the protease is
very shallow presenting a challenge to develop high affinity and low molecular
weight inhibitors.
Product inhibition by the N-termini of the trans-cleavage sites [72,73] formed
the basis for the development and optimization of peptidomimetic inhibitors of
the NS3/4A protease. [74] The proof-of-concept for antiviral efficacy was first
demonstrated in 2002 with the macrocyclic inhibitor BILN-2061 (ciluprevir), which
was later discontinued due to concerns about its cardiotoxicity. [75–77] In May
2011, the FDA approved two NS3/4A PIs, telaprevir [78,79] and boceprevir [80],
for treatment of chronic HCV genotype 1 infection to be used in combination with
Peg-IFN/RBV. Both telaprevir and boceprevir are acyclic ketoamide inhibitors
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that associate with the protease through a reversible, covalent bond with the cat-
alytic serine (S139) as well as short-range molecular interactions with the binding
site. The limitation of these drugs to a single genotype pushes the research for
developing inhibitors with broader activity.
Several non-covalent NS3/4A inhibitors, including macrocyclic compounds,
are at various stages of clinical development (Figure 1.4). The non-covalent
acylsulfonamide inhibitors contain a macrocycle connecting either P1 and P3
groups (ITMN-191 or danoprevir [81]) or alternatively P2 and P4 groups (MK-
5172 [82], MK-7009 or vaniprevir [83]). These compounds have higher efficacies
than telaprevir and boceprevir against the wild-type enzyme. However, in addi-
tion to the reported resistance in replicon studies, HCV quickly evolves to confer
resistance to these protease inhibitors even at early stages of clinical trials com-
promising their high efficacy (Table 1.2). [84–89]
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Figure 1.4: HCV NS3/4A protease inhibitors. The canonical nomenclature for
drug moiety positioning is indicated using telaprevir. Telaprevir and boceprevir,
recently approved for clinical use, are linear, reversible-covalent ketoamide in-
hibitors. Danoprevir, vaniprevir, and MK-5172 are macrocyclic acylsufonamide
inhibitors. Danoprevir has a P1-P3 macrocycle, while vaniprevir and MK-5172
have a P2-P4 macrocycle. Vaniprevir and MK-5172 differ in their P2 moieties.
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Figure 1.4
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Table 1.2: Reported sites of drug resistance mutation in HCV NS3/4A .
Drug Site Mutation Drug Site Mutation
Telaprevir V36 M, A, L, G, I Vaniprevir F43 S
T54 A, S R155 K, T, G
I132 V D168 A, G, V, Y
R155 K, T, M, G
A156 F, N, S, T, V
D168 N
Boceprevir V36 M, A MK-5172 R155 G, Q
T54 A, S, G, C A156 T, V
V55 A D168 Y, E, T, A
R155 K, T
A156 S, T, V
V158 I
D168 N
I170 A, T
M175 L
Danoprevir Q41 R
F43 S, C
S138 T
R155 K, T, I, M, G, L, S
A156 V, T, S, I
D168 A, V, E
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An important lesson learned from studying HIV-1 is that the key to designing
robust inhibitors is to pay attention to the details of the balance between the natural
substrate recognition and inhibitor binding. Mimicking the characteristics of the
substrate recognition motifs in the designed compounds results in inhibitors that
retain potency against drug resistant viral variants. The native function of the vi-
ral protease imposes an evolutionary constraint on the protease under the selective
pressure of drug therapy. According to the substrate envelope hypothesis, resis-
tance reflects a subtle change in the balance of molecular recognition events, in
favor of substrate processing versus inhibitor binding. The drug-resistant protease
variants are no longer effectively inhibited by the competitive drug molecules but
can process the viral Gag and Gag-Pro-Pol polyproteins efficient enough for viral
survival. Therefore, to guide the design of robust inhibitors, the specificity deter-
minants of substrate recognition and how these determinants are maintained by
the resistant variants should be elucidated for HCV as previously done for HIV-1.
High resolution co-crystal structures have been determined for the NS3/4A
protease domain with the cleavage products as well as inhibitors, including danopre-
vir, MK-5172, and vaniprevir. [9, 90] In these structures, the products, despite
the low sequence homology, adopted a consensus volume at P6 to P1 residues;
the substrate envelope. The most severe resistance mutations occur at protease
residues that are contacted by the inhibitors outside the substrate envelope.
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1.9 Protein Dynamics
1.9.1 Protein Dynamics is Key to Molecular Recognition
Proteins are inherently flexible, undergoing functionally relevant conforma-
tional transitions under native state conditions on a wide range of scales, both in
time and space. Atomic fluctuations and internal motions are key components of
intra- and intermolecular communication, thus protein dynamics are essential for
biological function and activity.
Thinking about proteins as dynamic entities that are in constant motion is
fundamental to our understanding of molecular recognition, including substrate
binding-catalysis-turnover and small-molecule inhibitor binding. The initial lock-
and-key theory of molecular recognition conceptualized a rigid receptor accom-
modating a small molecule without undergoing any conformational rearrange-
ments. [91] More recent binding models account for conformational changes caused
by ligand binding, induced fit, [92] and random conformers of receptor that are se-
lectively bound by ligand, conformational selection. [93–96] Both induced fit and
conformational selection models are plausible and likely exist in Nature depend-
ing on the extent of inherent flexibility of a receptor protein.
The interplay between the internal motions of an enzyme and its activity has
been reported repeatedly for various systems. Independently determined crystal
structures of ligand-bound and free states of some enzymes have substantially dif-
ferent conformations. [97, 98] Catalytic activities of many enzymes are closely
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associated with loop motions over the active site that orient key residues in the
binding site relative to the substrate, including HIV-1 protease. [99–106] Equi-
librium fluctuations in enzymes are also indispensible for substrate binding and
product release. [107, 108] More indirect indications of protein dynamics include
non-additive effects of double mutations at distal regions within proteins and sub-
stituted functional groups of inhibitors, suggesting a dynamic cooperativity of
molecular interactions. [109–113]
The research cited here is only a small fraction of ever-growing evidence for
the essential role of conformational dynamics in molecular recognition and func-
tion. Protein dynamics is a complex problem to access experimentally and re-
searchers have used several techniques to address this problem. While techniques
such as fluorescence spectroscopy, [114] spin label electron paramagnetic reso-
nance (EPR), [115] and small angle X-ray scattering [116] have applications in
elucidating some aspects of protein flexibility, x-ray crystallography and nuclear
magnetic resonance (NMR) spectroscopy are the key experimental methods for
characterizing molecular structures. X-ray crystallography has traditionally pro-
vided snapshots of one or only some of the conformations accessible to proteins
in cryogenic conditions. However, technological advances in synchrotron X-ray
sources have recently allowed time-resolved measurements on single crystals with
the possibility of obtaining probability density for atoms. [117] Also recently de-
veloped computational tools for electron-density sampling, model refinement, and
molecular packing analysis allow monitoring room-temperature conformational
ensembles with x-ray crystallography that reveal motions in crystals crucial for
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catalysis, ligand binding, and allosteric regulation. [118] In contrast to crystallog-
raphy, NMR experiments are performed in solution and can allow direct observa-
tion of flexibility of proteins in structure and molecular interactions with ligands.
The general consensus is that solution mimics the biological environment better
than crystal, although molecular crowding has been reported to exert changes in
structure. [119, 120] Protein size has been a limitation of this technique, but in-
creasing field strengths in spectrometers will not only expand the range of protein
size tractable with NMR but also enhance the resolution of spectra leading to the
identification of more conformers accessible to the protein. [117]
Experimentally obtained structural data, whether by means of crystallography
or NMR, provide a basis for understanding protein dynamics but currently can-
not fully elucidate the details of conformational flexibility in full-atomistic scale.
Molecular dynamics (MD) simulations are being more and more combined with
experiments because MD is a powerful computation tool that tracks rapid pro-
cesses across a spatiotemporal domain at atomic resolution for many biologically
relevant systems at reasonable computational cost. MD simulations generate suc-
cessive conformations of a system, so-called trajectory, by iterating Newton’s
second law of motion. MD has been successfully applied to many systems to ad-
dress numerous biologically relevant questions, including protein folding, [121]
enzyme catalysis, [122] and binding kinetics. [123] While the force field describ-
ing the molecular interactions can still benefit from improvements, the advance-
ments in parallel computing architectures and algorithms have tremendously rev-
olutionized the MD field and increased the accessibility of wider timescales and
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larger systems. The earlier simulations of a ≈900 atom protein lasted 9 ps [124]
while now protein folding simulations as long as 1 ms [125] or 50 ns simulation
of an intact virion of 1 million atoms [126] can be performed.
Each of the techniques mentioned here has its own advantages and limita-
tions. Being aware of the drawbacks and accordingly taking advantage of multi-
ple techniques in concert would serve best for the purpose of obtaining a complete
“movie” of protein dynamics at atomic resolution.
1.9.2 Change in Dynamics as a Drug Resistance Mechanism
Characteristics of the structural fluctuations contribute to the activity of an
enzyme. Both nuclear magnetic resonance experiments and molecular dynam-
ics simulations show that the flap region of HIV-1 protease is highly mobile and
can adopt a large number of conformations on the nanosecond to microsecond
timescale. [101, 102, 105] The exchange between these conformational states is
correlated with structural reorganization of the active site, and the active site pre-
organization is a rate-limiting factor in native function of the protease. [127] Bind-
ing of a small-molecule inhibitor and recognition of a natural substrate may have
differential protein dynamics, even for a competitive active site inhibitor. Ad-
ditionally, single or multiple amino acid substitutions in the protease may alter
dynamics of protein-ligand interactions. In fact, NMR relaxation experiments
combined with extensive molecular dynamics simulations revealed differential
dynamics in the flaps between the wild-type and a drug resistant variant of HIV-1
protease. [128] Consistently, mutations that stabilize a closed-like conformation
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correlate with enzymes of lowered activity and with higher affinity for inhibitors,
which is corroborated by a further increase in the fractional occupancy of the
closed state upon addition of inhibitor or substrate-mimic. [129] In addition to the
flaps, a change in the flexibility of the hydrophobic core of HIV-1 protease, caused
by various mutations selected under drug therapy, also modulates the enzymatic
activity. [127,130] All these results suggest that modulation of protein dynamics is
a molecular mechanism of drug resistance. To avoid resistance in drug discovery,
crystallographic studies should be coupled with methods probing for the altered
dynamics in resistant variants relative to the wild-type to fully characterize the
molecular mechanism of drug resistance.
1.9.3 Protein Dynamics is Often Neglected in Drug Design
Identifying potential drug leads by brute force, making as many compounds
as possible with the hope that some would eventually have desirable activity, is
no longer an effective method for drug discovery but structure-based drug design
is now an integral part of most industrial drug discovery programs. [131] Nev-
ertheless, structure-based drug design typically relies on static protein structures.
Although incorporating ligand flexibility into design is routine, target flexibility is
often ignored despite significant evidence for the need to consider the role of dy-
namics in recognition. [132] Instead, a common strategy has been to generate hy-
drophobic and conformationally constrained ligands with an entropically-driven
binding affinity. This strategy raises the issue of drug resistance since confor-
mationally constrained ligands cannot easily adapt to changes in the geometry of
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the binding site but the enthalpically-driven inhibitors can be less susceptible to
resistance. [133]
A single protein structure is only useful to identify inhibitors for that particu-
lar narrow state of the conformational ensemble. To obtain promising leads and
accurately predict affinity of existing compounds, targeting multiple structures is
a better strategy. Although assessing protein dynamics is not yet an established
step of structure-based drug design in pharmaceutical industry, researchers have
long been working on this problem. [134]
In earlier efforts, keeping the protein fixed but using a soft scoring function
implicitly accounted for flexibility. [135] This method, soft docking, allows for
overlap between the ligand and the protein, giving a small estimate of the plastic-
ity of the receptor. Soft docking is computationally cheap due to the fixed scoring
function but is not very effective in identifying binders with varied size and con-
formation. Another approach is the relaxed complex method, in which ligands
are docked to an ensemble of conformations of the target, and the best complexes
are re-scored to provide predictions of optimal binding geometries. [136, 137]
Receptor-based pharmacophore models that use a collection of crystal structures
have been proposed to account for the inherent protein flexibility in structure-
based drug design. [138, 139] Keeping the protein backbone rigid but sampling
the side chain conformations of the receptor is another technique to account for
flexibility in the binding site. This technique uses rotamer libraries, which are
collections of low energy amino acid side chain conformers and their frequency
of observation, compiled from high-resolution x-ray structures. [140] Computa-
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tionally more rigorous simulated annealing was used for conformational search
with a rapid grid-based method of energy evaluation in flexible docking algo-
rithms. [141, 142] More recently, use of multiple crystal structures has been com-
bined with regular and replica exchange molecular dynamics simulations to sam-
ple the conformational space accessible to the binding surface. [143]
Although flexibility has not been a major concern in earlier stages of drug de-
sign, with the recent innovations in computational and experimental methods to
characterize protein dynamics, new approaches based on ensemble structures are
expected to emerge. Ultimately, accurate incorporation of conformational flexi-
bility will improve the productivity of drug discovery efforts. [117, 144]
1.10 Scope of Thesis
The substrate envelope hypothesis provides a fundamental explanation to the
very complicated problems of substrate specificity, drug resistance, and co-evolution
of the natural cleavage sites with the drug resistant variants. Although the sub-
strate envelope, defined by the crystal structures, has greatly enhanced our under-
standing of the structural basis for these three phenomena, the picture it draws
cannot be complete when protein dynamics is left out. All biological macro-
molecules, including enzymes and their substrates, sample ensembles of confor-
mations. Even the native state cannot be thought of as one static structure, but a
collection of similar conformations sampled around a common minimum in the
energy landscape. Therefore, it is crucial to take into account these local fluc-
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tuations around the native state, a static image of which is captured in a crystal
structure. In my thesis, I attempt to fill this gap and evaluate the generality of the
substrate envelope hypothesis from a protein dynamics point of view. I first intro-
duce the dynamic substrate envelope by sampling the local conformational space
accessible to the substrates bound to HIV-1 protease and characterize the dynam-
ics of preferential substrate recognition by the wild-type HIV-1 protease. Then I
validate the HIV-1 dynamic substrate envelope by investigating the dynamic prop-
erties of three drug-resistant protease-substrate complexes that have co-evolved
under therapy. Next, I assess the generality of the dynamic substrate envelope by
applying it to the NS3/4A protease of another quickly evolving virus, Hepatitis
C. This part of my thesis also highlights considerable deviations in inhibitors’ dy-
namic interactions from those of substrates and suggests inhibitor modifications
to improve resistance profiles. Finally, I highlight the importance of complement-
ing the structural studies with protein dynamics by showing a distal mutation’s
effect on the NS3/4A binding site structural organization and the overall protease
dynamics.
Chapter II
Dynamics of Preferential Substrate
Recognition in HIV-1 Protease:
Redefining the Substrate Envelope
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2.1 Abstract
HIV-1 protease (PR) permits viral maturation by processing the Gag and Gag-
Pro-Pol polyproteins. Though HIV-1 PR inhibitors (PIs) are used in antiviral ther-
apy, the emergence of drug resistance has limited their efficacy. The rapid evo-
lution of HIV-1 necessitates the consideration of drug resistance in novel drug-
design strategies. Drug-resistant HIV-1 PR variants, while no longer efficiently
inhibited, continue to efficiently hydrolyze the natural viral substrates. Though
highly diverse in sequence, the HIV-1 PR substrates bind in a conserved shape
we defined as the “substrate envelope”. Resistance mutations arise where PIs pro-
trude beyond the substrate envelope, as these regions are crucial for drug binding
but not for substrate recognition. Here, we extend this model by considering the
role of protein dynamics in the interaction of HIV-1 PR with its substrates. Seven
molecular dynamics simulations of PR-substrate complexes were performed to
estimate the conformational flexibility of substrates in their complexes. Interde-
pendency of the substrate-protease interactions may compensate for the variations
in cleavage-site sequences, and explain how a diverse set of sequences can be
recognized as substrates by the same enzyme. This diversity may be essential
for regulating sequential processing of substrates. We also introduce a dynamic
substrate envelope as a more accurate representation of PR-substrate interactions.
The dynamic substrate envelope, described by a probability distribution function,
is a powerful tool for design efforts targeting ensembles of resistant HIV-1 PR
variants to develope drugs that are less susceptible to resistance.
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2.2 Introduction
Drug resistance reflects a subtle change in the balance of molecular recogni-
tion: the resistant viral enzyme is no longer effectively inhibited by drugs, but
can still recognize and process its natural substrates. Targeting resistance in drug
design, therefore, requires a detailed understanding of substrate recognition. The
principles underlying substrate recognition are especially important in the case
of HIV-1 protease, a 99-residue, homodimeric aspartyl protease, since all cur-
rently available FDA-approved protease inhibitors are competitive inhibitors. The
natural substrates of HIV-1 PR are cleavage sites on the Gag and Gag-Pro-Pol
polyproteins, whose processing is crucial for the maturation of infectious virions.
The cleavage sites, however, share little sequence homology, making the determi-
nants of substrate specificity difficult to identify.
To address the substrate recognition problem, Prabu et. al., has solved crystal
structures of an inactive variant (D25N) HIV-1 PR bound to decameric peptides
corresponding to the cleavage sites within the Gag and Gag-Pro-Pol polyproteins.
[6, 7] These crystallographic studies revealed that the common structural feature
of the natural substrates is the conserved consensus volume that they adopt within
the binding site of the enzyme. This consensus volume, the substrate envelope, is
hypothesized to be the key element for substrate recognition rather than a specific
amino acid sequence. [7]
The structural basis for drug resistance came from further crystallographic
studies on protease-inhibitor complexes. [145] The inhibitor molecules in these
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crystal structures also adopted a conserved consensus volume, the inhibitor enve-
lope. The superposition of the inhibitor and substrate envelopes showed that the
inhibitors protrude beyond the substrate envelope and make contact with some
protease residues. These residues corresponded to the previously known drug re-
sistance mutation sites in the protease. This observation lead to the hypothesis,
that the inhibitors, when designed to fit within the substrate envelope, are less
likely to elicit drug resistance mutations. Following this hypothesis, the substrate
envelope has been used successfully as a constraint to guide the design of new
drug molecules that are effective inhibitors of protease variants, including highly
resistant variants. [44–46, 48]
Some cleavage sites co-evolve with the drug resistant protease variants, pre-
sumably complementing the emergence of drug resistance mutations in the pro-
tease. Previous crystallographic and structural modeling studies on resistant protease-
substrate complexes suggested that these co-evolving substrates make extensive
contacts with drug resistance mutation sites on the protease and hence co-mutate
with them. [39, 40] However, the compensatory mutations on these co-evolving
cleavage sites are not always at the positions that interact with the drug resistance
mutation site on the protease, but sometimes they occur at another residue on the
cleavage site. Modeling studies on Nelfinavir-resistant PRD30N/N88D in complex
with p1-p6WT and p1-p6LP1′F suggested that the protease-substrate interactions
lost in PRD30N/N88D are recovered by the LP1′F substitution in p1-p6. [39] Sim-
ilarly, the multi-drug resistant PRV 82A does not interact with the wild-type NC-p1
cleavage site as favorably as it does with NC-p1AP2V . [40] According to the sub-
37
strate envelope hypothesis, substrates that protrude beyond the envelope and make
contact with the drug resistance mutation sites on the protease co-evolve with re-
sistant protease variants.
In this study we elucidate the balance between the variation and commonality
of the natural substrates of HIV-1 PR in terms of differential substrate recognition
by investigating the conformational ensembles of protease-substrate complexes.
Clues to substrate recognition by HIV-1 PR can be found in two characteristics
of substrate cleavage. The sites in gag and gag-pro-pol polyproteins are cleaved
each with specific unique enzyme kinetics and in a tightly regulated required or-
der. [146] This variation in substrate processing, complements the commonality
between the substrates found in the conserved shape. Although initially we an-
alyzed various crystal structures of HIV-1 PR-substrate complexes, these crystal
structures only represent an average of the trapped low energy states of the en-
zyme. However, the activity of HIV-1 PR is intimately related to its dynamics,
from local to global motions. Consideration of this flexibility is essential to un-
derstanding how the specificity of substrate recognition is determined. To capture
aspects of this dynamics, the substrate complexes were simulated using molecular
dynamics (MD). From these simulations, the conformations and dynamic cooper-
ativity of the substrates with the protease were analyzed as a dynamic ensemble.
Most of the protease-substrate interactions observed in the crystal structures were
conserved during the MD simulations, validating our understanding of substrate
recognition. The dynamic ensemble was further analyzed in terms of a dynamic
substrate envelope, to ascertain how molecular dynamics affects the consensus
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volume of the bound substrates. The dynamic substrate envelope reproduces the
main characteristics of the static substrate envelope, providing a more realistic
and accurate representation of the consensus volume. Essentially the dynamic
substrate envelope is a probability distribution function in contrast with the static
substrate envelope, which is a step function. Thus, the dynamic substrate enve-
lope is potentially a more powerful tool in computer-aided drug design, easily
incorporated as an added constraint in structure-based design algorithms.
2.3 Results
2.3.1 Molecular Interactions Between Protease and Substrates:
Analysis of vdW Contacts
As the HIV-1 protease active-site is mainly hydrophobic, understanding the
preferential substrate recognition requires quantitatively analyzing van der Waals
(vdW) contact potentials between the protease and its substrates. Such an eluci-
dation is essential to reveal and compare how well a particular substrate fits into
the binding site.
Comparison of crystal structures and molecular dynamics trajectories. Crys-
tal structures of substrate complexes provide a starting conformation for exam-
ining vdW contacts between the enzyme and its substrate but do not assess the
stability of these contacts. Therefore, the crystal structures were examined quan-
titatively for the PR-substrate vdW interactions, and then compared with those
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from the MD trajectories. An average contact potential is shown in Figure 2.1
for each protease residue interacting with at least one substrate. Each average
was calculated for each protease residue over the set of seven PR-substrate crys-
tal structures (Figure 2.1, black bars) and their respective MD trajectories (light
gray bars), enabling a quantitative comparison of static and dynamic contacts. Al-
though the standard deviations of individual residue vdW contact potentials from
the dynamic ensembles are larger than those from the various crystal structures,
the general pattern of protease residue potentials is very similar. Thus, the crys-
tal structures provide a good representation of the contact potentials between the
protease and substrates.
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Figure 2.1: Contact potentials between the protease and seven substrates are
well represented by crystal structures. For each protease residue contacting at
least one substrate, its potential energy of vdW contact is averaged over seven
PR-substrate crystal structures (black bars), and their respective MD trajectories
(light gray bars). Each panel shows one monomer of the protease. Stars repre-
sent PR drug-resistance mutation sites according to the Stanford Database of HIV
Drug Resistance. [27] Most of these sites do not make extensive contacts with the
natural substrates, suggesting that these residues are more important for inhibitor
binding than substrate recognition. A few of these sites contact natural substrates
and have been reported to co-evolve with natural substrates, i.e., D30N/N88D
with p1-p6, I50V with both NC-p1 and p1-p6, V82A with NC-p1.
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Figure 2.1
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Interaction of drug-resistance mutation sites with substrates. Drug-resistance
mutation sites (shown as stars in Figure 2.1) tend to have less contact potential
with substrates than other sites. This occurs presumably as a result of these sites
are more important for inhibitor binding than substrate recognition. To investi-
gate the change in role of these PR residues for recognizing particular substrates,
both the crystal structure and the dynamic ensemble of each substrate were exam-
ined. The overall trend of vdW contacts averaged over various crystal structures
matches the trend of time-averaged contact potentials. However, for a few pro-
tease residues, including: I47/I47′, F53/F53′ and L76′, the contact decreases with
certain substrates and no contact is formed with other substrates. These residues
are among the list associated with drug-resistance in the Stanford Database. [27]
Since these residues do not preserve their crystal contacts with any substrates, they
are indeed less important for substrate recognition than inhibitor binding.
At some protease residues, the interactions with the substrates are more com-
plex. One such special case occurs with D30 and D30′, which make fewer contacts
with p2-NC and CA-p2, respectively, during the course of MD simulations than
in the crystal structures. Nonetheless, D30 preserves high interaction potential
with the majority of substrates. In the case of p1-p6, D30 forms a dynamically
stable interaction with the substrate. The alteration of the interaction by the D30N
mutation may provide a structural explanation for the observed co-evolution of
this cleavage site. Generalization of this analysis requires further attention to co-
evolved residues in the protease and substrates.
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Figure 2.2: Protease structures have similar interaction profiles although
they are in complex with non-homologous substrates. (A) Unprimed monomer
(B) Primed monomer.
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Figure 2.2
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Protease-substrate vdW interactions in the context of preferential substrate
recognition. Each non-homologous substrate cleavage site forms unique inter-
actions with the mainly hydrophobic protease active site, although the protease
residues have fairly similar vdW interaction profiles (Figure 2.2). The overall
vdW potential energy of substrate-protease binding is conserved at approximately
-45 kcal/mol (Figure 2.3), suggesting an optimal interaction for the cleavage sites
despite their low sequence homology. In all substrates, however, individual con-
tributions to the overall interaction energy by the eight residues, P4 through P4′
positions, are not the same (Figure 2.3). P4 and P4′ positions, in general, have
lower interaction potential probably because they are more flexible and solvent
exposed. The majority of substrates interact extensively with the protease through
the P3-P3′ region, though each interaction is unique. For example, P3 and P2′
have the highest vdW contact potential in CA-p2 due to relatively bulkier amino
acids at these positions (R-P3 and E-P2′) while in p2-NC, Q-P2′ and R-P3′ are
the main interacting residues. MA-CA and RT-RH have a more symmetrical in-
teraction profile along their sequence presumably due to their pseudo-symmetry
around the cleavage site. Symmetry of vdW contact potential around the cleav-
age site appears to be associated with symmetry in the side-chain size of substrate
residues. Thus, overall vdW interaction potential is an important indicator for
a sequence to be recognized by HIV-1 protease as a substrate. However, these
substrates have varied contacts due to their diverse sequences, suggesting that the
cleavage-sites have been evolutionarily optimized to maintain a particular degree
of vdW interaction within the protease active site.
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The hypothesis of evolutionary optimization of cleavage-site sequences to
maintain their overall interaction potential with the protease can hold true only
if there is dynamic interdependency among the cleavage-site residues. A PR in-
teraction lost at one substrate residue should be compensated by an increased
interaction at another residue. To examine this possibility, the vdW contact poten-
tial of each substrate residue was calculated over time in MD simulations, and a
correlation coefficient was computed for each possible residue pair (Figure 2.4).
All substrates showed a similar pattern of coupled residues, which compensate
each other for vdW interaction (shown in blue in Figure 2.4). This consensus in-
terdependency between the substrate amino acid positions appears to be critical
for recognition by HIV-1 protease, supporting the hypothesis above.
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Figure 2.3: Substrates maintain a consensus vdw interaction potential with
the protease independent of sequence. (A) Despite low sequence homology,
substrates have an optimal total vdW interaction with the PR. (B) The interaction
potential between the PR and substrate differs by the individual contribution of
substrate residues P4 to P4′.
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Figure 2.3
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Figure 2.4: Fluctuations in the vdW interaction potential within/among sub-
strate residues are negatively correlated, revealing their interdependency.
The vdW contact potential of each substrate residue with the PR was calculated
over time. Fluctuations in this potential with respect to every other residue in
the same substrate were estimated by computing Pearson correlation coefficients.
The correlation coefficients are contoured for each substrate and color-coded from
red (fully correlated) to blue (fully anti-correlated). (A) MA-CA, (B) CA-p2, (C)
p2-NC, (D) NC-p1, (E) p1-p6, (F) RT-RH, (G) RH-IN.
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2.3.2 Molecular Interactions Between the Protease and Substrates:
Analysis of Hydrogen Bonds
Though vdW interactions are fairly important for stabilizing the substrates in
the mainly hydrophobic binding groove, analysis of hydrogen bonds in variant
substrates is necessary for better understanding the specificity of substrate recog-
nition. To this end, both the intermolecular hydrogen bonding networks between
the protease and substrates and the intramolecular hydrogen bonds within the sub-
strates were investigated.
The hydrogen bonds between the protease and substrates were analyzed in two
groups: the substrate backbone and substrate side-chain hydrogen bonds regard-
less of whether the acceptor/donor is in the protease backbone or side-chains. This
analysis showed that the backbone hydrogen bonds are more stable throughout the
trajectories, also more conserved across the substrates than the hydrogen bonds
formed by substrate side-chains (Figure 2.5). Majority of the backbone hydrogen
bonds appear to be consistently observed within the course of the simulations with
varied frequencies (Figure 2.5). There are a few exceptions; the bonds formed by
P4 and P3 backbones do not appear to be stable in the simulations. In addition,
the protease forms hydrogen bonds with substrate backbones via D29/D29′ in
both monomers, yet these hydrogen bonds are not conserved across the substrates
in the simulations. No additional hydrogen bonds are formed in the MD simula-
tions except for those formed with N25. In all the crystal structures, a hydrogen
bond was observed between N25′ and the substrate backbone at P1 position. In
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the MD simulations, however, this hydrogen bond keeps alternating between N25
and N25′, more than 50% of the time in some substrates. The active site is formed
by the two D25/D25′ in the catalytically active species. Thus, this pattern, alter-
nating between the two monomers, of hydrogen bonding is in agreement with the
necessity of the two Asp residues for catalytic activity. [147] The substrates inter-
act with both the ASP residues in a balanced manner, hence a single mutation at
this position in tethered dimers results catalytic inactivity.
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Figure 2.5: Backbone hydrogen bonds are more conserved across varied sub-
strates and more stable than the side-chain hydrogen bonds. Frequency of
occurrence of hydrogen bonds during the simulations between any protease atom
and substrate backbone (A) and substrate side-chains (C), and the hydrogen bonds
observed in the crystal structures between any protease atom and substrate back-
bone (B) and substrate side-chains (D). The side-chain hydrogen bonds are shown
by residue (B, D) for the crystal structures and simulations, respectively. In panels
A and C, the hydrogen bonds are color-coded with respect to the time percentage
of occurrence throughout the simulations with red being 100%. Only the hydrogen
bonds that existed more than 50% of the time were shown, below 50% occurring
bonds are shown in white. In panels B and D, gray indicates a hydrogen bond
observed in the crystal structure and white shows that the bond does not exist in
that structure.
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The side-chain hydrogen bonds have variations between the crystal structures
and MD simulations when analyzed at the atomistic level. In contrast, when an-
alyzed in a residue-based manner, hydrogen bonding potential of any protease-
substrate residue pair does not deviate from the crystal structures significantly
whether or not the acceptor-donor atoms change in the simulations (Figure 2.5).
The protease residues cluster in the specificity of their interactions with the
substrates. Some residues form hydrogen bonds only with the backbones of al-
most all substrates, while others make hydrogen bonds with substrate side-chains
in a more specific way. D29 and D30 interact with the substrate side-chains in
either monomer, while N25, G27, and G48 typically make hydrogen bonds with
the substrate backbones. p2-NC and p1-p6 appear to have very stable side-chain
hydrogen bonding patterns mainly at their P2′ position. RT-RH and RH-IN side-
chains lose their hydrogen bonds with the protease immediately in the simulations,
while they maintain most backbone hydrogen bonds. Despite the obvious simi-
larity in the backbone hydrogen bond patterns of varied substrates, the side-chain
hydrogen bonds appear to be unique for individual substrates.
Almost every substrate has an intramolecular hydrogen bond within its se-
quence (Table 2.1). Most of these intramolecular hydrogen bonds are formed
within the substrate backbone and all between the ith and i+2th residues within
the P3-P3′ region. Although the hydrogen bonding patterns may have been af-
fected by the D25N substitutions, these hydrogen bonds likely stabilize the back-
bone conformation within the active site, contributing to the conserved consensus
volume occupied by the substrates.
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Table 2.1: Hydrogen bonds within the substrates of HIV-1 protease that
exist more than 50% of the time .
Hydrogen Bond Substrate (%)
P3 O ... P1 N
NC-p1 (61.8%)
RH-IN (64.4%)
P2 O ...P1′ N p2-NC (91.7%)
RT-RH (83.6%)
P2 OD1 ... P1′ N p1-p6 (87.3%)
P1′ O ... P3′ N CA-p2 (56.6%)
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2.3.3 Analysis of Atomic Fluctuations
Dynamic coupling between the protease and its substrate. Proteins are dy-
namic; even a relatively stable, highly populated enzyme-substrate complex state
can visit multiple local conformations. During sampling of these conformations,
the substrate complexes of HIV protease fluctuate around the native states in a
coupled manner. Correlation coefficients of mean-square fluctuations between
HIV-1 PR residues and substrate residues are shown for all seven PR-substrate
complexes (Figure 2.6). Protease residues that fluctuate in correlation with any
substrate residue are the same in all complexes, corresponding to mainly three re-
gions around positions 30, 50, and 80 in both monomers. The substrate residues
coupled with these protease regions are not, however, the same for all substrates.
In all substrates but CA-p2, the unprimed side moves in correlation with the re-
gion around position 50 in the unprimed monomer. In CA-p2, the primed side is
coupled to the same region of the protease. The 50′ region in the other monomer
is highly correlated to P3′ and P4′ of CA-p2, while the correlation of the 50′
region seems more dispersed with the other substrates. p1-p6 appears to be mod-
erately correlated with the 50 region compared to the other substrates. RH-IN
has a dual character; the prime side correlates with the primed PR monomer, and
the unprimed side with the unprimed monomer. The primed and unprimed sides
of RH-IN fluctuate independently of each other, almost like two distinct domains
(Figure 2.7).
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Figure 2.6: Interdependency within substrate residues revealed by cross-
correlations of mean-square fluctuations between protease and substrate residues.
Atomic positional fluctuations are calculated for all residues in the PR-substrate
complex. How one PR residue fluctuates with respect to a substrate residue was
estimated by computing cross-correlations (see ”Methods”). The correlation co-
efficients are contoured and color-coded from red (fully correlated) to blue (fully
anti-correlated). (A) MA-CA (B) CA-p2 (C) p2-NC (D) NC-p1 (E) p1-p6 (F)
RT-RH (G) RH-IN.
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Figure 2.7: Unique intrinsic dynamic coupling revealed by cross-correlations
of the substrate mean square fluctuations. The same cross-correlation analy-
sis in Figure 2.6 was repeated for the substrate residues. The correlation coef-
ficients are contoured and color-coded from red (fully correlated) to blue (fully
anti-correlated). (A) MA-CA, (B) CA-p2, (C) p2-NC, (D) NC-p1, (E) p1-p6, (F)
RT-RH, (G) RH-IN.
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This variation in PR-substrate dynamic coupling is unexpected, especially be-
cause the substrates are only eight amino acids long. CA-p2 and p1-p6 also have
two dynamically independent domains, whereas p2-NC, NC-p1, and RT-RH ex-
hibit autocorrelation among their primed and unprimed residues. The correla-
tions of these substrates with the PR monomers are also distributed throughout
the whole substrate sequence as opposed to clustering in certain residues as for
P3′-P4′ in CA-p2 and P2′-P4′ in RH-IN. Thus, the protease shows a conserved
pattern in maintaining cooperativity with its substrates, but substrates can differ
in their patterns of reciprocating signals from the protease. In other words, mul-
tiple correlation patterns satisfy the dynamic requirements of cooperativity of the
protease. This conclusion is only possible if the residues within a substrate are
interdependent, as shown also by vdW contact analysis.
2.3.4 Dynamics of the Substrate Envelope
Static versus dynamic substrate envelopes. Incorporating protein flexibility
into modeling the substrate envelope may make the envelope a more realistic rep-
resentation of the substrates. Both the static and dynamic substrate envelopes
were computed and the fit of each substrate within these envelopes was evaluated
by using a three-dimensional grid-based approach. The static substrate envelope
was defined using crystal structures of seven substrates in complex with the in-
active D25N protease variant. These crystal structures were used as initial struc-
tures for MD simulations, and the dynamic substrate envelope was defined using
snapshots throughout these trajectories. The substrate volumes lying within the
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dynamic substrate envelope (Vdynin ), within the static substrate envelope (V
stat
in ),
outside the dynamic substrate envelope (Vdynout ), and outside the static substrate en-
velope (Vstatout ) are shown in Figure 2.8, along with the total individual substrate
volumes (Vstattot and V
dyn
tot ). The total volumes of the static and dynamic substrate
envelopes are 1552±100 A˚3 and 1413±66 A˚3, respectively. These numbers show
that the fluctuations around the native state of substrates when bound to the pro-
tease decreased their consensus volume. According to the substrate envelope hy-
pothesis, the volume of a substrate protruding beyond the substrate envelope, i.e.
Vout determines whether or not that substrate will be susceptible to mutations in
the protease. Because the substrates have different total volumes, although Vin is
similar for each, they differ in their Vout. This is reflected in altered interactions
with protease residues (Figure 2.8). Although the dynamic envelope is slightly
smaller than the static envelope, the relative fit of a particular substrate within the
envelope is the same. For a particular substrate the Vout values do not vary dra-
matically throughout the simulations (Figure 2.8). The histograms of Vin, Vout,
and Vtot values for all substrates are shown in Figure 2.9. All substrates exhibit a
unimodal distribution for their Vout values, suggesting that they do not have mul-
tiple preferences in terms of their fit into the substrate envelope. Thus, although
the absolute values of static and dynamic Vout vary, their distribution is similar.
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Figure 2.8: The static and dynamic substrate envelopes share the same over-
all trend in Vout, i.e., the volume lying outside the envelope. The absolute val-
ues, however, vary for static and dynamic cases, most likely due to the dynamic
substrate envelope being more heterogeneous than the static envelope. The dy-
namic envelope is denser in the interior region, which consists of substrate back-
bones. Towards its surface, the dynamic envelope is less well-defined than its in-
terior. This contrast is not as pronounced in the static substrate envelope. Hence,
Vstatout is smaller than V
dyn
out for all substrates.
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Figure 2.8
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Figure 2.9: Distributions of Vout, Vin, and Vtot values throughout the MD
simulations are unimodal for each substrate. Mean of data was shown as a red
line in each histogram.
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Figure 2.9
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How a particular substrate fits within the substrate envelope is influenced by
both substrate dynamics and size. In general, substrates with bulky side-chains
protrude more extensively beyond the substrate envelope than smaller ones. To
test this expectation, the change in Vout was plotted as a function of Vtot (Fig-
ure 2.10). The overall volume of a particular substrate correlates with how much
that substrate protrudes beyond the substrate envelope, fitting a straight line with
R2=0.88. However, CA-p2, NC-p1, and p1-p6 are the exceptions; these substrates
protrude beyond the dynamic substrate envelope more than one would predict
based on their size. This behavior is explained by these substrates being more dy-
namic. Of these three substrates, p1-p6 is the least dynamic and comes closest to
fitting the regression line in Figure 2.10. More dynamic substrates sample a wider
conformational space, resulting in a higher deviation from the crystal structure
and worse fit within the substrate envelope. Mean-square fluctuations of substrate
residues were calculated for non-hydrogen atoms: (1) for the backbone, (2) for
side-chain, and (3) for the entire residue (Figure 2.11). Correlations were then
calculated between these fluctuations and the extent to which each residue pro-
truded beyond the dynamic substrate envelope (Figure 2.12). Among the seven
substrates, the greatest variation is in the center of mass fluctuations of their re-
spective side-chains. CA-p2, NC-p1, and p1-p6 are all more dynamic and protrude
more from the envelope. For MA-CA, on the other hand, both the substrate size
and flexibility/mobility appear to determine how much it protrudes beyond the
substrate envelope.
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Figure 2.10: Substrate size appears to determine how well the substrate fits
within the substrate envelope, except for CA-p2, NC-p1, and p1-p6.
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Figure 2.10
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Figure 2.11: The overall dynamics of the substrate in the active site is domi-
nated by side-chain fluctuations. Mean-square fluctuations of the center of mass
for each substrate are plotted for the backbone, side-chain, and the entire substrate
residue. Two substrates, NC-p1 and CA-p2, which protrude beyond the substrate
envelope more than their total volume, appear to have highly dynamic centers of
mass.
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Figure 2.11
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Figure 2.12: Intrinsic flexibility appears to play an important role in sub-
strate fit within the substrate envelope for substrates MA-CA, CA-p2, NC-p1,
and p1-p6. Correlation coefficients between center of mass fluctuations and Vout
for each substrate are plotted using the backbone, side-chains, and entire substrate
residues.
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Figure 2.13: The dynamic substrate envelope gives a probabilistic consen-
sus volume, which is easier and more accurate to incorporate into structure-
based drug design protocols than the static envelope, which is essentially a
step function. (A) Side and (B) top views of static substrate envelope, (C-D)
respective views of dynamic substrate envelope. The grid cell centers are color-
coded from high occupancy (red) to low occupancy (blue). Both envelopes are
visualized as superposed onto the wild-type PR-CA-p2 structure. The dynamic
substrate envelope is denser in the interior where the backbone is more rigid than
the side-chains. The static substrate envelope can be considered homogeneous
compared to the dynamic envelope. Individual substrate volumes for both the
crystal structures and conformational ensembles are also shown in Figure 2.14.
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Figure 2.14: Static and dynamic shapes of HIV-1 protease substrates. The
vdW volume of each substrate was generated using the map set function of Py-
MOL from the crystal structure and compared to the dynamic vdW volume from
the MD simulation.
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79
Mapping numerous substrate conformations onto a three-dimensional grid de-
fines a probabilistic substrate envelope rather than a deterministic envelope de-
fined by discrete boundaries. The static substrate envelope [7, 8] and the dynamic
substrate envelope are visualized in (Figure 2.13). The probabilistic consensus
volume of the dynamic substrate volume was color-coded by occupancy of the
grid cells, red being highly occupied and blue being less occupied. As in the static
envelope the dynamic substrate envelope is better defined in the positions close to
the cleavage site, but the envelope becomes less well defined at the substrate end
residues (P4 and P4′), which are exposed to solvent and highly flexible. Unlike
in the static representation, this ensemble envelope transitions smoothly with the
relative degree of occupancy.
The dynamic substrate envelope reproduces the essential characteristics of the
static substrate envelope. This more realistic dynamic envelope, however, appears
to be slightly smaller than the static one. The reason is that, in MD simulations,
unlike crystal lattices, atoms are allowed to fluctuate in solvated periodic boundary
conditions, reducing the residence time in the native state. In a crystal structure,
the probability of an atom being in an exact set of coordinates is 0 or 1 unless
the electron density is ambiguous. However, in an ensemble of conformations
generated in MD simulations, this probability ranges from 0 to 1. As a result, the
dynamic substrate envelope is more heterogeneous than the static substrate enve-
lope, being denser in the interior where the backbone is relatively rigid and less
dense towards the solvent-exposed regions where the side-chains are relatively
more flexible. Consequently, the consensus volume, which distinct substrate pep-
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tides adopt, becomes smaller than the crystal structures impose. Therefore, Vdynout
values are greater than those of Vstatout . This finding needs to be considered in de-
signing protease inhibitors, which fit better within the substrate envelope, in order
to minimize the likelihood of the emergence of drug resistance.
Individual analysis of amino acids for their fit into the substrate envelope is
also likely to help understand the nature of and to more realistically characterize
this probabilistic substrate envelope. Amino acids with larger and/or more mo-
bile/flexible side-chains generally contribute more to the overall Vout than other
amino acids in the corresponding residue of other substrates. This observation was
quantified by decomposing the overall protrusion of each substrate into single-
residue protrusions (Figure 2.15). In general, when an amino acid residue of a
particular substrate is larger than the corresponding amino acids in the same po-
sition of the other substrates, that particular substrate tends to protrude more than
others in that position. Another general observation is that asymmetry around the
cleavage site is preserved in terms of residue-based Vout values just as for vdW
contacts and mean-square fluctuations (except for RT-RH which is, to a certain
extent, symmetric in its Vout values, Figure 2.15).
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Figure 2.15: Residue-based Vout values for (A) MA-CA, (B) CA-p2, (C) p2-
NC, (D) NC-p1, (E) p1-p6, (F) RT-RH, and (G) RH-IN. The amino acids with
both flexible and bulky side-chains, i.e., Arg and Lys, tend to protrude beyond the
substrate envelope more than other amino acids with fewer degrees of freedom
and/or smaller side-chains, i.e., Met, and/or Val, Ala. The P4 and P4′ positions
usually have high Vout values, likely due to the less well-defined characteristic of
the substrate envelope in the more solvent-exposed regions of these substrate end
residues. Some substrates, however, have higher Vout values even in their more
buried positions, i.e., P1′ in NC-p1, P1 in p1-p6. According to our hypothesis,
these substrates co-evolve with drug-resistant PR because their greater protrusion
beyond the substrate envelope makes them more sensitive to changes in the PR.
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Figure 2.15
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A detailed look at the individual substrate residues in terms of their fit within
the substrate envelope explains the high-level p1-p6 protrusion despite its smaller
absolute volume compared with the other peptides. The results of this analy-
sis show that p1-p6 protrudes extensively beyond the dynamic substrate envelope
mainly at positions P4, P1, and P4′. (Figure 2.15). The residues at these positions
are Pro, Phe, and Arg, respectively. Arg and Phe are both large amino acids. Pro at
P4 and Arg at P4′ fluctuate the most among the eight residues of the whole p1-p6
sequence. Although the residues at P4 and P4′ protrude beyond the substrate enve-
lope, the co-evolutionary mutations in p1-p6 in response to drug-resistant protease
mutations occur mainly at P1′ and P3′ positions, which fit better within the sub-
strate envelope than P4, P1, or P4′. One possible explanation for this observation
is the interdependency among substrate residues discussed above regarding vdW
and dynamic cross-correlation analysis. Because of this interdependency, a muta-
tion at one position may result in another position fitting better within the substrate
envelope. Future investigation of mutant variants will elucidate this phenomenon.
2.4 Discussion
HIV-1 protease recognizes a conserved shape in non-homologous cleavage
sites, yet the cleavage sites are processed differentially. In this paper, we shed
light on this balance in substrate processing by investigating the effect of sub-
strate dynamics on the protease-substrate interactions, cooperative motions of the
complex systems, and the individual and consensus substrate volumes.
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The protease-substrate interactions in the complex structure are fairly stable
during the time course of MD simulations. Most of the interactions oscillate
around their measured value in the crystal structure. The substrates share a con-
served pattern in their backbone hydrogen bonds. This highly conserved pattern
of backbone hydrogen bonds may be a prerequisite for recognition by the pro-
tease. However, no single side-chain hydrogen bond is conserved across the sub-
strates. This variation in the side-chain hydrogen-bonding pattern likely causes the
substrates to be recognized and/or processed differentially. The balance between
the conserved backbone and varied side-chain hydrogen bonding characteristics
makes the substrates all recognizable to the protease, yet uniquely processed, con-
tributing to the accurate and precise cleavage. One caveat and an area for future
investigations is that all our simulations were performed with the inactive D25N
HIV protease. The active form of the enzyme may alter the overall stability of
the hydrogen bonds, but only would exist transiently before cleavage. In the inac-
tive form simulated here the highly stable and well-conserved backbone hydrogen
bonds contributes to the conserved consensus substrate volume in the active site,
by holding the substrates in place and stabilizing their shared conformational pref-
erence, we expect this conformation is relevant for the active enzyme as well.
The crystal structures provide a good representation of the vdW contact poten-
tials between the protease and the substrates. The extent of the fluctuation around
the crystal structures varies for each protease/substrate residue pair due to the
variations in flexibility across the complex structure. However, the high dynamic
stability of these interactions provides insights to why the rigid structural studies
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have been so far successful in structure-based design of protease inhibitors, es-
pecially considering the fact that protease inhibitors have less degree of freedom
than the natural substrates of HIV-1 protease and therefore less flexible.
The same overall vdW interaction potential with the protease is maintained
by substrates, although each one has a unique residual profile. HIV-1 PR dif-
ferentiates among its natural substrates both in cellular and molecular contexts.
[146, 148] This variation in substrate processing may be influenced by the vari-
ation in the distribution of the interaction potential along the cleavage site. That
is, the diversity in vdW contact potentials of substrate residues may contribute
to preferential substrate recognition. While the overall vdW interaction poten-
tial may be a prerequisite for recognition by the protease, the substrate specific
sequences may regulate their order of processing as well as the reaction kinetics.
The protease residues that interact with the substrates in the active site are
usually evolutionarily conserved since they are functionally important. Drug re-
sistance mutation sites 30, 48, 50, and 82 are among the exceptions. The protease
interacts with one or more of the natural substrates in these positions. As a result,
mutations at positions 30, 50, and 82 are associated with p1-p6 and NC-p1 cleav-
age site mutations. Thus, predicting co-evolution is possible through a combined
investigation of the protease-substrate interaction profiles and evaluating the fit
of the wild-type and co-evolved substrate variants within the substrate envelope.
For example, G48 interacts extensively with the substrates, suggesting the natural
substrates will likely co-evolve when G48 mutates to confer resistance. This pre-
diction awaits statistical confirmation by analyzing viral sequences from patients
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failing therapy for associations between mutations in position 48 and in cleavage
sites. Such predictions may validate our understanding of the substrate recogni-
tion and co-evolution.
The interplay between the conserved and varied properties of non-homologous
cleavage sites enables the substrate processing to be regulated. A sequence is
required to possess conserved properties to be recognized by the HIV-1 PR, yet the
unique properties of the sequences allow for sequential substrate recognition. This
interplay plays a key role in the tight regulation of gag and gag-pro-pol processing.
Non-homologous natural substrates of HIV-1 protease maintain conserved prop-
erties through interdependency within their residues. Among these properties the
most striking one is their ability to adopt a conserved consensus volume in the
active site despite of the lack of an obvious pattern in their sequence. More-
over, these separate substrates have a conserved vdW interaction potential with
the protease, although the interaction profiles along their sequences do not fol-
low a common trend. In addition, these substrates are dynamically coupled to
the same protease residues, although the intrinsic conformational dynamics of the
bound substrates are highly varied.
This adaptation ability, which is common for all non-homologous substrates
investigated in this study, should originate from the interdependent characteristics
of the cleavage site residues. This interdependency enables the protease to rec-
ognize a series of non-homologous sequences as specific substrates. Interdepen-
dency may not be sufficient, but appears to be necessary for substrate recognition.
The combination of the low homology in cleavage site sequences and interdepen-
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dency among their residues appear to contribute to preferential substrate process-
ing by both providing a common basis for substrate specificity and making each
substrate complex unique. This uniqueness results in highly specific sequential
substrate processing.
Dynamic Substrate Envelope: A more realistic representation of the consen-
sus volume. The substrate envelope hypothesis, which is based on crystallographic
data, explains the structural basis for the significantly represented mutation pat-
terns in HIV-1 PR and its substrates. The crystal structure represents a static image
of the native state of a protein. Protein recognition, however, is inherently a dy-
namic event as proteins adopt an ensemble of different conformations around their
native states. Consideration of this flexibility around the native state is essential to
arrive at a better understanding of the specificity determinants of substrate recog-
nition. Introducing molecular dynamics into the substrate envelope allows a more
realistic evaluation of the substrate envelope hypothesis.
Dynamic Substrate Envelope: A potential tool for structure-based drug de-
sign. Combining the molecular dynamics simulations with the three-dimensional
grid-based approach to model the substrate envelope allows the construction of
a probabilistic consensus volume. The edges of this probabilistic consensus vol-
ume are not defined by a sharp cutoff. The dynamic substrate envelope is es-
sentially a smooth probability distribution while the static substrate envelope is a
step function. This probability distribution function can easily be incorporated as
a constraint into the potential functions in structure-based computer-aided drug-
design algorithms, especially grid-based docking softwares like AutoDock. [149]
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Optimizing this energetically smoother potential function to minimize Vout will
be more feasible than fitting candidate inhibitor molecules into a homogeneous
substrate envelope with discrete boundaries. Ultimately, optimizing the dynamic
substrate envelope as a part of a potential function should be an easier and more
accurate way to incorporate the substrate envelope into structure-based drug de-
sign.
2.5 Methods
2.5.1 Protease-Substrate Complex Structures
Seven PR substrates in complex with an inactive, isosteric PR variant were
analyzed. Five of these peptides correspond to substrate sequences within the
gag polyprotein (matrix-capsid [MA-CA], capsid-p2 [CA-p2], p2-nucleocapsid
[p2-NC], nucleocapsid-p1 [NC-p1] and p1-p6), and two correspond to substrate
sequences within the gag-pro-pol polyprotein (reverse transcriptase-RNaseH [RT-
RH] and RNaseH-integrase [RH-IN]). The crystal structures of protease bound
to CA-p2 [6], MA-CA, p2-NC, p1-p6, RT-RH, and RH-IN [7], and NC-p1 [40]
were used as the starting structures in the MD simulations (PDB ID: 1F7A, 1KJ4,
1KJ7, 1KJF, 1KJG, 1KJH, 1TSU).
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2.5.2 MD Simulations
The AMBER [150, 151] simulation package (version 8) with the ff03 force
field was used in all simulations. All structures were solvated explicitly in a trun-
cated octahedron box using the TIP3P water mode. [152] Each system was neu-
tralized by adding Cl− counterions using a Coulombic potential on a 1 A˚ grid with
the preparatory program tleap of AMBER. The initial structures were first min-
imized at constant volume with convergence criteria of either maximum 90,000
cycles or an RMSD value of 0.01 A˚ by steepest descent integration algorithm
for 50 steps and then switched to conjugate gradient algorithm. Bonds involving
hydrogens were constrained by the SHAKE algorithm [153] with a relative geo-
metrical tolerance of 10E-5 A˚. Initial atom velocities corresponding to a temper-
ature of 10 K were generated from a Maxwellian distribution and the temperature
was gradually raised to 300 K. The temperature was maintained at 300 K, and the
pressure was maintained at 1 bar by the Berendsen weak-coupling approach. [154]
Constant pressure-periodic boundary conditions were used with isotropic position
scaling. The particle mesh Ewald (PME) method [155] was used to calculate the
full electrostatic energy of a periodic box, bypassing pair list creation and non-
bonded force and energy evaluation by calling special PME functions to calculate
the Lennard-Jones and electrostatic interactions with a cutoff distance of 9 A˚. A
time step of 2 fs was employed in the Leapfrog integrator. Coordinates and en-
ergies were written every 0.4 ps. All the complexes were simulated for 11 ns,
during which root-mean-square-deviation of backbone trace were monitored for
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convergence. From these simulations, snapshots, taken at regular intervals of 20
ps, were used to model the dynamic substrate envelope, calculate Vin and Vout
and to investigate the molecular interactions. Time evolution of Vout was also
investigated for convergence.
2.5.3 Modeling of the Dynamic Substrate Envelope
The substrate envelope was previously modeled by a quantitative approach
to evaluate the fit of protease inhibitors within the envelope. [41] This approach
was based on a three-dimensional grid with side length 10 A˚ and grid spacing
0.2 A˚ centered on the active site. The occupancy of each grid cell, gijk, was
assigned an initial value of 0. Then the number of times that a grid cell was within
the vdW volume of any peptide was counted. This value eventually became the
overall occupancy of that grid cell. The total volume of the substrate envelope
was essentially the summation over all grid cells with occupancy greater than 0
normalized by the total number of structures used.
In this study, this quantitative model was modified in two essential ways. The
most important modification was to incorporate the molecular dynamics into the
static substrate envelope, which was defined by the PR-substrate complex crystal
structures. To include protein dynamics in this model, multiple conformations for
each PR-substrate complex were extracted from MD trajectories at different time
frames. These conformations were mapped onto the grid centered in the active
site, instead of the crystal structures. This approach defined the dynamic substrate
envelope.
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The second modification was in the method for superimposing these multiple
conformations, which is extremely important as it directly determines the con-
sensus volume. The best way to see conformational differences in a series of
structures is to overlay them using the most rigid nodes in the structure; otherwise
the motion could be propagated to regions that are relatively immobile. Therefore,
instead of overlaying the PR-substrate structures based on their backbone atoms,
we determined the common hinge residues in protease bound to various substrates
from MD trajectories. When the trajectories of all seven complex structures were
analyzed, we found that the most immobile backbone carbons in both monomers
were residues 24-26 and 85-90. Using these residues, all frames were superim-
posed on the wild-type protease-CA-p2 complex structure by the RMSD trajectory
tool of the molecular visualization and trajectory analysis software, VMD. [156]
With this modified model for the substrate envelope, the substrates were then
compared to each other in terms of how much they protruded beyond the static ver-
sus dynamic substrate envelopes. Modeling the substrate envelope using this grid-
based approach allows construction of a probabilistic consensus volume without
sharp edges, which is likely more realistic than the static substrate envelope. The
static substrate envelope was previously modeled using the mathematical formula-
tion below. [41] The volume of an individual substrate lying outside the substrate
envelope, Vout, was calculated as follows, where d is the edge length of a single
grid cell and N is the total number of structures:
V statout =
d3
N
inside∑
i,j,k
(N − gijk) (2.1)
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Similarly, the volume of a substrate that fits within the substrate envelope was
computed as
V statin =
d3
N
inside∑
i,j,k
(gijk) (2.2)
Based on this model, equations were redefined in this study for the dynamic
substrate envelope. For that, the vdW volume of an individual substrate was com-
puted from N1 time points in the MD trajectory of that substrate. An initial value
of 0 was again assigned to each grid cell. Then a value of gijk,1 was incremented
by 1 for every snapshot where a grid cell (i, j, k) was considered to be contained
by a substrate frame if it lay within the AMBER vdW radius of any non-hydrogen
atom of the substrate. The resulting grid occupancy values range between 0 (out-
side all conformations of the individual substrate) and N1 (inside all conforma-
tions of the individual substrate), which is the total number of time points from
a single MD simulation. In the meantime, another variable, gijk,2, was updated
to map the dynamic substrate envelope on the grid. gijk,2 values vary between
0 (outside all conformations of all substrates) and N2 (inside all conformations
of all substrates), which is the total number of frames from all seven simulation
trajectories (= 7×N1).
The effective volume of an individual substrate outside the dynamic substrate
envelope (Vdynout ) was computed by summing the values of the grid points gijk,1
multiplied by N2− gijk,2, which is a measure of how dense the dynamic substrate
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envelope is at that grid point, and normalizing this sum by N1 ×N2:
V dynout = d
3
all grid points∑
i,j,k
(N2 − gijk,2)
N2
× gijk,1
N1
(2.3)
The final result for Vdynout was obtained after conversion to volume by multiply-
ing by the volume of a single grid cell d3. The volume of the substrate within the
dynamic substrate envelope was computed as follows:
V dynin = d
3
all grid points∑
i,j,k
gijk,2
N2
× gijk,1
N1
(2.4)
The total volume is computed by summing all occupancy values, multiplying
by d3, and normalizing by the number of structures used. This total volume for
each substrate was compared to the sum of Vout and Vin as a control for numerical
errors.
These new equations allow comparison of two probabilistic vdW volumes
quantifying the fit of an individual substrates probabilistic vdW volume within
the probabilistic dynamic substrate envelope.
Finally, the defined structures of the peptides in the crystal structures span
slightly different lengths of the cleavage sites including or not including P5 or P5′;
however, these differences likely have minimal or no impact on the bound confor-
mation of the substrate. [40] These positions are not buried in the active site, but
are highly solvent exposed, and in some crystal structures they were not modeled,
as these residues showed no obvious electron density. If P5 or P5′ residues were
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ordered in the crystal structure, they were included in the simulations. However,
they were highly mobile and their coordinates were not included in calculating
the substrate envelope. Only the region P4-P4′ was used for the substrate enve-
lope calculation.
2.5.4 Estimation of the vdW Potential
How a particular ligand interacts with a particular protease variant can be as-
sessed in terms of their detailed molecular interactions, i.e., hydrogen bonds and
vdW contact potentials. While hydrogen bonds can be easily counted based on
distance and geometry, assessing vdW contacts accurately is a more subtle anal-
ysis. A simple distance criterion of 4.2 - 5.0 A˚ often does not accurately dis-
tribute the energetic contributions. In this study, substrate-protease vdW contacts
were estimated by a simplified Lennard-Jones potential V (r) using the relation
4[(σ/r)12 − (σ/r)6], where r is the PR-substrate interatomic distance, and  and
σ are the well depth and hard sphere diameter, respectively, for each PR-substrate
atom pair. V (r) for all possible PR-substrate atom pairs was computed within 5
A˚, and when the distance between non-bonded pairs was less than , V (r) was
considered equal to . Using this simplified potential for each non-bonded PR-
substrate pair,
∑
V (r) was then computed for each protease and each substrate
residue.
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2.5.5 Evaluation of Hydrogen Bonding
A hydrogen bond was defined by a distance between the donor and the accep-
tor of less than 3.5 A˚ and a donor-hydrogen-acceptor angle of greater than 120◦.
The percentage of time these hydrogen bonds existed was calculated using the
trajectory analysis utility ptraj.
2.5.6 Fluctuation Dynamics
To see the similarities and differences in flexible regions of PR-substrate com-
plexes, atomic positional fluctuations were computed based on MD simulation
trajectories. The cross-correlations of these fluctuations were also calculated to
assess how the protease and substrate dynamics are coupled and if the protease
dynamics is affected in a different manner by binding of different substrates. The
normalized cross-correlations of residue pairs were defined as
COi,j =
〈∆Ri∆Rj〉
〈∆R2i 〉1/2 〈∆R2j 〉1/2
(2.5)
where ∆Ri is the fluctuation in the position vector R of site i and ∆Rj is the
fluctuation in the position vector R of site j. The brackets represent time averages
over recorded snapshots. The cross-correlations vary in the range [-1, 1], with
the lower and upper limits indicating fully anti-correlated and correlated atomic
fluctuations, respectively. COi,j = 0 gives uncorrelated atomic fluctuations.
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2.6 Supporting Information
Assessing the impact of structural alignment on the substrate envelope
Structural alignment may affect the shape of the dynamic substrate envelope.
Aligning the structures on their mobile residues may misrepresent the rigid re-
gions as being highly dynamic and reduce the consensus volume defined as the
volume occupied by the majority of the conformers. Hence, the alignment should
be based on relatively less mobile residues. However, even using different sub-
sets of these relatively less mobile regions as reference for structural alignment
could have affected the results. To address this issue, we redefined the wild-type
dynamic substrate envelope based on five separate structural alignments using the
Cα atoms of (1) all protease residues (1-99), (2) residues on the dimerization in-
terface excluding the flaps as flaps are highly mobile (1-9, 86-99), (3) the least
mobile residues in the MD simulations (24-26, 86-90), (4) catalytic triad (25-27),
and finally (5) only the highly flexible GLY-rich region of the flaps (48-51). The
purpose of the first four alignments was to probe for the effect of aligning dif-
ferent sets of rigid residues on the dynamic substrate envelope. The last one was
performed to see the effect of using more mobile residues during superposition on
the shape of the dynamic substrate envelope.
All the trajectories were aligned onto the wild-type CA-p2 crystal structure
using the VMD software. The substrate conformers from the aligned trajectories
were loaded to PyMOL and the van der Waals volume maps were generated for
each substrate and the dynamic substrate envelope. The consensus vdW volumes
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defined by each set of conformers are illustrated in Figure 2.16.
These results show that the shape of the dynamic substrate envelope is not
sensitive to the selection of the reference residues for structural alignment as long
as these reference residues are not in a highly mobile region of the protease. How-
ever, aligning the structures on the very flexible GLY-rich flap residues resulted in
a slightly smaller dynamic substrate envelope as expected.
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Figure 2.16: Effect of structural alignment on the substrate envelope. The
effect of residue selection on the shape of the dynamic substrate envelope was as-
sessed by aligning the trajectories using the Cα atoms of all protease residues,
dimerization interface excluding the flaps, catalytic triad, and finally only the
flaps. The results showed that the shape of the dynamic substrate envelope is
not sensitive to the selection of the reference residues for structural alignment as
long as these reference residues are not on a highly mobile region of the protease.
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Figure 2.16
Chapter III
HIV-1 Protease and Substrate
Co-evolution Validates the Substrate
Envelope as the Substrate
Recognition Pattern
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3.1 Abstract
Drug resistance of HIV-1 protease alters the balance in the molecular recogni-
tion events in favor of substrate processing versus inhibitor binding. To develop
robust inhibitors targeting ensembles of drug resistant variants, the code of this
balance needs to be cracked. For this purpose, the principles governing the sub-
strate recognition are required to be revealed. Previous crystallographic studies
on the wild-type protease-substrate complexes showed that the substrates have
a conserved consensus volume in the protease active site despite their low se-
quence homology. This consensus volume is termed as the substrate envelope.
The substrate envelope was recently reevaluated by taking the substrate dynamics
into account and the dynamic substrate envelope was reported to better define the
substrate specificity for HIV-1 protease. Drug resistance occurs mostly through
mutations in the protease, occasionally accompanied by cleavage site mutations.
In this study, three co-evolved protease-substrate complexes (AP2V NC-p1V 82A,
LP1′Fp1-p6D30N/N88D and SP3
′Np1-p6D30N/N88D) were investigated for structural
and dynamic properties by molecular modeling and dynamics simulations. The
results show the substrate envelope is preserved by these cleavage site mutations
in the presence of drug-resistance mutations in the protease, if not enhanced. This
study on the conformational and mutational ensembles of protease-substrate com-
plexes validates the substrate envelope as the substrate recognition motif for HIV-1
protease. The substrate envelope hypothesis allows for the elucidation of possible
drug resistance mutation patterns in the polyprotein cleavage sites.
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3.2 Introduction
Human immunodeficiency virus type-1 (HIV-1) protease (PR) is a key en-
zyme in the viral life cycle that processes the Gag and Gag-Pro-Pol viral polypro-
teins at 12 cleavage sites, yielding mature, infectious virions. [10] HIV-1 PR, a
99 residue, homodimeric aspartyl protease, [157, 158] is essential for viral matu-
ration, [10] hence is a main drug target. The US Food and Drug Administration
(FDA) has approved nine protease inhibitors (PIs) for clinical use. These PIs,
used as part of highly active antiretroviral therapy, have significantly improved
the management of disease condition by lengthening the life-span and increasing
the quality of life of HIV-infected patients. [159] However, the high rate of viral
replication [22] combined with the lack of proofreading mechanism in viral re-
verse transcriptase [160] generates massive amounts of genetically distinct viral
variants. Within these viral quasispecies, the selective pressure of drug therapy
populates the viral variants that are not completely inhibited by antiviral drugs
targeting viral enzymes.
At a molecular level, drug resistance reflects a subtle change in the balance
of enzyme recognition events, in favor of natural substrate processing versus in-
hibitor binding. Drug-resistant protease variants have mutations that significantly
alter inhibitor binding but do not drastically change substrate processing. In addi-
tion, emergence of resistance to protease inhibitors does not always depend solely
on protease mutational plasticity. The natural substrates can also mutate in associ-
ation with drug therapy. [29, 30, 37, 161] Two examples of this protease-substrate
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co-evolution are NC-p1 and p1-p6, two cleavage sites on the Gag polyprotein that
co-evolve with the viral protease to confer resistance to protease inhibitors. In
the NC-p1 cleavage site, Ala in the P2 position mutates to a Val in response to the
V82A multi-drug-resistance protease mutation (AP2V NC-p1V 82A). [28,29,37,162]
The p1-p6 cleavage site mutates predominantly at the P1′ or P3′ positions [39]
associated with the protease double mutation D30N/N88D (LP1′Fp1-p6D30N/N88D
and SP3′Np1-p6D30N/N88D), which is a signature of nelfinavir treatment. [163,164]
Replicative capacity assays showed that the D30N/N88D viruses with the com-
pensatory mutations in p1-p6 do not have improved fitness relative to viruses with
mutations in the protease alone. [32] V82A virus has an even lower replicative
capacity in combination with mutations at Gag 431, which corresponds to Ala-P2
of NC-p1 cleavage site, compared to those without this mutation. [32] However,
these co-occuring protease-substrate mutations were shown to significantly affect
the protease inhibitor susceptibilities. [32]
The structural basis for protease-substrate co-evolution in AP2V NC-p1V 82A
variant came from analyzing the crystal structures of inactive D25N wild-type
(WT) and V82A HIV-1 protease in complex with their respective WT and AP2V
mutant NC-p1 substrates. [7] The crystal structures revealed that WTNC-p1 binds
to HIV-1 protease less optimally than AP2V NC-p1 with fewer hydrogen bonds
and fewer van der Waals (vdW) contacts. In addition, Ala-P2 was observed to
incompletely fill the P2 pocket. For protease-substrate co-evolution in LP1′Fp1-
p6D30N/N88D or SP3
′Np1-p6D30N/N88D variants, however, no experimentally de-
termined structures have been reported so far.
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Completely understanding the molecular basis of substrate recognition is cru-
cial to develop robust inhibitors that better compete with natural substrates of
highly resistant protease variants. Co-evolution of protease and the natural sub-
strates allows for the study of the interdependency between HIV-1 protease and
its natural substrates, which facilitates the substrate recognition. The principles
underlying substrate recognition by HIV-1 protease are not sequence specific be-
cause the amino acid sequences of the cleavage sites on the Gag and Gag-Pro-Pol
polyproteins do not have an obvious sequence homology. These non-homologous
substrates, however, occupy a conserved consensus volume in the binding site of
the protease in crystal structures. [7, 8] This conserved three-dimensional shape,
describing the “substrate envelope”, was recently redefined by incorporating the
substrate dynamics within the protease binding site. [165] In that previous study,
the dynamic substrate envelope was shown to better define the substrate specificity
for HIV-1 protease, compared to the static substrate envelope.
In the present study the dynamics of three separate examples of HIV-1 protease-
substrate co-evolution were investigated, to elucidate the interdependence of sub-
strate recognition with mutations in the protease. The molecular interactions of
each set were analyzed, including with respect to the dynamic substrate enve-
lope. [165] The compensatory mutations in the cleavage sites were shown to fit
within the substrate envelope better than WT substrates. This was achieved by a
variety of changes in interactions, but not in one conserved manner for all three
substrates. Thus, the substrate envelope is preserved by the cleavage site muta-
tions in the presence of drug-resistance mutations in the protease, validating the
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substrate envelope as the substrate recognition pattern for HIV-1 protease, whether
or not the substrate evolves. The dynamic substrate envelope is potentially a pow-
erful tool to predict the co-evolution of the cleavage sites of HIV-1 protease.
3.3 Results and Discussion
The three separate cases of HIV-1 protease-substrate co-evolution investigated
in this study are listed in Table 3.3. The variants of the protease and the cleav-
age site are denoted by a subscript and a superscript, respectively. Details of the
nomenclature used throughout the paper are described in the section 3.5 section.
3.3.1 Fit within the Dynamic Substrate Envelope
Substrate fit within the binding groove was compared over the course of molec-
ular dynamics (MD) simulations with and without the effect of drug resistance by
first calculating the substrate volume within and outside the dynamic substrate
envelope and the overall vdW interactions of the substrate with the protease (Fig-
ure 3.1). Substrate volume in the binding groove can be analyzed in two com-
ponents: the substrate volume protruding beyond the substrate envelope (Vout),
and the substrate volume lying within the substrate envelope (Vin). High degree
of protrusion beyond the substrate envelope (quantified as high Vout values) was
shown in our earlier work to indicate substrates susceptible to drug-resistance
mutations in the protease, e.g., both p1-p6 and NC-p1 substrates have higher Vout
values than expected based on their molecular volume. [165]
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The current study shows that compensatory mutations in the cleavage sites
optimize the portion of the substrate volume that stays within the substrate en-
velope. This observation is quantified in Figure 3.1A, B, and C where Vin is
plotted for three cases of co-evolution (AP2V NC-p1V 82A, LP1
′Fp1-p6D30N/N88D
and SP3′Np1-p6D30N/N88D) with reference to their respective wild-type complex
structure (∆Vin = V MUTin − V WTin ). In each case, the substrate mutation compen-
sates for the decrease in Vin as a result of primary protease mutation.
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Figure 3.1: Protease-substrate co-evolution preserves the dynamic substrate
envelope. ∆Vin, ∆Vout and overall protease-substrate ∆vdW interactions are
shown in panels A-C, D-F, and G-I, respectively. The difference in these three
properties for each protease-substrate variant compared to the wild-type protease-
substrate complex is plotted as bars. Labels of the x-axes correspond to the mu-
tations in either the protease (V82A or D30N/N88D) or the cleavage site (AP2V,
LP1′F or SP3′N) or both.(∆Vin = V MUTin − V WTin , ∆Vout = V MUTout − V WTout ,
∆vdW=vdWMUT -vdWWT )
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Figure 3.1
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In co-evolution of NC-p1 cleavage site, ∆Vin increases from -26.3±1.9A˚3 in
WTNC-p1V 82A complex to 4.2±1.8 A˚3 in AP2V NC-p1V 82A (Figure 3.1A) while
in co-evolution of p1-p6 cleavage site, ∆Vin increases from -122.2±1.5 A˚3 in
WTp1-p6D30N/N88D to 8.2±1.3 A˚3 in LP1′Fp1-p6D30N/N88D (Figure 3.1B) and to
-48.5±1.8 A˚3 in SP3′Np1-p6D30N/N88D (Figure 3.1C).
AP2V NC-p1 is slightly larger than WTNC-p1 because of two additional methyl
groups on the side chain. Despite 2.5% larger volume, AP2V NC-p1 fills the dy-
namic substrate envelope better than WTNC-p1, i.e., the improvement in Vin
(30.5±2.6 A˚3, Figure 3.1A) is more pronounced than the increase in Vout (6.9±2.8
A˚3, Figure 3.1D) in AP2V NC-p1V 82A compared to WTNC-p1V 82A. Similarly, in
the presence of D30N/N88D mutations in the protease, LP1′F and SP3′N sub-
stitutions in p1-p6 improve Vin by 130.4±2.0 A˚3 (Figure 3.1B) and 73.7±2.3
A˚3 (Figure 3.1C), respectively, making the substrate better fill the substrate en-
velope. On the other hand, the reduction in Vout is 96.2±2.8 A˚3 (Figure 3.1E)
and 11.8±3.3 A˚3 (Figure 3.1F) upon LP1′F and SP3′N, respectively, occurs in
the context of D30N/N88D protease variant. These compensatory mutations in
p1-p6 optimize the substrate fit within the envelope by both increasing Vin and
decreasing Vout.
Preservation of substrate envelope upon compensatory cleavage site muta-
tions in drug-resistant protease variants is visualized in Figure 3.2 in the case of
LP1′Fp1-p6D30N/N88D. The altered fit of p1-p6 within the dynamic substrate enve-
lope in WTp1-p6D30N/N88D (Figure 3.2) and LP1
′Fp1-p6D30N/N88D (Figure 3.2B)
complexes is illustrated by mapping the ∆Vin grid matrix onto the co-crystal struc-
110
ture. The negative values of the difference matrix ∆Vin, shown in cyan, corre-
spond to the regions where the substrate in mutant complex fits poorly within
the dynamic substrate envelope compared to WTp1-p6WT . The positive values
of the difference matrix ∆Vin, shown in orange, correspond to the regions where
the substrate in mutant complex fits better within the dynamic substrate envelope
compared to WTp1-p6WT . The improvement in ∆Vin upon the compensatory mu-
tation in the p1-p6 cleavage site shown in Figure 3.1B is reflected by the complete
loss of negative regions in Figure 3.2B.
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Figure 3.2: The compensatory mutation LP1′F in the p1-p6 cleavage site pre-
serves the substrate envelope in drug-resistant D30N/N88D protease variant.
∆Vin is visualized for (A) WTp1-p6D30N/N88D and (B) LP1
′Fp1-p6D30N/N88D by
mapping the difference matrix (VMUT -VWT ) onto the co-crystal structure. The
negative values of the difference matrix ∆Vin, shown in cyan, correspond to the
regions where the substrate in mutant complex fits poorly within the dynamic sub-
strate envelope compared to WTp1-p6WT . The positive values of the difference
matrix ∆Vin, shown in orange, correspond to the regions where the substrate in
mutant complex fits better within the dynamic substrate envelope compared to
WTp1-p6WT . To get clear images, only the grid cells with an occupancy factor
of 0.5 or higher are visualized. The protease dimer is represented as light gray
ribbon. p1-p6 side-chains are shown as sticks. In both panels, the substrate is
oriented from N- to C-terminus (left to right). The figure was prepared with the
molecular visualization software, PyMOL. [166]
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Figure 3.2
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3.3.2 vdW Interactions Between the Protease and Substrates
Protease and/or cleavage-site mutations conferring drug resistance do not dras-
tically alter the overall vdW contact potential between the protease and substrates
(Figure 3.1G-I). This result is consistent with our earlier observation20 that a con-
served consensus overall vdW interaction potential might be a prerequisite for a
sequence to be recognized by the protease. This observation, combined with the
ability of drug-resistant protease variants to still process cleavage sites, leads to the
expectation that cleavage sites in the resistant viruses will naturally maintain this
optimal overall interaction potential. In fact, this optimal vdW potential is pre-
served by all the drug-resistant protease-substrate complex variants investigated
in this study, with overall ∆vdW on the order of ≈2.5 kcal/mol within the range
of WT contact potential (Figure 3.1G-I, middle bars). For example, the protease-
substrate vdW interaction potential of WTp1-p6D30N/N88D is 1.9±0.2 kcal/mol
(Figure 3.1H) less favorable than that of WTp1-p6WT . The loss of this interaction
due to D30N/N88D protease mutations is restored with LP1′F and SP3′N substi-
tutions in the cleavage site to a level of -1.7±0.2 (Figure 3.1H) and -3.2±0.2 (Fig-
ure 3.1I) kcal/mol, respectively. In contrast, WTNC-p1V 82A has -4.6±0.2 kcal/mol
more favorable vdW interactions compared to WTNC-p1WT (Figure 3.1G). NC-
p1 is inherently a very flexible substrate due to the P3′-Gly and P4′-Lys residues.
Substitution of Val-82 to an Ala results in a larger local volume for this flexible
peptide to sample. These conformations may not be accessible to the peptide in
WTNC-p1WT complex because of the additional methyl groups in Val-82. Provid-
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ing extra volume in the variant allows the peptide to sample conformations that
have more favorable interactions with the protease, as is evident by the change in
vdW interaction potential.
AP2V mutation in NC-p1 substrate brings down vdW interactions by 1.1±0.3
kcal/mol, but still keeps it more favorable than the WT level. This increase in the
overall vdW contact potential might contribute to AP2V NC-p1 being better recog-
nized than WTNC-p1 by the wild-type protease. [161] However, the processing
efficiency of each cleavage site should be optimal for viral fitness. A significantly
lower efficiency leaves unprocessed viral polyproteins packaged in the virion,
while a significantly higher efficiency might interfere with the accurate and precise
regulation of Gag and Gag-Pro-Pol processing. NC-p1 is the rate-limiting cleav-
age site in HIV-1 Gag during processing by the viral protease. [167, 168] Better-
than-optimum cleavage efficiency for this site might introduce temporal impre-
cision in the regulation of its hydrolysis, leading to immature Gag processing.
This may be the reason why (1) on average AP2V NC-p1V 82A variants have lower
replicative capacity than WTNC-p1V 82A16, and (2) the more efficiently cleaved
AP2V NC-p1 is not highly populated in the absence of drug resistance mutations in
the protease. [40]
Although drug resistance does not severely impact the overall protease-substrate
contact potential, the vdW contact potential profiles of substrate residues with any
protease atom significantly deviate from the WT substrate behavior (Figure 3.3).
The nature of this deviation, however, is not shared by all substrate variants. The
loss of interactions on the primed side of the NC-p1 cleavage site is compensated
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by the gain of interactions on the unprimed side (Figure 3.3A). This compensation
supports that the substrate amino acid residues are interdependent despite the very
short substrate sequence. Consequently, this interdependence among the amino
acid residues helps maintain the overall vdW interaction potential at an optimal
level within ≈3 kcal/mol of the WT range. [165]
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Figure 3.3: Residue-based view of the effect of drug resistance on protease-
substrate vdW interactions. Substrate residual ∆vdW interactions with the pro-
tease for (A) NC-p1 variants (WTNC-p1V 82A, AP2V NC-p1V 82A, AP2V NC-p1WT ),
(B) the first set of p1-p6 variants (WTp1-p6D30N/N88D, LP1
′Fp1-p6D30N/N88D, LP1
′Fp1-
p6WT ) and (C) the second set of p1-p6 variants (WTp1-p6D30N/N88D, SP3
′Np1-
p6D30N/N88D, SP3
′Np1-p6WT ) with reference to their respective WT complexes
(∆vdw=vdWMUT -vdWWT ).
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In contrast, the compensatory mechanism is more symmetric in the p1-p6
cleavage site than in NC-p1 (Figure 3.3B, and C). WTp1-p6D30N/N88D loses 4.3±2.0
kcal/mol vdW interactions at the P4′ position and gains comparable interactions
at the P2 position (-4.0±0.9 kcal/mol, Figure 3.3B, blue bars). This severe devi-
ation from the WT profile at these two positions is moderated with either LP1′F
or SP3′N substitutions in p1-p6. LP1′Fp1-p6D30N/N88D has more favorable P4′
interactions than WTp1-p6D30N/N88D, although the loss of interaction potential at
this position is considerably higher than WTp1-p6WT . Loss of interactions at P4′
position in LP1′Fp1-p6D30N/N88D with respect to WTp1-p6WT (2.3±0.1 kcal/mol,
Figure 3.3B, green bars) is compensated by the gain of interactions at two other
substrate residues, P1′ (-2.3±0.1 kcal/mol) and P2′ (-1.1±0.1 kcal/mol).
In addition, P2 in LP1′Fp1-p6D30N/N88D does not interact with the protease as
favorably as P2 in WTp1-p6D30N/N88D (∆vdW =-4.0±0.1 kcal/mol), even though
P2 is invariant. The dramatic change in the vdW contacts of this invariant position
is caused by the side chain rearrangements within the substrate and the binding
site upon LP1′F. The conformational flexibility of the substrate combined with the
interdependency within the substrate sequence allows for the altered vdW interac-
tions in an invariant position (Asp P2) as a result of a mutation in another position,
LP1′F (Figure 3.4), within the cleavage site. Thus, a single mutation manages to
alter the whole vdW interaction profile along the sequence.
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Figure 3.4: The compensatory mutation in the p1-p6 cleavage site, LP1′F,
causes major structural rearrangements reducing vdW interaction potential
of the invariant Asp P2. The side chains of the protease residues that interact
with Asp P2 at 10 ns are displayed as dotted spheres for (A) WTp1-p6D30N/N88D
and (B) LP1′Fp1-p6D30N/N88D. The substrate residues were colored based on the
vdW interaction potential with any protease atom and the protease residues were
colored based on the vdW interaction potential with any substrate atom. The
substrate residues are shown in italic and the mutated residues in bold.
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In addition, SP3′N has a similar impact on the per residue vdW interaction
profile of p1-p6. Compared to the WTp1-p6WT complex, P1 and P1′ in SP3
′Np1-
p6D30N/N88D have slightly less favorable interactions with the protease, on the
order of total ≈1 kcal/mol (Figure 3.3C). This decreased interaction, however,
is compensated by the improved contact potentials of the surrounding residues,
P3, P2, P2′ and P3′. Overall, the vdW contacts are preserved, however through
a different interaction profile, likely facilitated by the interdependence within the
substrate sequences.
3.3.3 Hydrogen Bonds between the Protease and Substrates
The hydrogen bonds formed between the protease and substrates were ana-
lyzed in two groups: hydrogen bonds formed by the (1) substrate backbone, and
(2) substrate side chains. The backbone hydrogen bonds are conserved among
various natural substrates, while no single side-chain hydrogen bond is shared by
all or most of the substrates. [7,165] Therefore, hydrogen bonds between the side
chains and any protease atoms are more likely than the backbone hydrogen bonds
to contribute to substrate specificity. [165] The less specific backbone hydrogen
bonds are not altered by drug-resistance mutations in the protease and/or substrate
despite remarkable local conformational rearrangements (Figure 3.5A-D). The
three complexes of WTp1-p6WT , WTp1-p6D30N/N88D and LP1
′Fp1-p6D30N/N88D
are superimposed to highlight these rearrangements (Figure 3.5A and E.). The
percentage of time the hydrogen bonds existed throughout the simulations is listed
in Table 3.1. The most stable NC-p1 backbone hydrogen bonds are formed be-
122
tween P2 and G48, P3′ and G48′ and P2′ and G27′ existing more than 90% of the
time in most variants. These hydrogen bonds should contribute to stabilizing the
substrate when bound to the protease active site. The hydrogen bonds formed by
NC-p1 side-chains, on the other hand, are more variable (second main column,
Table 3.1). The bonds formed in WTNC-p1WT between the side chain of P1 and
I50, N25′ and G27 were not stable throughout the MD trajectories. However, both
AP2V NC-p1WT and AP2V NC-p1V 82A has more consistent hydrogen bonds formed
by P1 and I50 and G27. These presumably stronger hydrogen bonds might be
important for the increased substrate affinity in both AP2V NC-p1WT and AP2V NC-
p1V 82A variants, consistent with AP2V NC-p1 being more efficiently cleaved than
WTNC-p1 by the wild-type HIV-1 protease. [161]
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Figure 3.5: Substrate backbone hydrogen bonds are robust against the local
conformational rearrangements due to drug resistance mutations. The side
chain hydrogen bonding pattern, however, is altered by protease mutations but re-
stored by cleavage site mutation. Coordinates of WTp1-p6WT , WTp1-p6D30N/N88D,
and LP1′Fp1-p6D30N/N88D after 10 ns were superimposed to reveal the local con-
formational rearrangements due to the drug resistance mutations (A, E). Substrate
backbone (A) and side chain (E) atoms are displayed as sticks. The backbone
and side chain hydrogen bonds are shown as dashed lines for (B and F) WTp1-
p6WT , (C and G) WTp1-p6D30N/N88D, and (D and H) LP1
′Fp1-p6D30N/N88D. The
substrate residues are labeled in italic, mutated residues in bold.
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WTp1-p6WT forms substrate backbone hydrogen bonds at P1 and P3′ positions
(Figure 3.5B). The majority of these bonds are preserved in drug-resistant WTp1-
p6D30N/N88D although the bond between backbone nitrogen of P1 and backbone
oxygen of G27 no longer exists in WTp1-p6D30N/N88D (Figure 3.5C). This loss of
a hydrogen bond, however, is compensated by the hydrogen bonds newly formed
by substrate P3 and P2′ positions. LP1′Fp1-p6D30N/N88D has almost the same
pattern of hydrogen bonding network as WTp1-p6WT (Figure 3.5D). In addition,
the P1, P2′ and P3′ positions make backbone hydrogen bonds with the protease
in SP3′Np1-p6D30N/N88D (Table 3.1). In complex with the WT protease, these
mutant substrates have more backbone hydrogen bonds with decreased percent
time of existence. Drug resistance, conferred by mutations in the protease and/or
the substrate, does not alter the backbone hydrogen bonding pattern drastically.
Even though the side chains vary by drug resistance, the substrates can still form
these less specific hydrogen bonds with the protease, presumably stabilizing the
substrates in the binding groove.
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Table 3.1: Effect of drug resistance on intermolecular hydrogen bonding pattern
Backbone Side-chain
WT V82A AP2V/V82A AP2V WT V82A AP2V/V82A AP2V
P3...D29 <50 92.3 99.8 99.1 P4...D30 62.7 73.8 52.4 79.8
P2...G48 97.6 80.1 98.7 100.0 P1...I50 <50 <50 98.4 95.5
P1...N25 67.5 83.7 59.6 54.4 P1...N25′ 63.1 <50 <50 <50
P1...N25′ <50 79.1 <50 <50 P1...G27 <50 <50 77.883.6
P2′...G27′ 86.0 91.5 53.8 <50
P2′...D29′ 58.0 <50 <50 <50
P3′...G48′ 96.9 92.1 78.2 66.2
P4′...G48′ <50 <50 62.0 <50
WT D30N/N88D D30N/N88D/LP1′F LP1′F WT D30N/N88D D30N/N88D/LP1′F LP1′F
P4...R8′ <50 <50 <50 <50 P2...N25 <50 84.7 <50 <50
P3...G48 <50 90.7 <50 55.5 P2...D30 <50 83.1 <50 <50
P3...D29 <50 <50 <50 <50 P2...I85 <50 52.7 <50 <50
P2...G48 <50 <50 <50 72.4 P2′...D29′ 91.6 81.3 74.7 86.8
P1...G27 97.3 <50 98.8 97.1 P2′...D30′ 89.1 87.6 86.8 81.8
P1...N25′ 72.9 95.9 81.2 64.3 P4′...D30′ 96.0 <50 <50 91.1
P2′...G27′ <50 91.5 76.5 94.9
P3′...G48′ 99.8 98.3 99.7 99.3
P4′...D29′ <50 <50 <50 <50
WT D30N/N88D D30N/N88D/SP3′N SP3′N WT D30N/N88D D30N/N88D/SP3′N SP3′N
P4...R8′ <50 <50 <50 60.7 P2...N25 <50 84.7 57.8 <50
P3...G48 <50 90.7 <50 70.0 P2...D30 <50 83.1 60.7 <50
P3...D29 <50 <50 87.3 59.1 P2...I85 <50 52.7 <50 <50
P2...G48 <50 <50 <50 83.3 P2′...D29′ 91.6 81.3 87.1 58.0
P1...G27 97.3 <50 <50 98.2 P2′...D30′ 89.1 87.6 96.2 61.1
P1...N25′ 72.9 95.9 92.4 89.1 P4′...D30′ 96.0 <50 <50 98.2
P2′...G27′ <50 91.5 98.4 97.5
P3′...G48′ 99.8 98.3 93.1 88.7
P4′...D29′ <50 <50 63.3 50.7
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Table 3.2: Effect of drug resistance on intramolecular substrate
hydrogen bonding pattern. Duration of hydrogen bonds within sub-
strates that exist greater than 50% of the time are shown for substrate
variants. The table is color-coded based on the frequency of hydro-
gen bonds as a spectrum; red being highest frequency and green being
lowest frequency hydrogen bonds.
WTNC-p1WT WTNC-p1V 82A AP2V NC-p1V 82A AP2V NC-p1WT
P1(N)...P3(O) 61.8 <50 <50 <50
P1(ND2)...P3(OE1) <50 <50 78.0 81.6
WT p1-p6WT WT p1-p6D30N/N88D LP1
′F p1-p6D30N/N88D LP1
′F p1-p6WT
P2(O)...P1′(N) <50 79.9 <50 <50
P2(OD1)...P1′(N) 87.3 <50 83.7 69.0
P3′(O)...P2′(NE2) <50 61.6 73.7 <50
WT p1-p6WT WT p1-p6D30N/N88D SP3
′Np1-p6D30N/N88D SP3
′Np1-p6WT
P2(O)...P1′(N) <50 79.9 <50 <50
P2(OD1)...P1′(N) 87.3 <50 <50 71.6
P3′(O)...P2′(NE2) <50 61.6 <50 <50
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WTp1-p6D30N/N88D has consistent protease-substrate side-chain hydrogen bonds
formed by P2 and P2′ residues (Figure 3.5G). P2′ side-chain hydrogen bond is not
affected by drug resistance (Figure 3.5F, H). However, both SP3′N and LP1′F
substitutions weaken P2 hydrogen bonds from ≈85% to 60% and less than 50%,
respectively. These three P2 bonds (P2...N25, P2...D30, and P2...I85) do not occur
in the WT complex, either. The viral advantage of weakening highly consistent
hydrogen bonds formed in LP1′Fp1-p6D30N/N88D could be to optimize substrate
binding for optimal viral fitness. Stronger hydrogen bonding between the pro-
tease and substrate could negatively impact substrate turnover, possibly resulting
in product inhibition.
In WTp1-p6WT , the substrate side chains have very consistent hydrogen bonds
between P2′-D29′, P2′-D30′, and P4′-D30′ existing more than 90% of the time
(Figure 3.5F). These hydrogen bonds are preserved in all mutant complexes from
75 to 96% of the time; hence they should be crucial for the recognition of p1-p6
substrate (Figure 3.5G and H).
The natural substrates, in their bound conformation, have intramolecular hy-
drogen bonds that stabilize the preferred conserved consensus volume. [165] The
drug-resistant protease-substrate complexes were evaluated for these intramolec-
ular hydrogen bonds (Table 3.2). In WTNC-p1WT , backbone nitrogen of the P1
position makes a hydrogen bond with the backbone oxygen of P3 position. This
bond is lost upon V82A mutation in the protease, but compensated by the sec-
ondary mutation AP2V in AP2V NC-p1V 82A. Similarly, in LP1
′Fp1-p6D30N/N88D,
LP1′F mutation restores the hydrogen bond between P2 and P1′ positions of the
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substrate that is lost upon D30N/N88D protease mutations in WTp1-p6D30N/N88D.
In SP3′Np1-p6D30N/N88D complex, on the other hand, no intramolecular hydro-
gen bond exists more than 50% of the time, suggesting that these hydrogen bonds
are not necessary for this variant to adopt the required three-dimensional shape
that fits the binding groove. These results point out that maintaining a stable in-
tramolecular hydrogen bonding network is only one of the various mechanisms
through which the recognition motif is preserved by compensatory mutations.
3.3.4 Analysis of Atomic Fluctuations
The interdependency within the substrate residues was earlier shown [165]
to play a key role in maintaining the balance between the conserved (i.e. their
consensus volume and overall vdW contact potential with the protease) and var-
ied (i.e. distribution of vdW contact potential across the substrate sequence and
variations in the mean square fluctuations of the substrate residue side-chains)
properties of the substrates. The dynamic cooperativity within the substrate se-
quence as a way to maintain this balance was evaluated for drug-resistant variants
by computing the cross-correlation of the atomic positional fluctuations within the
substrate. The heat maps for the NC-p1 and p1-p6 complexes are shown in Fig-
ure 3.6 and Figure 3.7, respectively, where the correlation coefficients are color
coded as a red to blue spectrum for full positive correlation to full negative correla-
tion in the fluctuations. This analysis showed that WTNC-p1V 82A is less coopera-
tive compared to WTNC-p1WT (Figure 3.6A versus B). The cleavage site mutation
AP2V appear to improve cooperativity (increased red regions in Figure 3.6C). The
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P4-P4′ residues of AP2V NC-p1WT are even more interdependent. This enhanced
intrinsic cooperativity in AP2V NC-p1 should cause better communication within
the substrate residues. The fact that AP2V NC-p1 is a better-processed substrate for
even the wild-type protease supports that this interdependency within the substrate
residues is a critical aspect of efficient substrate processing.
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Figure 3.6: Effect of drug resistance on intrinsic dynamic cooperativity of
NC-p1 substrate variants. The cross-correlations of the atomic positional fluc-
tuations are color-coded (red: positively correlated, blue: negatively correlated).
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Figure 3.6
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p1-p6 substrate appears to be highly cooperative in both LP1′Fp1-p6D30N/N88D
and SP3′Np1-p6D30N/N88D complexes compared to WTp1-p6WT (Figure 3.7). In
WTp1-p6WT complex, the regions P4-P2′ and P3′-P4′ fluctuate almost like two
independent domains while the residues in each region are highly correlated with
other residues in the same region (Figure 3.7A). The same substrate sequence be-
haves slightly differently in WTp1-p6D30N/N88D (Figure 3.7B), where the P4-P1
and P1′-P4′ residues define the two regions that fluctuate independently. Upon
cleavage site mutations, these two distinct regions in the heat maps (Figure 3.7C
and E) become less obvious. The cooperativity is evenly distributed across the
substrate sequence through neighboring residues. These results show that corre-
lated motion of the peptide sequence may be important to maintain the interde-
pendent nature of the cleavage sites. In principle, both the substrate structures and
protease-substrate interactions should have an impact on this interdependence.
The alterations in the substrate conformations and protease-substrate interactions
are not independent but rather highly interdependent.
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Figure 3.7: Effect of drug resistance on intrinsic dynamic cooperativity of
p1-p6 substrate variants. The cross-correlations of the atomic positional fluctu-
ations are color-coded (red: positively correlated, blue: negatively correlated).
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Figure 3.7
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3.4 Conclusions
Drug-resistant HIV-1 protease variants maintain substrate specificity, although
they do not bind as tightly to protease inhibitors as the wild-type enzyme, which
the inhibitors were designed to target. Resistance against these inhibitors is usu-
ally conferred by mutations in the protease gene. However, cleavage site muta-
tions are also associated with resistance to certain protease inhibitors. Some of
these substrate mutations co-occur with the primary drug resistance mutations in
the protease. In this study, structural properties of two drug resistant protease vari-
ants (V82A and D30N/N88D) and the substrates that co-evolved with these two
variants (AP2V NC-p1 and LP1′Fp1-p6/SP3′Np1-p6, respectively) were investigated
in conformational ensembles obtained from molecular dynamics simulations. We
found that the substrate envelope is preserved by the cleavage site mutations in
the presence of primary drug resistance mutations in the protease. These compen-
satory mutations make the substrate fit better within the envelope in the context of
drug-resistant protease by increasing Vin. Consistency of these results ensures our
understanding of the specificity determinants of substrate recognition. Protease-
substrate co-evolution validates the substrate envelope as the substrate recognition
motif for HIV-1 protease.
The results of substrate co-evolution and flexibility can potentially predict
what other cleavage sites may be susceptible to co-evolution. The increase in
Vin is achieved by a variety of mechanisms; recovery of protease-substrate hydro-
gen bonding, van der Waals interactions or the dynamic cooperativity within the
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substrate sequence. For each substrate we studied this increase in Vin is achieved
by a different mechanism, but in every case upon mutation the amino acid side
chain becomes larger (Ala to Val in NC-p1 and Leu to Phe or Ser to Asp in p1-
p6) resulting in substrate variants that better fill the substrate envelope. Thus we
would expect that other compensatory mutations in the cleavage site would likely
involve mutations to larger residues. Our results also highlight the importance of
the substrate conformational plasticity in the binding site. The mutant substrates
that are intrinsically more flexible undergo local conformational rearrangements
that assist a better fit within the substrate envelope. However this flexibility also
can cause a larger Vout making the sequence more susceptible to co-evolution.
The exact effect of the substrate flexibility on the fit within the substrate envelope
cannot be predicted based solely on the cleavage site sequence. Our approach of
combining the dynamic substrate envelope with the molecular dynamics simula-
tions of model structures of the mutant complexes can assist in this prediction.
Theoretically, ∆Vin upon a single amino acid substitution could be estimated by
combining in silico mutagenesis followed by energy minimization, molecular dy-
namics simulations and three-dimensional grid based volume calculations. The
substrate mutations resulting in higher ∆Vin values should be beneficial for the
drug resistant protease variants. Ultimately, the approach we present here could
be useful in predicting the enzyme-substrate mutations that will more likely be
tolerated in drug resistant viral variants.
Being able to accurately predict the substrate co-evolution is critical to avoid
drug resistance in drug design process. Our work highlights the importance of
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paying attention to the details of natural substrate recognition in designing in-
hibitors targeting resistant viral variants. We demonstrate, in this study, the impact
of drug resistance mutations on substrate recognition in addition to inhibitor bind-
ing. Protease inhibitors, when designed fit within the substrate envelope, are less
likely to elicit protease mutations that can ultimately be compensated by mutations
in the cleavage sites. In designing new inhibitors, staying within the substrate en-
velope the potency of the inhibitors must be maintained. Some inhibitors may
protrude beyond the envelope to make favorable contacts with a protease residue
to preserve affinity. In those cases, accurately predicting how likely for one or
more substrates to co-evolve with a potential resistance mutation in that particu-
lar protease residue is crucial. The availability of this probabilistic information
can be used to decide at which location an inhibitors protrusion beyond the enve-
lope is more affordable in terms of avoiding the emergence of drug resistance via
cleavage site mutations.
Researchers have so far used evolutionary information to predict the structural
and functional features of proteins and their complexes. Sequence conservation
allows for modeling the structure of a protein based on the experimentally deter-
mined structure of a homologous protein, while sequence variation, especially in
the form of correlated mutations, is useful to infer functional features. This study,
on the other hand, proposes the substrate envelope based on structural data, as a
tool to predict the evolution due to drug pressure for a protease-substrate system.
Using the dynamic substrate envelope, the substrates can be assigned a probability
of mutating in the presence of a particular protease mutation. To the best of our
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knowledge, this is the first structure-based approach to predict evolution under the
selective pressure of drug therapy.
Using the substrate envelope in prediction of co-evolution in other systems
In general, viral replication is a highly interdependent process that involves
very complex interactions between separate viral macromolecules (proteins and
polynucleotides) as well as host-virus interactions. This highly interdependent
character of viral life cycle should make the co-evolution of separate viral genes
inevitable. In particular, HIV is a well-studied model system, with a massive
amount of structural, biochemical, and sequence data on HIV are available in the
published literature and online databases, [27,169–171] allowing for indepth anal-
ysis to occur. In other viral systems far less data is available, but we expect the
substrate envelope hypothesis to be applicable. For example, co-evolution of in-
dividual sites within the Hepatitis B Viral genome has been reported to contribute
to the rate of drug resistance. [172] In addition, correlated mutations in four of
the influenza proteins have been reported to be critical for host adaptation and
pathogenicity [173], demonstrating the interdependence of the viral genomic sites
in evolution.
Hepatitis C Virus (HCV) is also among these systems. The viral RNA-dependent
RNA-polymerase, just like the HIV-1 reverse transcriptase, is inherently inaccu-
rate accounting for a very high mutation rate. [174] A very recent Bayesian net-
work analysis of viral polyprotein sequences has shown that the intrahost evolu-
tion of HCV is a complex process encoded in the interrelationships among many
sites along the entire viral polyprotein. [175] Crystallographic studies from our
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group on the serine protease of this virus, NS3/4A, complexed with its natu-
ral substrates have shown that the substrate envelope hypothesis is valid also for
HCV in explaining (1) the specificity determinants of the natural substrate recog-
nition and (2) emergence of primary drug resistance mutations. [9] The most se-
vere resistance-conferring mutations occur where the inhibitors protrude from the
NS3/4A substrate envelope, as these changes selectively weaken inhibitor bind-
ing without compromising the binding of substrates. The high mutation rate of
HCV can also impact the sequence variability of the cleavage sites of NS3/4A, as
a lesson learned from studying HIV-1 protease-substrate co-evolution. No data on
substrate co-evolution has been reported so far. Nevertheless, the characteristics
of the protease-substrate co-evolution in HCV and other viral systems should be
investigated. Our combined approach, involving molecular modeling, molecular
dynamics, and grid-based volume calculations, will better elucidate the interde-
pendency of viral evolution by predicting the general sequence variability of each
cleavage site and the particular cleavage site mutations that are likely to be se-
lected in the context of a primary drug resistance protease mutation.
3.5 Methods
3.5.1 Nomenclature
HIV-1 protease variant (WT, V82A or D30N/N88D) and the cleavage site vari-
ant (AP2V, LP1′F or SP3′N) in a protease-substrate complex are designated by a
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subscript and a superscript to the name of the cleavage site. For example, LP1′Fp1-
p6D30N/N88D denotes a complex of D30N/N88D protease variant with the LP1′F
mutant of the p1-p6 cleavage site where LP1′F refers to a Leu-to-Phe mutation at
P1′ position of the cleavage site.
3.5.2 Protease-Substrate Complex Structures
Two PR substrates and their mutant variants in complex with inactive, isosteric
PR variants were investigated for structural and dynamic properties. All these in-
active protease variants have D25N mutation that has been shown to minimally
alter the overall structure of the protease complexes [176]. This D25N mutation is
not associated with drug-resistance; therefore we refer to D25N as WT throughout
the paper for simplicity in nomenclature. The crystal structures of WTp1-p6WT [7]
and WTNC-p1WT [40] and AP2V NC-p1V 82A variants were used as the starting
structures in the MD simulations (PDB ID: 1KJF, 1TSU, 1TSQ). The other struc-
tures were modeled by side-chain mutations performed in PyMOL [166] by se-
lecting the most probable rotamer from the rotamer library followed by energy
minimization as described below. The protease-substrates complex variants are
listed in Table 3.3.
142
Table 3.3: HIV-1 protease-substrate complexes
Protease-substrate Drug-resistance mutations Starting structure
complex variant Protease (D25N)a Substrate (PDB Code)
WTp1-p6WT –– –– WTp1-p6WT (1KJF)
LP1′Fp1-p6WT –– LP1′F WTp1-p6WT (1KJF)
SP3′Np1-p6WT –– SP3′N WTp1-p6WT (1KJF)
WTp1-p6D30N/N88D D30N/N88D –– WTp1-p6WT (1KJF)
LP1′Fp1-p6D30N/N88D D30N/N88D LP1′F WTp1-p6WT (1KJF)
SP3′Np1-p6D30N/N88D D30N/N88D SP3′N WTp1-p6WT (1KJF)
WTNC-p1WT –– –– WTNC-p1WT (1TSU)
AP2V NC-p1WT –– AP2V WTNC-p1WT (1TSU)
WTNC-p1V 82A V82A –– WTNC-p1WT (1TSU)
AP2V NC-p1V 82A V82A AP2V AP2V NC-p1V 82A (1TSQ)
aAll 10 PR variants have D25N mutation. This mutation inactivates the PR allowing for natural
substrate co-crystal structure determination and is known to hardly alter the structure. [176] D25N
is not a resistance mutation; hence, the PR with D25N is referred WT to simplify the notation.
143
3.5.3 MD simulations
The AMBER [150, 151] simulation package (version 8) with the ff03 force
field was used in all simulations. All structures were solvated explicitly in a trun-
cated octahedron box using the TIP3P water model. [152] Overall charge of each
system was neutralized by adding the appropriate number of Cl− counterions us-
ing a Coulombic potential on a 1 A˚ grid with the preparatory program tleap of
AMBER. The initial structures were first minimized at constant volume with con-
vergence criteria of either maximum 90,000 cycles or an RMSD value of 0.01 A˚by
steepest descent integration algorithm for 50 steps and then switched to conjugate
gradient algorithm. Initial atom velocities corresponding to a temperature of 10 K
were generated from a Maxwellian distribution and the temperature was gradually
raised to 300 K. The temperature was maintained at 300 K, and the pressure was
maintained at 1 bar by the Berendsen weak-coupling approach. [154] Constant
pressure-periodic boundary conditions were used with isotropic position scaling.
The particle-mesh-Ewald (PME) method [155] was used to calculate the full elec-
trostatic energy of a periodic box, bypassing pair list creation and nonbonded force
and energy evaluation by calling special PME functions to calculate the Lennard-
Jones and electrostatic interactions with a cutoff distance of 9 A˚. Covalent bonds
involving hydrogen atoms were constrained by the SHAKE algorithm [153] with a
relative geometrical tolerance of 10E-5 A˚. A time step of 2 fs was employed in the
Leapfrog integrator. Various system properties (Total, kinetic and potential ener-
gies, temperature, pressure, density, root-mean-square-deviation of the backbone
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atoms and Vin/out) were monitored during equilibration to ensure the stability of
the simulations. Coordinates and energies were written every 0.4 ps during the 11
ns production phase.
3.5.4 Fit within the Substrate Envelope
The dynamic substrate envelope was previously modeled by a quantitative ap-
proach using the molecular dynamics of seven protease-substrate wild-type com-
plexes. [165] This approach was based on a three-dimensional grid with side
length 10 A˚and grid spacing 0.2 A˚located in the binding site. The occupancy of
each grid cell, gijk, was assigned an initial value of 0. Then the number of times
that a grid cell was within the vdW volume of any peptide was counted. This
value eventually became the overall occupancy of that grid cell. The total volume
of the substrate envelope was essentially the summation over all grid cells with
occupancy greater than 0 normalized by the total number of structures used. This
dynamic substrate envelope was used in this study as a basis for the conserved
consensus volume that is occupied by the substrates in the binding groove.
In this study, the substrate vdW volumes were mapped on the same grid to
define probability distributions of the volume occupied by each substrate variant.
Before this mapping, all frames from each trajectory were superimposed using the
least flexible/mobile residues 24-26 and 85-90 on the WTCA-p2WT complex struc-
ture using the RMSD trajectory tool of the molecular visualization and trajectory
analysis software, VMD. [156] The effect of residue selection on the shape of the
dynamic substrate envelope was assessed in chapter II by aligning the trajectories
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using the Cα atoms of all protease residues, dimerization interface excluding the
flaps, catalytic triad, and finally only the flaps. The results showed that the shape
of the dynamic substrate envelope is not sensitive to the selection of the reference
residues for structural alignment as long as these reference residues are not on a
highly mobile region of the protease (Figure 2.16).
The substrates in various complexes were then compared to each other in terms
of how well they fit within (Vin) and how much they protruded beyond the dy-
namic substrate envelope (Vout). For this comparison, the vdW volume of an
individual substrate was computed from N1 time points in the MD trajectory of
that substrate as described earlier. [165]
3.5.5 Estimation of vdW Potential
Protease-substrate vdW contacts were estimated by a simplified Lennard-Jones
potential V (r) using the relation 4[(σ/r)12−(σ/r)6], where r is the PR-substrate
interatomic distance, and  and σ are the well depth and hard sphere diameter, re-
spectively, for each PR-substrate atom pair. V (r) for all possible PR-substrate
atom pairs was computed within 5 A˚, and when the distance between non-bonded
pairs was less than , V (r) was considered equal to . The rationale for this modifi-
cation to the original 6-12 Lennard-Jones potential was previously described in de-
tail. [165] Using this simplified potential for each non-bonded protease-substrate
pair,
∑
V (r) was then computed for each protease and each substrate residue.
For comparison with the wild-type values, the property of interest (Vin, Vout,
or vdW) was calculated for each frame taken from an MD trajectory as described
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above. These time-series data were first plotted as a histogram to ensure Gaus-
sian distribution and the sample mean and standard error were calculated. The
difference between two distributions (for example ∆Vin = V MUTin − V WTin ) was
computed by subtracting the sample mean of one from the other. The correspond-
ing error was estimated by combining the individual standard errors in quadrature
assuming VWTin and V
MUT
in are independent variables.
SE∆x =
√
SE2xMUT + SE
2
xWT
(3.1)
Finally, the calculated parameters were reported as ∆x ± SE∆x in Figures 1
and 3, where x is Vin, Vout, or vdW. The details of the mathematical proof can be
found elsewhere. [177]
3.5.6 Evaluation of Hydrogen Bonding
The trajectory analysis program ptraj was used to calculate the percentage of
time a hydrogen bond existed during the simulated trajectories. A hydrogen bond
was defined by a distance between the donor and acceptor of less than 3.5 A˚ and a
donor-hydrogen-acceptor angle of greater than 120◦. Hydrogen bonds that existed
more than 50% of the time were analyzed.
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3.5.7 Fluctuation Dynamics
The normalized cross-correlations of residue pairs were defined as
COi,j =
〈∆Ri∆Rj〉
〈∆R2i 〉1/2 〈∆R2j 〉1/2
(3.2)
where ∆Ri is the fluctuation in the position vector R of site i and ∆Rj is the
fluctuation in the position vector R of site j. The brackets represent time averages
over recorded snapshots. The cross-correlations vary in the range [-1, 1], with
the lower and upper limits indicating fully anticorrelated and correlated atomic
fluctuations, respectively. COi,j = 0 gives uncorrelated atomic fluctuations.
The computer programs for calculating Vin, Vout, vdW contact potential, and
the cross correlations of the atomic fluctuations were written in FORTRAN pro-
gramming language. The vdW radii necessary for the volume and vdW contact
potential calculations were taken from the amber03 forcefield. The error analysis
was performed using MATLAB®. [178]
Chapter IV
Dynamic Substrate Envelope in
Hepatitis C Virus NS3/4A Protease:
Predicting Resistance and Guiding
the Design of Novel Inhibitors
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4.1 Abstract
Drug resistance is a major problem in quickly evolving diseases, including in-
fection by Hepatitis C Virus (HCV). The viral protease NS3/4A is a primary drug
target for HCV. At the molecular level, drug resistance reflects a subtle change in
the balance of molecular recognition by NS3/4A; the drug resistant protease vari-
ants are no longer effectively inhibited by the competitive active site inhibitors
but can still process the natural substrates with enough efficiency for viral sur-
vival. Therefore, the inhibitors that better mimic the natural substrate molecular
recognition features, including the dynamic characteristics of the complex, should
result in more robust inhibitors that are less susceptible to drug resistance. When
bound to the enzyme, the native substrates of NS3/4A adopt a consensus volume,
termed the substrate envelope. The most severe drug resistance mutations occur at
protease residues that are contacted by the inhibitors but are outside the substrate
envelope. To guide the design of robust inhibitors, we investigate the enzyme
complexes of four natural substrates using molecular dynamics and define the
dynamic substrate envelope of NS3/4A. Comparative analyses of substrates and
inhibitors distinguish unique structural and dynamic features of substrates that are
not shared by inhibitors and suggest changes to inhibitors to improve resistance
profiles. This study provides a template for guiding the development of novel in-
hibitors that will be more robust against resistance by mimicking the static and
dynamic binding characteristics of natural substrates.
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4.2 Introduction
Drug resistance presents a great challenge in treating quickly evolving dis-
eases, including the hepatitis C viral (HCV) infection. Direct-acting anti-viral
agents specifically target the viral enzymes, inhibiting viral replication and eventu-
ally the disease progress. Two inhibitors targeting HCV NS3/4A protease, telapre-
vir and boceprevir, are approved by the US Food and Drug Administration (FDA)
for treatment of chronic HCV genotype 1 infection in combination with pegy-
lated interferon and ribavirin. Both telaprevir and boceprevir are peptidomimetic
small-molecule inhibitors that associate with NS3/4A through a reversible cova-
lent linkage to the catalytic serine (S139) as well as short-range molecular inter-
actions with the binding site. The narrow selectivity of the two FDA-approved
drugs to a single genotype renders them susceptible to drug resistance and creates
a demand for methods to assist in developing inhibitors with broader selectivity
profiles.
Several non-covalent NS3/4A inhibitors, including macrocyclic compounds,
are at various stages of clinical development. These inhibitors contain a macrocy-
cle connecting either the P1 and P3 groups (ITMN-191 or danoprevir [81]) or al-
ternatively the P2 and P4 groups (MK-5172 [82], MK-7009 or vaniprevir [179]).
These compounds are more potent than telaprevir and boceprevir against wild-
type virus. Nevertheless, HCV quickly evolves due to the high replication rate
combined with the lack of proofreading in the viral RNA-dependent RNA poly-
merase. Under the selective pressure of drug therapy, resistant variants are rapidly
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populated even at early stages of clinical trials, compromising the high efficacy
of protease inhibitors and eventually restricting their usage to treatment-nave pa-
tients for a limited period of time. [174, 180, 181]
Ideally, the molecular recognition aspects of drug resistance should be eluci-
dated and incorporated a priori into the structure-based design process to develop
more robust inhibitors. To achieve this goal, structural requirements for the pro-
tease to fulfill its enzymatic function in the viral life cycle should be thoroughly
studied, since the biological function imposes evolutionary constraints on the pro-
tease under the selective pressure of drug therapy. An important lesson learned
from studying human immunodeficiency virus type 1 (HIV-1), also a quickly
evolving enzyme, is that designing robust protease inhibitors can be facilitated
by an understanding of the key molecular recognition elements of the natural
substrates. For example, inhibitors should stay within the substrate recognition
regions (the “substrate envelope”) in order to minimize the likelihood that the en-
zyme can mutate to reduce the inhibitor efficacy while still maintaining sufficient
enzymatic activity on the substrates. [45, 46, 48, 49, 182] Resistance to protease
inhibitors reflects a subtle change in the balance of molecular recognition events,
in favor of substrate processing versus inhibitor binding.
Crystallographic studies from our group have shown that the substrate recog-
nition motif for HIV-1 protease is not a consensus sequence of the substrates but a
consensus volume adopted by the non-homologous cleavage site sequences within
the binding site, which is termed the substrate envelope. [7] In addition, protein
dynamics have been incorporated into the substrate envelope to assess the effects
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of local conformational fluctuations of the bound substrate. [165] The dynamic
substrate envelope better captures the specificity determinants of substrate recog-
nition [165] and is preserved even in drug resistant protease variants in the pres-
ence of compensatory mutations in the cleavage sites. [183] The primary drug
resistance mutations in HIV occurs at protease residues that are contacted by the
inhibitors outside the substrate envelope. [8] These residues are expected to be
more important for inhibitor binding than substrate recognition. Therefore, sim-
ilar to HIV-1 protease, the specificity determinants of substrate recognition and
how these determinants are maintained by the resistant variants should be eluci-
dated to guide the design of robust HCV NS3/4A protease inhibitors.
HCV NS3/4A protease is the N-terminal domain of the viral bifunctional pro-
tein NS3, which also has a C-terminal helicase domain. Efficient proteolytic
activity of NS3 requires a cofactor NS4A, a 54-amino acid peptide that tightly
associates with the protease. [184] The viral genome is translated as a single
polyprotein along the endoplasmic reticulum by host cell machinery. NS3/4A
hydrolyzes the polyprotein precursor at four known cleavage sites (3-4A in cis,
4A-4B, 4B-5A, 5A-5B) yielding structural and non-structural proteins essential
for viral maturation. [65, 185] The full-length apo NS3/4A crystal structure has
the C-terminal six residues of the helicase sitting at the binding site of the protease
domain. [186] The binding mode of these six residues, which correspond to the
unprimed side of the 3-4A junction, provided the basis for structure-based drug
design efforts targeting the NS3/4A protease. The four known substrates of HCV
share little sequence homology except for an Asp/Glu at P6, Cys/Thr at P1, and
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Ser/Ala at P1′ positions. Our group reported co-crystal structures of the wild-type
protease domain bound to substrate cleavage products and inhibitors that included
the macrocyclic compounds ITMN-191, MK-5172, and MK-7009, which are used
in the current study. [90] In the co-crystal structures, the unprimed side substrate
products adopt a consensus volume despite the low sequence homology. Similar
to HIV-1 protease, the most severe resistance mutations in NS3/4A correspond
to the residues that are contacted by the inhibitors outside the substrate envelope
defined by the cleavage products.
Protein dynamics is especially critical to consider when characterizing the sub-
strate envelope of HCV NS3/4A, as the very shallow binding site may allow more
flexibility for the bound ligands. In this study, the cleavage products of the natural
substrates and three inhibitors in complex with HCV NS3/4A protease are com-
pared using the dynamic substrate envelope. The structural and dynamic analyses
reveal several features of the intermolecular interactions between the protease and
ligands providing insights into drug resistance. This analysis in particular (1) al-
lows predictions of potential drug resistance mutation sites, at which the enzyme
can afford amino acid substitutions with minimal effect on substrate recognition
and (2) reveals the untapped regions of the HCV NS3/4A protease binding site that
satisfy the substrate envelope and can be explored by new inhibitors to potentially
gain affinity without compromising flat resistance profiles.
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4.3 Results and Discussion
Comparative analysis of the binding modes and molecular interactions of sub-
strates versus inhibitors is critical to guide the design of new small-molecule in-
hibitors that better overlap the natural substrate binding features, minimizing the
likelihood of resistance. Toward this goal, the regions of the substrate binding sur-
face that are untapped by the current inhibitors as well as the regions the inhibitors
contact on the protein surface beyond the substrate envelope were revealed using
molecular dynamics simulations.
Three macrocyclic NS3/4A protease inhibitors, ITMN-191, MK-5172, and
MK-7009, were compared to the natural substrates, 3-4A, 4A-4B, 4B-5A, and
5A-5B, in terms of dynamics in the bound state and interactions with the protease
(Table 4.1). For substrates, each of the six amino acid residues defines a site
(P6 to P1, Figure 4.1A); the inhibitor functional groups were assigned positions
by superimposing the inhibitor complexes onto the substrates and grouping the
inhibitor atoms. Because none of the inhibitors span the P6-P5 region, only four
chemical groups (P4 to P1, Figure 4.1B) and one group outside the envelope (P1′)
were defined for the inhibitors.
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Table 4.1: The cleavage site products and macrocyclic small-molecule inhibitors of HCV NS3/4A Protease
Substrates
P6 P5 P4 P3 P2 P1 PDB ID # of atoms Vout (A˚3) Vtot (A˚3) vdW (kcal/mol)
3-4A D L E V V T 1CU1 47 341 ± 31 1042 ± 14 -26.9 ± 2.8
4A-4B D E M E E C 3M5M 50 431 ± 40 1097 ± 15 -31.9 ± 2.5
4B-5A E C T T P C 3M5N 43 300 ± 26 950 ± 17 -27.7 ± 2.7
5A-5B E D V V C C 3M5O 44 318 ± 24 993 ± 14 -27.9 ± 2.2
Inhibitors
PDB ID # of atoms Vout (A˚3) Vtot (A˚3) vdW (kcal/mol)
ITMNN-191 (Danoprevir) 3M5L 51 567 ± 18 1082 ± 15 -36.5 ± 2.0
MK-5172 3SUD 54 633 ± 16 1165 ± 16 -35.0 ± 2.8
MK-7009 (Vaniprevir) 3SU3 53 606 ± 14 1152 ± 14 -36.6 ± 1.8
156
Figure 4.1: HCV protease substrate and inhibitor structures. (A) The over-
layed substrate cleavage products (3-4A, 4A-4B, 4B-5A, and 5A-5B) are dis-
played in sticks with the substrate sites indicated by distinct colors. (B) The in-
hibitors (ITMN-191, MK-5172, and MK-7009) superimposed onto the substrates,
inhibitor chemical moieties colored in the same scheme as the substrates (addi-
tionally P1′: white). The substrates do not have a P1′ position in the co-crystal
structures due to the residual activity of the S139A protease construct used in
crystallization.
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Figure 4.1
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4.3.1 Substrate Shape and the Dynamic Substrate Envelope
The conformations of four substrates in complex with NS3/4A protease adopt
a similar overall shape in each of their crystal structures (Figure 4.2A), and the
overlapping consensus volume defines the static substrate envelope (Figure 4.2B).
To incorporate the dynamic nature of the protease-substrate complex, the most
probable volume occupied by at least 75% of each substrates conformers dur-
ing MD simulations was calculated (labeled as dynamic in Figure 4.2A). How-
ever, the somewhat arbitrary cutoff of 75% and the high mobility of substrates
resulted in a smaller and more restrictive dynamic consensus volume. Therefore,
a continuous representation of the dynamic substrate envelope was defined by
mapping vdW volumes of P6 to P1 residues of substrate conformers onto a three-
dimensional grid, similar to the case for HIV-1 protease. [165, 183] The dynamic
substrate envelope is a probability distribution of vdW occupancies at each grid
point (Figure 4.2B). This probabilistic dynamic substrate envelope allows all the
information from MD conformers to be properly incorporated for a more accurate
comparison between substrate and inhibitor complexes.
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Figure 4.2: (A) Substrate flexibility reduces the consensus volume as reflected
in dynamic volumes smaller than static substrate volumes. The vdW volume
occupied by 75% of substrate conformers during MD simulations (Dynamic) is
compared to the vdW volume of the crystal structure conformation (Static) for
substrates 3-4A, 4A-4B, 4B-5A, 5A-5B. (B) Dynamic substrate envelope is a
more realistic representation of the conserved substrate volume. The dynamic
consensus volume is the volume occupied by at least 75% of substrate conformers
in the MD simulation trajectories, whereas the static consensus volume is the
volume occupied by at least 3 of 4 substrates in the crystal structures. The dynamic
substrate envelope is the probability distribution of vdW volume occupied by all
substrate conformers in the MD simulations. Substrate co-crystal structures in
stick representation are superposed (P6 to P1 orientation left to right) onto the
grid matrix of the dynamic substrate envelope.
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In the dynamic substrate envelope, the most conserved and dynamically re-
stricted region is defined by the P4 to P1 residues, as indicated by the low Vout
values (Vout range 26±4 A˚3 to 56±22 A˚3) (Figure 4.4A). The 4A-4B cleavage
site is an exception, with larger Vout values, especially at P2 position (80±19 A˚3).
Two factors contribute to this: first, 4A-4B has a bulky glutamic acid at P2 with a
higher degree of side-chain conformational freedom; and second, 4A-4B appears
to be inherently more flexible than the other substrates as suggested by alpha car-
bon root-mean-squared fluctuations (RMSF of 1.6 A˚, average for other substrates
is 1.0-1.2 A˚; Figure 4.3) resulting in a smaller dynamic volume for this substrate
than other substrates (Figure 4.2A). With 4A-4B being the exception, the P4-P1
region is the key conserved volume within which the inhibitors should be designed
to fit with minimal protrusion to avoid resistance mutations.
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Figure 4.3: P4-P1 substrate region is less mobile compared to P6 and P5
residues, contributing to the highly conserved consensus volume. The root-
mean-squared-fluctuations (RMSF) of Cα atoms of each substrate were calculated
from MD simulations. The relatively high mobility of 4A-4B likely causes the
substrate to sample a wider conformational space, resulting in a smaller dynamic
volume.
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P5 and P6 have higher mobility during the MD simulations (Figure 4.3). The
P6 positions of all four substrates have relatively high Vout values compared to
the other residues in the range of 82±15 A˚3 for 3-4A to 132±18 A˚3 for 4B-5A,
which corresponds to 23% to 40% of the total Vout of the respective substrate.
Similarly at the P5 position, the substrates have a lower consensus volume. In
general, the lower density at P6 and P5 is consistent with the higher temperature
factors of P6 and P5 in the crystal structures. [9] The high dynamics and rela-
tively lower occupancies at P6 and P5 positions is also reflected in the inhibitors,
as none of the more potent macrocyclic inhibitors have P6 and P5 groups. In-
deed, telaprevir, an FDA-approved non-macrocyclic ketoamide inhibitor, has a
P5 moiety that does not improve its binding compared to the macrocyclic com-
pounds without a P5 moiety. The Ki for telaprevir is 34.4±3.0 nM against wild
type enzyme, while macrocyclic compounds without a P5 moiety are more po-
tent (ITMN-191=1.0±0.1 nM, MK-5172=0.74±0.07 nM, MK-7009=0.14±0.02
nM). [90] Thus extending inhibitors into the P5-P6 subpockets observed in the
crystal structures may not result in more potent inhibitors unless moieties with
highly specific, possibly electrostatic interactions with the protease are introduced.
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Figure 4.4: The HCV NS3/4A dynamic substrate envelope is more conserved
in the P4 to P1 region. The volume outside the dynamic substrate envelope for
each (A) substrate and (B) inhibitor moiety, Vout, is colored in a spectrum of blue
to red. Warmer and cooler colors indicate a higher and lower level of protrusion
beyond the dynamic substrate envelope, respectively. The macrocyclic inhibitors
protrude from the substrate envelope mainly at P2 and P1′ positions.
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Overall, the shared features of the P4-P1 region appear to be the common mo-
tif recognized by the protease. However, the fact that the flanking residues do
not adopt a consensus volume does not exclude their role in substrate recognition.
These residues can change the context of the cleavage site as has been shown
in substrate cleavage efficiency in the viral protease of HIV. [187] The fact that
the P5′ residue in HIV-1 protease has co-evolved with drug resistant HIV-1 pro-
tease variants suggests that this position plays a role in substrate binding and/or
processing. [32] In HCV, the P6 substrate residue makes extensive electrostatic
interactions with the protease binding site residues R119, R123, R161 or K165,
as discussed below. Flanking residues may also have key interactions with the
protease in the cellular context that aid substrate recognition. Although these pos-
sible additional interactions of protease with viral polyprotein precursor in the cell
are not captured by peptide complex structures, the details of molecular interac-
tions within the binding site may be essential to develop robust small-molecule
inhibitors.
4.3.2 Inhibitor Shape
To assess the three macrocyclic compounds in terms of their mimicry of the
substrate envelope, the probabilistic volume occupied by each inhibitor during
MD simulations was compared with the dynamic substrate envelope. The in-
hibitors are not as conformationally flexible as the substrates and therefore they
sample a relatively restricted local conformational space than the substrates (more
red regions in Figure 4.5). This conformational restriction results in the more
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homogeneous volume distribution for inhibitors. The inhibitors, being relatively
rigid, are expected to be more severely affected by mutations at the binding site
compared to the flexible substrates. In fact, the recently published co-crystal struc-
tures of these inhibitors with the wild type and three of the most severe drug re-
sistant protease variants (R155K, A156T, D168A) revealed a complete shift in the
binding mode of the inhibitor. [90] This shift in the binding mode is likely due to
the rigidity of the inhibitors, which prevent them to adapt to amino acid changes
in their target enzyme.
For each inhibitor, the portion of the volume that fails to fit within the dynamic
substrate envelope was quantified as Vout (Table 4.1). The contribution of each
moiety (P4 to P1′) to Vout was also calculated (Figure 4.4B). The P2 group in
each inhibitor is completely outside the substrate envelope. This group makes up,
on average, 33% of an inhibitor’s total volume. The P1 moiety, although not as
severely as P2, fails to fit exclusively within the substrate envelope, with a Vout
value of 78±10 A˚3 for ITMN-191 and MK-5172 and 83±10 A˚3 for MK-7009.
The inhibitors also have a P1′ moiety that protrudes beyond the substrate envelope.
A corresponding residue for P1′ does not exist in the product crystal structures;
in fact no crystallographic data is currently available on the binding mode of the
primed side of the cleavage sites. The inhibitor moieties that do not overlap with
the substrate volume, especially within the P2 groups, are responsible for the loss
of binding affinity upon resistant mutations.
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Figure 4.5: Macrocyclic inhibitors are more rigid than the substrates, result-
ing in a more homogeneous dynamic volume. The four superposed substrates,
3-4A, 4A-4B, 4B-5A, 5A-5B, are shown as sticks in red, green, blue, yellow,
respectively. The dynamic substrate envelope and the volume distribution of in-
dividual inhibitors are represented with a spectrum from red to blue, reflecting
respectively more and less likely occupied regions.
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In addition to staying within the substrate envelope, a robust inhibitor ideally
fills the substrate envelope efficiently to gain maximum potency. The three in-
hibitors were assessed in terms of their efficient use of the substrate envelope by
calculating the volume of the dynamic substrate envelope that is not being occu-
pied by inhibitor atoms over the course of the MD simulations, Vremaining (Fig-
ure 4.6). The volume of inhibitors that are outside the substrate envelope (Vout
values are 567±18 A˚3, 633±20 A˚3, 606±19 A˚3, Table 4.1) is comparable to the
part of the dynamic substrate envelope that is not occupied by any inhibitor atom
(Vremaining values are 506±15 A˚3, 489±16 A˚3, and 474±16 A˚3, Figure 4.6).
Therefore, in principle, a compound with the same total volume as the existing
inhibitors can be designed to fit fully within the envelope by removing the parts
outside the substrate envelope and adding atoms to the regions of the substrate en-
velope currently not filled. The challenging goal of developing robust inhibitors
that avoid drug resistance mutations may be achieved by optimizing the com-
pounds to minimize Vout and Vremaning metrics while retaining potency.
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Figure 4.6: Macrocyclic inhibitors do not fully occupy the dynamic substrate
envelope. The portion of the dynamic substrate envelope that is not used by the
inhibitor molecules, Vremaning, is shown on the structures of (A) ITMN-191, (B)
MK-5172, and (C) MK-7009. Stereo images were prepared with PyMOL. [166]
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4.3.3 Molecular Flexibility and Atomic Fluctuations - Substrates
Protease-bound substrates undergo conformational fluctuations around the na-
tive state of the complex, reflected in the probabilistic profile of the dynamic sub-
strate envelope. [165] Molecular flexibility is also critical for the substrates to
adapt to mutations in the protease and to be recognized as substrates. [183] An
ideal inhibitor should mimic aspects of the dynamic characteristics of the natural
substrates to have the flexibility to achieve a flat resistance profile. For this rea-
son, the dynamic features of substrates were characterized to compare with those
of the inhibitors, by calculating root-mean-squared-fluctuations (RMSF) of alpha
carbon atoms in MD simulations, and the intramolecular cooperativity of these
fluctuations in the bound state.
Fit of a substrate within the substrate envelope is not solely dependent on
the size of the side chains but also the inherent flexibility of the substrate. [165]
The two substrates 3-4A and 4A-4B are comparable in size (1042±14 A˚3 and
1097±15 A˚3, respectively) and larger than 4B-5A and 5A-5B (950±17 A˚3 and
993±14 A˚3, respectively). However, 3-4A is inherently less flexible than the
other substrates (Figure 4.3) and has a more conserved volume (Figure 4.2A).
In addition, the P4-P1 regions of all substrates are more rigid than the P6-P5 (Fig-
ure 4.7A), resulting in a more homogeneous volume distribution of the dynamic
substrate envelope at P4-P1 and a relatively heterogeneous volume at P6-P5 sites
(Figure 4.2B). Hence, the most likely volume that a substrate adopts in the enzyme
binding site should be evaluated based not only on sequence and the binding con-
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formation observed in the crystal structure, but also on the local conformational
plasticity of the substrate in complex with the protease.
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Figure 4.7: Compound flexibility is dictated by a combination of features
(status/location of the macrocycle, connection points of the linker, and iden-
tity of the P2 moiety connected by the linker). The RMSF of substrate and
inhibitor atoms are mapped onto the structures of (A) four substrates, (B) ITMN-
191, (C) MK-5172, and (D) MK-7009. Warm colors indicate more flexible re-
gions while cool colors correspond to rigid regions.
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Interdependence of the dynamics of substrate residues plays a role in main-
taining the molecular shape necessary for substrate recognition. [165, 183] This
can be assessed as a time-dependent correlation of atomic fluctuations among the
residues of each substrate (Figure 4.8). The residues that fluctuate in a coopera-
tive manner are dynamically coupled. Strikingly, positive correlations within the
P4-P1 region are more pronounced than the correlations across the P6-P5 and P4-
P1 regions for all four substrates. These correlations within the P4-P1 region last
longer than others and still exist even after 1 ns. The positive correlation within
the P4-P1 region is likely to aid in maintaining the substrate consensus volume
conserved across the four substrates, thereby contributing to substrate recogni-
tion.
Substrates exhibit subtle variations in the positional fluctuations and their rel-
ative time-evolved interdependence (Figure 4.8). For 3-4A and 4A-4B, atomic
fluctuations of the P6 residue are negatively correlated to those of the P3-P1 re-
gion. The cooperativity within the 4A-4B substrate is considerably higher than the
other substrates even after 1 ns. This higher cooperativity may correlate with the
number of charged residues and the higher net charge in 4A-4B. Since electrostatic
interactions are long range, movements in one charged residue are more likely to
propagate and influence a distal residue if the distal residue is also charged. In fact,
movement of the negatively charged Asp-P6 is coupled to the negatively charged
Glu-P3 and Glu-P2 since their movement in opposite directions would maximize
their separation. This kind of cooperativity may result in interdependence within
the substrate sequence. Because 4A-4B protrudes beyond the substrate envelope,
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especially at P2 site, more than the other substrates (Figure 4.4), the 4A-4B cleav-
age site is expected to be more susceptible to co-evolution with drug resistant
protease variants. The cooperativity within the 4A-4B sequence suggests that a
compensatory mutation in the cleavage site may occur at a position other than P2
that would allow the substrate to adapt to drug resistance mutations in the pro-
tease.
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Figure 4.8: Correlation of substrate atomic fluctuations within P4-P1 region
survives longer compared to those across P6-P5 and P4-P1. Residues are sep-
arated by lines, the P6-P5 and P4-P1 regions are separated by a thicker black line.
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4.3.4 Molecular Flexibility and Atomic Fluctuations - Inhibitors
The conformational flexibility of an inhibitor is dictated by a combination of
its structural features. Macrocyclic inhibitors may be more susceptible to resis-
tance mutations than more flexible acyclic analogues. Location of a macrocycle
linkage (whether the linkage connects the P1 group to P3 or P2 to P4) and the
particular atom involved with the linking may also impact the inhibitor’s flexibil-
ity. The P2-P4 moieties in NS3/4A inhibitors are highly solvent-exposed; hence
they are relatively free to move while the P1-P3 moieties are fully buried within
the binding site and therefore more conformationally restricted. As a result, a
macrocycle connecting the more flexible P2 and P4 moieties may be more effec-
tive in constraining the small molecule inhibitor than a linker connecting P1 and
P3 moieties that are already relatively rigid. However, the packing of the flexible
P2 group may also affect the flexibility of an inhibitor in the binding site. Very
tight interactions may lock the inhibitor in a single conformation.
For example, both MK-5172 and MK-7009 have a P2-P4 linker; however their
dynamic envelopes suggest that more local conformational states are accessible to
MK-5172 than MK-7009, especially for the P2 group and the linker. MK-5172
has an ether-linked quinoxaline P2 group and a linker to C2 of quinoxaline, while
MK-7009 has a carbamate-linked isoindoline P2 group and a linker to the C4 of
the isoindoline (Table 4.1). In MK-5172, the quinoxaline group is pointing away
from the flexible C2-linker and the local fluctuations of this group creates enough
momentum to affect the local fluctuations of the linker. In contrast, the isoindoline
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in MK-7009 is linked at C4 position, which is located at the tip of the P2 group
and renders the constraint more effective. Thus the C4 connection in MK-7009 is
more restrictive than the C2 connection.
Interestingly, ITMN-191 entirely lacks this linker, which makes the isoin-
doline more flexible than MK-7009. Yet the enhanced flexibility of C2-linked
quinoxaline in MK-5172 is comparable to the free P2 group of ITMN-191. Thus
a P2-P4 macrocycle does not guarantee a severe dynamic constraint in a com-
pound, but the connection point of the P2-P4 linker also has a role in the extent
of flexibility. All three effects combined together (location of the macrocycle, the
connection points of the linker, and the identity of the P2 moiety connected by the
linker) are responsible for the differential dynamics observed in the bound state
(Figure 4.7).
In contrast, the backbone of the inhibitors is always stable, consistent with
the substrate P4-P1 backbone stability (Figure 4.7). P1-P3 moieties of all three
inhibitors have very homogeneous volume distributions due to their rigidity in
the bound state (Figure 4.5). The interplay between the rigidity of the P1-P3
groups and the stability of the favorable interactions with the corresponding bind-
ing subsite contributes to the tight binding characteristics to these inhibitors. The
structural rigidity of these very tight binding compounds, relative to natural sub-
strates, gives rise to high orientational correlations of motion within a compound
(Figure 4.9). The effect of a slight movement in one moiety is propagated rapidly
to the rest of the molecule because of this rigidity. This propagation of movement
is facilitated by the linkers (Figure 4.9), which couple the moieties that they con-
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nect. The cross-correlations of atomic fluctuations within the P2-P4 macrocyclic
compounds, MK-5172 and MK-7009, are much higher and last a longer timescale
than those within the P1-P3 linked compound, ITMN-191, (Figure 4.9). The high
cooperativity may prevent the inhibitors from conformational readjusting to adapt
to resistance mutations in the protease. For example, the P2-P4 linked inhibitors
are more susceptible to A156T mutation than the P1-P3 linked compound (The
fold-change in Ki relative to the wild-type is 4429 and 1295 for MK-5172 and
MK-7009, respectively but 45 for ITMN-191 [90]), because the relatively more
rigid and highly cooperative macrocyclic compounds cannot adjust a single moi-
ety to avoid resistance mutations. To overcome this opportunity for resistance,
robust inhibitors to NS3/4A protease should be designed to have an intrinsic flex-
ibility consistent with natural substrates.
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Figure 4.9: Inhibitor atomic fluctuations are highly correlated and corre-
lations survive longer in compounds with P2-P4 macrocycle (MK-5172 and
MK-7009). Residues are separated by lines, and the macrocycle linker atoms are
indicated by darker lines.
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4.3.5 vdW Contacts at the Binding Surface
Van der Waals (vdW) interaction energies at a protein interaction surface rep-
resent the local packing. A comparative view of protease vdW energies with sub-
strates versus inhibitors during MD simulations reveals the regions on the sub-
strate binding surface that are untapped by the inhibitors, as well as the protease
residues that should be avoided in designing new inhibitors to minimize the like-
lihood of drug resistance (Figure 4.10 and 4.11). The protease residues that are
contacted by substrates and the extent of these interactions are conserved across
the four substrates (Figure 4.10). The vdW interaction energy of each protease
residue was averaged over four substrates and mapped onto the binding surface
(Figure 4.10). The interactions with the catalytic H57 appear to be critical for all
substrates as well as K136, A156, A157, V158, and S159. A comparison of the
natural polymorphisms and drug resistance mutation sites and the contact poten-
tial of these sites with the natural substrates reveal that the drug resistance muta-
tions have been selected at sites that are not major contact points for substrates,
namely Q41, T42, F53, K80, S138, and D168 (Figure 4.10E). However, R155,
A156, and V158 mutate to confer drug resistance although they have extensive,
stable interactions with the natural substrates. Based on this structural observa-
tion, the viral variants carrying the mutations at these three sites are expected to
pay a fitness cost because of a likely interference with substrate recognition, yet
the selective pressure of the drug therapy populates the viral variants carrying
these mutations.
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Figure 4.10: Differences between the binding surfaces of inhibitors versus
substrates provide opportunity for resistance mutations. The protease residues
that contact (A) the substrates, (B) ITMN-191, (C) MK-5172, and (D) MK-7009
are colored with respect to their vdW contact potential energies. The catalytic triad
residues, H57, D81 and S139, are indicated by underlined labels in italics. The
substrate residues P6 and P1 are labeled to show the orientation of the cleavage
products while all five moieties (P4 to P1′) are labeled for inhibitors. (E) vdW
contact potentials for protease residues. The black and red stars correspond to the
natural polymorphic and drug resistance mutation sites, respectively.
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Figure 4.11: Differential interaction profiles of inhibitors versus substrates
suggest potential improvement at P1 moiety of inhibitors. The vdW contact
potential of (A) substrate residues P6 to P1, and (B) inhibitor moieties P4 to P1′.
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The subtleties between the overlapping binding surfaces of the substrates ver-
sus inhibitors are reflected in their differential vdW interaction energies with the
protease (Figure 4.10). The substrate complexes have larger fluctuations than the
inhibitor complexes (higher standard deviations in Figure 4.10E), likely as a result
of their greater structural flexibility. The lower standard deviation of inhibitor in-
teractions indicates that a particular interaction has remained stable throughout the
simulated time interval. The total vdW interaction energy of the three inhibitors is
comparable, -36.5±2.0, -35.0±2.8, and-36.6±1.8 kcal/mol for ITMN-191, MK-
5172, and MK-7009, respectively. The catalytic histidine is the main contact for
all inhibitors. The extensive interactions with H57 may contribute to the broad
activity of MK-5172 across different genotypes and resistant variants. [188] The
residues H57, S139, R155, and D168 have more favorable interactions with the
inhibitors than substrates, while the residues Q41, T42, F43, Y56, G58, V78, D79,
K80, and D81 do not contact the substrates at all but interact with the inhibitors.
These residues have low contact potential (in the range of 0 to -1 kcal/mol) but
may have a collective impact on the binding affinity. Taken together, targeting the
protease residues that are major contact points for natural substrates, including
the catalytic triad (H57, D81, S139), and minimizing interactions with the vari-
able sites is a promising strategy for avoiding resistance without compromising
selectivity.
While the maximum possible interaction potential is desired for potent in-
hibitors targeted against an ensemble of resistant variants, the substrates also need
to be specifically recognized to permit enzyme cleavage. Suboptimal interaction
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potential between the protease and a substrate may negatively impact the recog-
nition at the binding interface, decreasing the association rate and/or increasing
the dissociation rate, while higher-than-optimal interaction potential may inter-
fere with product release, causing product inhibition. 4A-4B is a larger substrate
with 50 non-hydrogen atoms in the P6-P1 sequence (Table 4.1), making slightly
more favorable vdW contacts with the protease (-31.9±2.5 kcal/mol) while 3-4A
has a lower contact potential (-26.9±2.8 kcal/mol). The more favorable contacts
of 4A-4B likely compensate for the high degree of inherent conformational flex-
ibility of this substrate, ensuring sustained affinity. In contrast for 3-4A, making
less favorable contacts than average may be tolerated as 3-4A is processed in a cis
cleavage reaction, increasing the effective concentration through the intramolecu-
lar nature of the processing of this particular site.
A large portion of substrate vdW energy with the protease (≈40%) involves
interactions with P1 position (Figure 4.11). Indeed, the Cys in 3-4A and Thr in
the other substrates at P1 position are nicely packed in this small cavity compared
to the other substrate residues, which contact the relatively shallower parts of the
binding surface. The macrocyclic inhibitors make more favorable vdW contacts
than the substrates at the P2 position due to the bulky isoindoline (ITMN-191/MK-
7009) or quinoxaline (MK-5172) groups. While the P2 interactions contribute to
the high affinity to the wild-type protease, most of them are outside the substrate
envelope (Figure 4.4) and therefore render the inhibitors susceptible to resistance
mutations.
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4.3.6 Electrostatic Network
Electrostatic interactions are typically more specific and longer range than
vdW interactions and contribute significantly to molecular recognition. All of the
protease-substrate hydrogen bonds, except for the one formed by R123, are con-
served across the substrates in the crystal structures. [9] A majority of these hy-
drogen bonds also persists during the MD simulations (Table 4.2), especially the
ones involving A157 and C/S159. The protease-substrate hydrogen bonds formed
by the substrate backbone are more stable, with all except one (between the 2
oxygen of the Glu-P4 of 3-4A substrate) existing for at least 50% of the simulated
time. Backbone hydrogen bonds are independent of sequence as all amino acids
share the same backbone, hence the same hydrogen bond donors/acceptors. This
relative non-specificity of shared backbone hydrogen bonds suggests that binding
specificity is due to other molecular recognition motifs. Although the hydrogen
bonds are conserved across the substrates, the percent time that these interactions
exist throughout the simulations vary between the complexes. Substrate 4B-5A
preserves the complete hydrogen-bonding network with the protease in the simu-
lation while 4A-4B preserves half of the hydrogen bonds, consistent with higher
flexibility. All P1 terminal carboxyl groups sit in the oxyanion hole, hydrogen
bonding with the 2 nitrogen of the catalytic histidine (H57), which exists 97%
of the time in 4B-5A complex while in other substrates this bond exists ≈70%
of the time. Similarly, the backbone hydrogen bond between P1 and G137 is
present 89% of the time in the 4B-5A complex whereas the same bond exists 59%
195
of the time or less for other substrates. These variations likely arise from other
differences in molecular interactions with the enzyme and inherent differences in
substrate flexibilities and contribute to the substrate specificity.
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Table 4.2: The frequency of the protease-substrate/inhibitor hydrogen
bonds in MD simulations
Substrates
Protease Cleavage site
3-4A 4A-4B 4B-5A 5A-5B
H57 –– NE2 P1 –– O 72 71 97 69
G137 –– N P1 –– O 55 <50 89 59
S139 –– OG P1 –– O 53 <50 58 <50
R155 –– O P1 ––N <50 <50 56 <50
A157 –– N P3 –– O 69 85 76 80
A157 –– O P3 –– N 87 82 72 84
R123 –– NH2 P4 –– OE2 51 <50 <50 <50
C/S159 –– N P5 –– O 78 63 57 81
S159 –– O P5 –– N <50 <50 <50 59
Inhibitors
Protease Inhibitor
ITMN-191 MK-5172 MK-7009
G137 –– N P1′ 78 77 74
S139 –– N P1′ 71 67 69
G137 –– N P1 <50 <50 <50
S139 –– OG P1 95 95 90
R155 –– O P1 89 53 93
A157 –– N P3 89 87 89
A157 –– O P3 76 90 88
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Interestingly, despite not being an essential part of the dynamic substrate enve-
lope, the P6 residue is conserved at the amino acid level (Asp or Glu), suggesting
functional importance. Structural evidence suggests that this arises from the po-
tential electrostatic interactions of P6 acid with the protease and possibly in long-
range substrate recognition, and thus is included in the definition of the dynamic
substrate envelope. In all crystal structures except for the product complex 4B-5A,
K165 forms salt bridges with the P6 acids. [189] In the MD trajectories, the P6
acid-K165 salt bridge criterion was satisfied for 12%, 26%, 35%, and 57% of 100
ns simulated time for 3-4A, 4A-4B, 4B-5A, 5A-5B, respectively. The percentages
are relatively low for the first three complexes, however the disrupted salt bridge
reforms in a recurring manner. In addition, the percentage of time P6 acid forms a
salt bridge with any one of the four binding site basic residues (R113, R119, R161,
K165) is 53%, 68%, 50%, and 83% for 3-4A, 4A-4B, 4B-5A, 5A-5B, respectively
(Figure 4.12). These numbers suggest that the P6 acid, in solution, interacts with
at least three more basic residues on the binding surface in a dynamic manner in
addition to K165 observed in the crystal structures. The P6 position, while form-
ing salt bridges with a series of binding site residues, does not adopt a conserved
consensus volume. The highly dynamic interaction pattern of the P6 acid with the
protease binding surface rationalizes the strong conservation of Asp or Glu at this
position as well as the dramatic reduction in cleavage efficiencies of substrates
with positively charged P6 substitutions. To mimic the salt bridges between the
protease and the P6 acid, inhibitors would require a negatively charged P6 and/or
P5 moiety that is flexible enough to form interchanging salt bridges with a series
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of binding site residues. The probabilistic character of the dynamic substrate en-
velope provides a basis for building the P5 and/or P6 moieties with the relevant
charge and flexibility requirements, preventing potential pitfalls and misleading
results in case the static P6 crystallographic volume were to be satisfied.
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Figure 4.12: P6 Asp/Glu of substrates participates in a dynamic salt bridge
network with the protease residues R119, R123, R161 and K165. The salt
bridge distance over simulation time (left) and the corresponding histogram (right)
is displayed for (A) 3-4A, (B) 4A-4B, (C) 4B-5A, and (D) 5A-5B. Salt bridges
were defined as an interaction between a side-chain oxygen atom of Asp or Glu
within 4.0 A˚ of a nitrogen atom of Arg or Lys (indicated by the red horizontal and
vertical lines).
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The protease-inhibitor hydrogen bonds are also formed by the backbone of
protease binding site residues, except for the γ oxygen of the catalytic serine S139
with the P1 group of each inhibitor. The backbone hydrogen bonds should in the-
ory be preferred while designing new drugs to avoid losing a specific hydrogen
bond donor/acceptor in a side chain upon an amino acid substitution, however
a drug resistance mutation may also cause slight backbone structural changes,
which may or may not affect the distance/angle between the donor and the accep-
tor of a hydrogen bond. For example, R155, which is a site of drug resistance
mutations, makes a backbone hydrogen bond with the P1 position of all three
inhibitors, with MK-5172 being less stable. The stability of this backbone hy-
drogen bond in the simulations of mutant complexes deserves further attention
in a follow-up study. A157 makes two backbone hydrogen bonds with P3 posi-
tion of all four substrates, which is successfully mimicked by the inhibitors. The
backbone hydrogen bond formed by G137 and P1 of at least three substrates is
also formed by the P1′ moiety of inhibitors. In addition, the P1′ moiety makes
a hydrogen bond with the backbone nitrogen of the catalytic serine ≈70% of the
simulated time. The inhibitors fail to mimic the hydrogen bond with the catalytic
histidine that appears to be conserved across the substrates.
The electrostatic network along one surface of the bound cleavage products
between protease residues R123, D168, R155, and the catalytic D81 has been pro-
posed to increase the stability of the bound state and therefore contribute to sub-
strate recognition. [189] The salt bridges D81-R155 and R155-D168 in the sub-
strate complexes appear to be mutually exclusive, suggesting that R155 is shared
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between D81 and D168 (Figure 4.13). This exchange of salt bridges along the
binding surface does not occur in inhibitor complexes as the rigid tight binding
inhibitors lock the conformation of the side chains at the binding site stabilizing
individual salt bridges. In the inhibitor-bound complexes, R155-D168 salt bridge
is extremely stable (Figure 4.14). The D81-H57 salt bridge exists throughout the
inhibitor simulations, as R155 is not available for salt bridging to D81.
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Figure 4.13: R155 is shared by D81 and D168 in a salt bridge network along
the binding surface. The salt bridges formed along the binding surface by three
pairs of protease residues (D81-R155, R155-D168, and D168-R123) were moni-
tored throughout the 100 ns MD simulation trajectory for four substrate complexes
(3-4A, 4A-4B, 4B-5A, 5A-5B).
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The D168-R123 salt bridge is an exception, which appears to be transient
in both substrate and inhibitor MD simulations (Figure 4.13 and 4.14). The en-
hanced flexibility towards the P6 site in the substrates may have given a relative
conformational freedom to the R123 side chain while the inhibitors have minimal
interactions with this residue due to the lack of P6-P5 moieties. Two of the most
severe drug resistance mutations, R155K or D168A, could disrupt this salt bridge
causing an energetically unfavorable perturbation in the inhibitor complexes. The
maintenance of this electrostatic network within the protease residues should also
be assessed in inhibitor design.
In addition to the electrostatic interactions within the protease substrate or
inhibitor complexes, recent work also suggests that water molecules can play an
important role in molecular recognition. [190–192] While the substrates do not
have conserved water-mediated hydrogen bonds with the protease in the crystal
structures, the inhibitors ITMN-191 and MK-7009 have eight crystallographic
water molecules that are within 4 A˚ of both protease and inhibitor. The solvent
exposure of the binding site combined with the effects of crystal contacts may
present challenges in accurately assessing the relative importance of these water
molecules.
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Figure 4.14: The R155-D168 salt bridge is stabilized by D81-H57 salt bridge
in inhibitor complexes. The salt bridges formed along the binding surface by
three pairs of protease residues (D81-H57, R155-D168, and D168-R123) were
monitored throughout the 100 ns MD simulation for three inhibitor complexes
(ITMN-191, MK-5172, and MK-7009).
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4.4 Conclusion
Understanding differential interaction patterns between substrates and inhibitors
can help guide the design of new inhibitors that better target resistant protease
variants. Comparison of a series of structural and dynamic features of inhibitors
and substrates reveals key insights for structure-based design of inhibitors that are
robust against resistance mutations. One aspect of substrate specificity that can be
used to optimize inhibitors is the dynamic substrate envelope. This is a two-sided
optimization problem: (1) the volume of the compound that stays outside the enve-
lope (Vout) should be minimized to avoid contacts with protease residues that are
not important for substrate recognition and at the same time (2) the portion of the
substrate envelope that is not being filled by the inhibitor (Vremaining) should be
minimized to efficiently use the substrate envelope when growing the compounds.
These need to be achieved while maintaining the potency of the inhibitors.
Considering the effect of protein dynamics in substrate binding modes and
defining the substrate envelope as a probability distribution is especially critical
for the HCV NS3/4A protease. The high solvent exposure of NS3/4A binding
site allows the substrates to be highly flexible. Accessibility of more conforma-
tional states to the substrates means they are less constrained within the consensus
volume defined by the crystal structure conformations; thus, the increased space
explored by the substrates results in a smaller consensus volume. The dynamic
substrate envelope, defined as a probability distribution of the substrate volume
in the binding site, better captures the substrate binding features and allows for a
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more accurate assessment of the inhibitors during drug design. This probabilistic
dynamic substrate envelope allows for a detailed investigation of the individual
moieties on an inhibitor and an accurate evaluation of the similarities/differences
between substrate and inhibitor complexes.
The most conserved substrate volume, when protein dynamics is taken into
account, is defined by the P1 to P4 residues while P5 and P6 have more confor-
mational freedom. P6 is able to serve as a hub in an intermolecular electrostatic
network involving the protease residues R119, R123, R161 or K165, dynamically
flipping between these basic residues. In theory, an inhibitor can be designed to
have a charged P6 moiety with molecular flexibility consistent with the natural
substrates to facilitate these electrostatic interactions with the protease. Including
the P6 residues of the substrates in the dynamic substrate envelope will provide a
useful basis to guide the design of these charged compounds. Based on this pro-
file, inhibitors should be designed such that their regions spanning P1-P4 portion
of the substrate envelope are more restrained while the moieties spanning P5-P6
sites are more flexible. Ideal inhibitors of NS3/4A protease should be designed to
have the intrinsic flexibility consistent with the natural substrates.
To minimize the susceptibility of an inhibitor to drug resistance mutations,
interactions with functional residues, which include the catalytic triad and also
the residues that play a key role in substrate recognition in HCV protease, should
be enhanced. In contrast, the interactions with known drug resistance mutation
sites or polymorphic sites should be minimized. R155, which is among the most
severe drug resistance mutation sites, is in extensive contact with the P2 groups
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of all three inhibitors. During the optimization of new compounds, favoring the
P2 conformation over D81 and H57 away from R155, as in MK-5172, is expected
to be useful for better performance against the R155K variant. In fact, the fold-
change in the inhibition constant Ki against the R155K variant relative to the wild
type is 162, 6, and 749 for ITMN-191, MK-5172, and MK-7009, respectively.
[90] In addition, the P2-P4 macrocycle enhances the protease interactions through
D168 and V158. Breaking this macrocycle could reduce the resistance severity
of the D168A mutation. In fact, fold changes in Kivalues for ITMN-191 and
MK-7009 are 208 and 3561, respectively, against the D168A variant. [90] Finally,
P1-P3 macrocycle appears to hinder P1 to fill the S1 pocket completely. P1 may
be modified to explore the possibility of enhancing the interactions with F154 in
the S1 pocket, consistent with the substrates very favorable interactions at P1 site.
Another binding interaction to optimize is the hydrogen bonding. When plac-
ing the hydrogen bond donors/acceptors in the compounds, the protease backbone
donors/acceptors could be targeted at polymorphic sites. While a conformational
readjustment is possible with an amino acid substitution at these sites, a hydrogen
bond with the side chain is more likely to be lost upon a mutation. In addition, the
substrate P6 residues salt bridges with a series of protease binding site residues.
Maintenance of this electrostatic network within the protease could also be taken
into account during inhibitors design.
In conclusion, the binding volume of a robust inhibitor should ideally not fall
outside of the dynamic substrate envelope to achieve a better resistance profile.
When searching the chemical space in the design process, ranking the candidates
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based on their Vout and Vremaining in combination with vdW contacts and the
electrostatic interactions may predict which compounds will be more suscepti-
ble to resistance. The exact location where the inhibitor protrudes beyond the
substrate envelope is also critical. Some regions of the dynamic substrate enve-
lope is more heterogeneous, therefore the compound could have more freedom
at those regions. Relative importance of subpockets should be explored for each
compound in development. Protruding beyond the substrate envelope might be
tolerable to pick up interactions with the catalytic triad since the catalytic residues
are evolutionarily conserved and highly unlikely to mutate to confer drug resis-
tance. In addition, modifications to ligands may be needed to alter properties
other than target affinity and selectivity (i.e. solubility, metabolism, permeability,
or efflux). [193] Extending beyond the substrate envelope in regions that do not
contact the enzyme could be used to tune such properties and modifications in
these regions are likely to be better tolerated than those that contact the enzyme.
Finally, designing inhibitors to have flexibility consistent with substrates should
improve the chances of avoiding resistance mutations.
4.5 Methods
4.5.1 Protease-Substrate/Inhibitor Complex Structures
Structural and dynamic properties of four substrates and three small-molecule
inhibitors in complex with the NS3/4A serine protease were investigated (Ta-
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ble 4.1). Crystal structures of the three protease-substrate complexes, which cor-
respond to the cleavage sites 4A-4B, 4B-5A, and 5A-5B on the viral polyprotein,
were available (PDB ID: 3M5M, 3M5N, 3M5N). [9] The structure of the fourth
cleavage site, 3-4A, was modeled based on the full-length helicase/protease struc-
ture [186] (PDB ID: 1CU1) by deleting the helicase domain but keeping the C-
terminal eight residues in the enzyme binding site. This C-terminal region corre-
sponds to the product of the cleavage site 3-4A. In addition, the co-crystal struc-
tures of three macrocyclic inhibitors ITMN-191, MK-5172, and MK-7009 (PDB
ID: 3SU0, 3SUD, 3SU3) were used. [9]
4.5.2 Structure Preparation
For the co-crystal structures in which more than one molecule exists in the
asymmetric unit, all of the molecules were inspected for major structural changes
in the backbone, average temperature factors, the number of missing side chains,
and the ambiguity of the electron density for the substrate or inhibitor in the bind-
ing site. A choice of molecule was made when molecules were equivalent in terms
of structural quality. The complex molecules with protease chain IDs A, B, D, and
A were chosen for the simulations of 3-4A, 4A-4B, 4B-5A, and 5A-5B, respec-
tively. The crystallographic waters within 4.0 A˚ of any protein or ligand atom
were kept, however all the buffer salts were removed from the coordinate files.
The protease in the substrate co-crystal structures, except for the 3-4A com-
plex, has the S139A substitution in the active site, which was originally thought
to inactivate the enzyme, prevent hydrolysis, and allow capturing the intact sub-
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strates in the active site. To get a more realistic model of the active enzyme in-
teractions with the substrates, the A139S back-mutation was introduced in silico
to the crystal structures by deleting the Ala side chain and predicting the confor-
mation of the Ser side chain using the software Prime. The N-terminal residues
in the protease construct, GSHMASMKKK, were extremely flexible in the first
set of trial simulations and did not form stable secondary structure. In addition,
these residues did not interact with either protease or substrate. Therefore, this
region was deleted in subsequent simulations to reduce the computational cost of
the simulations.
As the x-ray structures are not suitable for immediate use in MD simula-
tions, [194] the above described structures were prepared using the Protein Prepa-
ration Wizard from Schro¨dinger. The process adds hydrogen atoms, builds side
chains with missing atoms, and determines the optimal protonation states for ion-
izable side chains and ligand groups. In addition, the hydrogen bonding network
is optimized by flipping the terminal chi angle of Asn, Gln, and His residues and
sampling hydroxyl/thiol polar hydrogens. The exhaustive sampling option with
the inclusion of water orientational sampling was used. Following this step, the
structure was minimized in vacuum with restraints on heavy atoms using the Im-
pact Refinement module with the OPLS2005 force field and terminated when the
root-mean square deviation (RMSD) reached a maximum cutoff of 0.3 A˚. This
step allows hydrogen atoms to be freely minimized, while allowing heavy-atom
movement to relax strained bonds, angles, and clashes.
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4.5.3 MD simulations
Desmond [195] with OPLS2005 force field [152, 196] was used in all simula-
tions. The prepared systems were solvated in an orthorhombic solvent box with
the SPC water model extending 10 A˚ beyond the protein in all directions using
the System Builder utility. The overall charge of the system was neutralized by
adding the appropriate number of counterions (Na+ or Cl−).
Each system was relaxed using a protocol consisting of an initial minimization
restraining the solute heavy atoms with a force constant of 1000 kcal mol−1 A˚−2
for 10 steps with steepest descent and with LBFSG method up to 2000 total steps
with a convergence criterion of 50.0 kcal mol−1 A˚−2. The system was further
minimized by restraining only the backbone and allowing the free motion of the
side chains. At this stage, the restraint on the backbone was gradually reduced
from 1000 to 1.0 kcal mol−1 A˚−2 with 5000 steps (250 steepest descent plus 4750
LBFSG) for each value of force constant (1000, 500, 250, 100, 50, 10, 1.0 kcal
mol−1 A˚−2) and finally an unrestrained energy minimization was performed.
After energy minimization, each system was equilibrated by running a series
of short MD steps. First, a 10 ps MD simulation at 10 K was performed with
a 50 kcal mol−1 A˚−2 restraint on solute heavy atoms and using Berendsen ther-
mostat in the NVT ensemble. MD steps were integrated using a two time-step
algorithm, with 1 fs steps for bonded and short-range interactions within the 9 A˚
cutoff and 3 fs for long-range electrostatic interactions, which were treated with
the smooth particle-mesh Ewald (PME) method. [155, 197] Time steps were kept
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shorter at this first MD stage to reduce numerical issues associated with large ini-
tial forces before the system equilibrates. This was followed by another restrained
MD simulation for 10 ps at 10 K with a 2 fs inner and 6 fs outer time step in NPT
ensemble. The temperature of the system was slowly increased from 10 K to 300
K over 50 ps retaining the restraint on the system and 10 ps MD was performed
without the harmonic restraints. Production MD simulations were carried out at
300 K and 1 bar for 100 ns using the NPT ensemble, Nose-Hoover thermostat,
and Martyna-Tuckerman-Klein barostat. The long-range electrostatic interactions
were computed using a smooth particle mesh Ewald (PME) [155] approximation
with a cutoff radius of 9 A˚ for the transition between the particle-particle and
particle-grid calculations and van der Waals (vdW) interactions were truncated at
9 A˚. The coordinates and energies were recorded every 5 ps.
4.5.4 Quantitative Definition of the Dynamic Substrate Envelope
All MD trajectories were aligned onto the 4A-4B co-crystal structure using the
alpha carbon of binding site residues 137-139 and 154-160, which are less flexible
compared to the rest of the molecule. The effect of structural alignment on the
resulting substrate envelope was previously assessed to show that the selection of
residues for alignment does not have a significant impact on the final substrate
envelope as long as the selected residues are located in a relatively less mobile
region of the enzyme. [183] The structural alignments were performed using the
Visual Molecular Dynamics (VMD) software. [156]
Substrate conformers were extracted from the aligned MD trajectories. The
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vdW volumes of all conformers were mapped onto the three-dimensional grid
placed on the binding site of the enzyme and normalized by the total number
of conformers to obtain a probability distribution. The vdW radii were taken
from OPLS2005 force field. The mathematical details of the grid-based volume
calculations can be found elsewhere. [165]
4.5.5 Visualizing the Dynamic Substrate Envelope
The substrate conformations from pre-aligned snapshots of MD simulations
were loaded into PyMOL. A vdW map was generated for each conformer using
the map new functionality. The maps were then summed using the map set func-
tion. The final map was shown in surface representation with a contour level that
corresponds to 25% of the total number of conformations used.
4.5.6 Estimating the vdW Contact Potential
The vdW contact energy between the protease and a substrate/inhibitor was
estimated by a simplified Lennard-Jones potential, V (rij), using the equation
V (rij) = 4
[(
σ
rij
)12
−
(
σ
rij
)6]
(4.1)
where rij is the interatomic distance between the protease atom i and the sub-
strate/inhibitor atom j. The  and σ are the well depth and hard sphere diameter,
respectively, for the ij protease-substrate/inhibitor atom pair. V (rij) for all pos-
sible protease-substrate/inhibitor atom pairs was computed within 6 A˚, and when
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the distance between nonbonded pairs are less than that corresponds to , V (rij)
was equated to . The rationale for this modification to the original 6-12 Lennard-
Jones potential was previously described in detail. [165] Using this simplified po-
tential for each nonbonded protease-substrate/inhibitor pair,
∑
V (r)ij) was then
computed for each protease and substrate/inhibitor residue. The vdW parameters,
 and σ, were taken from OPLS2005. For the pairs involving two separate atom
types, the vdW parameters were geometrically averaged.
4.5.7 Hydrogen Bonds and Salt bridges
The percentage of time a hydrogen bond existed between the protease and a
substrate/inhibitor was calculated using VMD. [156] A hydrogen bond was de-
fined by a distance between the donor and acceptor of less than 3.5 A˚ and a
hydrogen-donor-acceptor angle of less than 30◦. Only the hydrogen bonds that
existed more than 50% of the time were considered in the analyses. Salt bridges
were defined as an interaction between a side-chain oxygen atom of Asp or Glu
within 4.0 A˚ of a nitrogen atom of Arg or Lys.
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4.5.8 Root-Mean-Squared Fluctuations and Time-Delayed
Correlations
The normalized time-delayed orientational cross-correlations between residue
pairs are defined as
COi,j(τ) =
〈∆Ri(t)∆Rj(t+ τ)〉
〈∆Ri(t)2〉1/2 〈∆Rj(t+ τ)2〉1/2
(4.2)
where ∆Ri(t) is the fluctuation in the position vector Ri of site i at time t around
its average position throughout the trajectory and ∆Rj(t+ τ) is the fluctuation in
the position vectorRj of site j at time t+τ . The brackets represent time averages.
The cross-correlations vary in the range [-1, 1] with the upper and lower limits
indicating fully correlated (moving in the same direction) and fully anti-correlated
(moving in the opposite direction) atomic fluctuations, respectively. τ = 0 gives
the equal-time cross-correlations of atomic fluctuations.
Chapter V
Structural Insights into the Drug
Resistance Conferred by
R155K/V36M in HCV NS3/4A
Protease
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5.1 Abstract
NS3/4A protease inhibitors telaprevir and boceprevir were recently approved
by FDA for treatment of chronic HCV genotype 1 infection to be used in combina-
tion with Peg-IFN/RBV. Both telaprevir and boceprevir are acyclic ketoamide co-
valent inhibitors. Several non-covalent NS3/4A inhibitors are at various stages of
clinical development, including danoprevir (ITMN-191), which is a macrocyclic
acylsulfonamide inhibitor. The co-occuring protease mutations R155K/V36M
have been reported to confer drug resistance both in replicon assays and in clinic.
R155K is an active site mutation that directly alters the electrostatic characteris-
tics of the binding surface on the enzyme. In contrast, V36M is a distal mutation
that is not in direct contact with either bound inhibitors or active site residues
but in direct contact with the cofactor NS4A and the B1 β-strand of NS3. The
molecular mechanism by which V36M in the presence of R155K confers higher
levels of resistance than R155K alone is not known. In this chapter, the molec-
ular basis of drug resistance conferred by V36M in the R155K background has
been investigated using a combination of drug susceptibility assays, x-ray crys-
tallography, and molecular dynamics simulations. R155K and R155K/V36M co-
crystal structures of each inhibitor differ mainly in residues on α2 helix and E2
strand near the active site. Telaprevir-bound R155K/V36M had alternate confor-
mations at the site of V36M mutation and the two binding site residues, D168 and
R123, suggesting a coupling between the structural destabilization at the bind-
ing surface and distal V36M mutation site. The R155K mutation disrupts the
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electrostatic network along the binding surface. Danoprevirs P2 moiety is highly
flexible in the MD simulations since its P2 moiety packs against R155 and upon
R155K mutation; danoprevir loses significant interactions with both R/K155 and
catalytic H57 and D81. Finally the significant changes in the internal distance
distributions of residues 36 and 43 as well as 43 and a series of binding surface
residues 136/155/156/157 are considerably different in the wild-type, R155K, and
R155K/V36M complexes. The unbound form also samples conformations where
the internal distances vary within the three variants. Based on these observations,
one possible mechanism is that the impact of V36M mutation may be propagated
to the binding site through a conformational shift in B1 β-strand, which is a spatial
neighbor of both V36M and the binding site. V36M mutation may also interfere
with the binding of the cofactor NS4A, which aids in the proper folding of NS3.
5.2 Introduction
The new standard of care for Hepatitis C patients emerged in 2011 with the
regulatory approval of the first generation NS3/4A protease inhibitors, telaprevir
(Incivek(®)) and boceprevir (Victrelis(®)). These protease inhibitors, combined
with Peg-IFN/RBV, offer genotype-1 infected patients significantly improved sus-
tained virologic response rates (68-75%) and the potential for shorter durations
of therapy. [198–200] However, efficacy of the approved inhibitors is limited to
a single genotype. In addition, severe side effects such as anemia, rash or de-
pression [201] combined with pill burden, food requirements, and emerging drug
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resistance [202–206] are serious drawbacks to these PIs. Thus, HCV therapeutics
continues to evolve and there are several drugs currently in development targeting
NS3/4A. Among these drugs, danoprevir (RG7227/ITMN-191) is a macrocyclic
inhibitor that is currently being administered in Phase II clinical trials to genotype-
1 patients.
Response to therapy is varied in HCV patients, but cross-resistance to PIs
is a common issue. In patients with genotype 1a, the R155K mutation causes
resistance against nearly all inhibitors, [207] though it rarely occurs in geno-
type 1b patients due to high genetic barrier in 1b. [85, 208–214] In genotype
1b patients, resistance mutations arise depending on the class of inhibitors use;
A156 mutates in response to treatment with linear ketoamide protease inhibitors
[85, 213, 214] while macrocyclic PIs mainly select for D168A and R155K vari-
ants. [207, 209, 210] Mutations at V36, T54, V36/R155 were initially reported
to be associated with resistance to ketoamide inhibitors. [85, 213, 214] However,
recent data released at the Liver Meeting 2012 [215] shows that an interferon-
free mericitabine/danoprevir combination therapy resulted in a confirmed viral
breakthrough in 21% of patients. These patients had danoprevir-resistant variants,
including R155K/V36M.
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Figure 5.1: Sequence and topology of HCV NS3/4A protease
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Figure 5.1
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NS3/4A, a serine protease with a chymotrypsin-like fold, has two globular
domains surrounding a cleft containing the active site residues, H57-D81-S139,
on the N-terminal β-barrel. The same nomenclature introduced by Barbato et al.
was used for the secondary structural organization of NS3/4A (Figure 5.1). [216]
R155 is located at the binding site of NS3/4A and is in direct contact with the
inhibitors while V36 is a distal mutation site, which is located on A1 β-strand
about 13 A˚ away from the catalytic histidine and 15 A˚ from R155 (Figure 5.1).
Crystallographic studies showed that R155K disrupts the electrostatic network
among R123-D168-R155-D81 altering the charge distribution along the binding
surface and affecting the P2 cyclopentylproline and P4 cyclohexylalanine moieties
of telaprevir. [90] Meanwhile, danoprevir loses a favorable cation-pi interaction at
the P2 isoindoline upon R155K, shifting the P2 moiety. Pan et al. performed
molecular dynamics simulations and per-residue binding free energy composi-
tion on the wild-type and four variants of NS3/4A protease carrying the active
site drug resistance mutations (A156V, D168A, D168E, and R155K) and reported
that the destruction of the salt bridge between 168 and 155 causes large confor-
mational changes in the binding pocket and A156V mutation changes the binding
pocket with an extra bulky methyl group possibly resulting in resistance. [217]
While these studies provided a structural mechanism of resistance for R155K, the
molecular basis of the distal mutation V36M is unknown. Welsch et al., based
on molecular modeling studies, hypothesized that the distal mutations at V36 and
T54 result in impaired interaction of the protease residues with telaprevir’s cyclo-
propyl group, however this hypothesis has not been experimentally proven. [218]
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In this study, we take a multidisciplinary approach to elucidate the molecular
basis of the susceptibility of telaprevir, boceprevir, and danoprevir to R155K/V36M
variant of NS3/4A. Through a combination of drug susceptibility assays, crys-
tallography, and molecular dynamics simulations, we reveal possible molecular
mechanisms underlying the drug resistance conferred by the distal V36M muta-
tion.
5.3 Results and Discussion
5.3.1 Drug Susceptibility and Enzyme Inhibition Assays
Resistance to inhibitors was tested by measuring the enzymatic inhibition con-
stant, Ki, with both isolated full-length and single domain NS3/4A protease and
determining the cellular half-maximal inhibition constant, IC50. Susceptibilities
of telaprevir and danoprevir against the R155K variant were recently reported as
a fold-change relative to the wild-type. [90] For this study, these two PIs were
tested against R155K/V36M variant in addition to boceprevir. Telaprevir loses
about 20-fold inhibitory activity against R155K variant of both the full-length and
the single domain isolated proteases (Table 5.1). More than 200-fold reduction in
Ki was measured for telaprevir against both R155K/V36M constructs. Bocepre-
vir, despite its binding mode being very similar to telaprevir, loses 7- and 31-fold
inhibitory activity against the isolated R155K and R155K/V36M protease and the
loss is 11- and 29-fold against the full-length NS3/4A. Danoprevir, despite being
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much more potent against the wild-type, loses more than 100- and almost 200-
fold inhibitory activity against the full-length and single domain proteases. On
the other hand, the reason for danoprevir having a lower IC50 than Ki is not clear
because typically higher drug concentrations are needed to inhibit the protease in
a replicon system than an isolated protease. Nevertheless, the general trend of the
data from the replicon and enzymatic assays is consistent. Antiviral activity (IC50)
loss is more dramatic against the HCV clones carrying R155K/V36M than those
carrying R155K, which trends with the enzymatic inhibition assays. Telaprevir
and danoprevir appear to be more susceptible to R155K/V36M than boceprevir
reflected in the fold-change relative to the respective IC50 against the wild-type.
In conclusion, the susceptibility of all three inhibitors tested here increased with
V36M in the presence of R155K, which is striking considering the distal location
of V36M from the binding site.
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Table 5.1: Drug susceptibilities against wild-type and resistant HCV
clones and inhibitory activities against NS3/4A proteases
Full-length NS3/4A Enzyme - Ki (nM)a
WT R155K R155K/V36M
Telaprevir 40.9 ± 3.7 824.0 ± 75.1 (20) >10,000 (>244)
Boceprevir 34.7 ± 2.9 390.8 ± 43.0 (11) 1018.0 ± 192.3 (29)
Danoprevir 1.2 ± 0.1 132.0 ± 18.0 (111) 292.9 ± 38.6 (246)
Protease domain - Ki (nM)a
WT R155K R155K/V36M
Telaprevir 33.3 ± 4.0 803.7 ± 89.9 (24) 7342 ± 1281 (220)
Boceprevir 35.4 ± 3.3 236.7 ± 44.3 (7) 1097.0 ± 120.4 (31)
Danoprevir 1.0 ± 0.1 157.9 ± 20.5 (158) 295.5 ± 34.3 (295)
Replicon IC50 (nM)a
WT R155K R155K/V36M
Telaprevir 1349 4740 (3.5) 15759 (12)
Boceprevir 971 2788 (3) 3941 (4)
Danoprevir 0.24 >100 (>416) >100 (>416)
aNumbers in paranthesis reflect fold-change relative to wild-type;
> indicates IC50 and Ki values higher than the maximum drug
concentration tested in the assay.
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5.3.2 Crystallographic Binding Mode of Inhibitors
To shed light on the molecular basis of resistance conferred by R155K/V36M,
high-resolution crystal structures of the R155K/V36M variant were determined
in complex with telaprevir, boceprevir, and danoprevir (Table 5.2). Our group
recently published the crystal structures of the telaprevir- and danoprevir-bound
R155K variant along with a series of other drug resistance mutants. [90] Bennett et
al. reported a crystal structure of the wild-type protease in complex with bocepre-
vir, however the resolution was only 2.65 A˚ with relatively higher temperature
factors around the binding site and Rfree was considerably higher than the Rfactor
(27% versus 19%). [219] Therefore, to determine a higher resolution structure,
boceprevir was also crystallized with the wild-type in addition to the R155K and
R155K/V36M variants. The structure of the wild-type apo NS3/4A protease do-
main was also determined. No crystallographic data were collected for the apo
R155K and R155K/V36M proteases; but these variants were modeled using the
crystal structures of the danoprevir-bound R155K and R155K/V36M variants and
the wild-type apo protease as templates by removing danoprevir from the mutant
protease complexes and introducing the mutations to the apo structure, respec-
tively.
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Table 5.2: X-ray data collection and crystallographic refinement statistics
Drug Apo Telaprevir Boceprevir Danoprevir
Protease variant WT R155K/V36M WT R155K R155K/V36M R155K/V36M
Resolution (A˚) 1.3 1.6 1.7 1.8 1.7 1.1
Space group P212121 P212121 P212121 P212121 P212121 P212121
a (A˚) 54.8 54.9 55.1 55.4 55.4 55.3
b (A˚) 58.6 58.7 58.8 59.0 58.9 58.5
c (A˚) 60.9 60.9 60.1 59.8 60.0 59.8
Molecules in AUa 1 1 1 1 1 1
Rmerge(%)b 4.8 7.2 4.5 3.2 3.4 5.2
Completeness(%) 93.1 99.8 95.8 90.8 90.8 97.2
I/σ 14.8 20.6 22.8 15.4 11.6 12.6
Measured reflections 190364 209787 96791 48641 41927 334751
Unique reflections 45595 26953 21118 15757 19992 69496
Redundancy 4.2 7.8 4.1 3.1 2.1 4.8
RMSDc Bonds (A˚) 0.009 0.010 0.012 0.006 0.007 0.009
RMSDc Angles (◦) 1.294 1.337 1.492 1.117 1.128 1.250
Rfree (%) 19.1 19.3 19.3 18.8 20.0 16.0
Rfactor (%) 16.1 17.5 15.6 15.2 16.3 14.1
No of waters 166 156 247 186 212 186
a AU, asymmetric unit.
b Rmerge =
∑
h
∑
i |Ii − 〈I〉| /
∑
h
∑
i Ii.
c RMSD, root mean squared deviation.
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Overall, the inhibitors superimpose well within the binding site except for
danoprevir’s flexible isoindoline at P2 moiety (Figure 5.2). The direct contact
of this moiety with the site of mutation causes a shift in the binding mode upon
R155K and loss of favorable interactions (Figure 5.3). The P2 isoindoline is desta-
bilized with R155K mutation, consistent with the simulation results of Pan et al..
This verifies that the extreme destabilization of P2 is not forcefield dependent and
is reproducible with alternate forcefields. This high flexibility causes loss of fa-
vorable interactions with the catalytic residues D81 and H57 while in the crystal
structure they are stable. On the other hand, structural perturbations are observed
in key protease residues that are in contact with telaprevir upon R166K/V36M
mutation (Figure 5.2). The R155K/V36M protease, when bound to telaprevir,
has alternate conformations at the M36 position. Substitution of a valine at a
relatively buried position to a larger methionine side chain likely alters the lo-
cal packing causing the M36 side chain to assume alternate conformations. This
alteration must somehow be transmitted to the binding site because the residues
D168 and R123, which are a part of the electrostatic network believed to be impor-
tant for stabilizing the tight binding substrates and inhibitors, also have alternate
positions. Having alternate conformations in the crystal structure for two mem-
bers of this important electrostatic network suggests that the network is even more
destabilized with V36M. In addition, K136 both plays an important role in sub-
strate recognition through its favorable electrostatic interactions with the acidic P6
position of the cleavage sites and makes favorable vdW contacts with telaprevir.
However, no clear density was observed for the K136 side chain suggesting that
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the distal V36M mutation also perturbed the likely stable interactions of K136 in
α1 helix with telaprevir.
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Figure 5.2: Binding modes of inhibitors in crystal structures. The protease
and inhibitor are represented as surface and sticks, respectively. The side chains
of key residues are also shown as sticks: the drug resistance mutation sites R155
and V36 (pink), the catalyic triad (yellow), and key binding site residues (green).
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Figure 5.3: Conformational flexibility of danoprevir’s P2 moiety (A) Crystal
structures and (B) representative snapshots with equal intervals of 6 ns superim-
posed on the C2, N2, N5, C11, and C15 atoms of danoprevir.
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5.3.3 Intermolecular Hydrogen Bonds
The hydrogen bonding network between the protease and each inhibitor, ob-
served in the crystal structures, has not been affected by the drug resistance mu-
tations (Figure 5.4). The distance between the hydrogen bond donor and acceptor
atoms vary 0.2 A˚ the most, but staying the same for the most part. However, the
relative stability of these potential hydrogen bonds can be evaluated in conforma-
tional ensembles from the MD simulations (Table 5.3).
The inhibitors make hydrogen bonds mainly with the backbone hydrogen
donor or acceptors in the binding site (Figure 5.4). Therefore, R155K does not
necessarily lead to the loss of a hydrogen bond. However, because of the struc-
tural rearrangement in the binding site caused by V36M, the likelihood of a hy-
drogen bond with the backbone oxygen decreases≈20% for telaprevir and≈10%
for boceprevir.
The most striking difference between the crystal and MD structures is that both
telaprevir and danoprevir loses the hydrogen bond with the catalytic H57, which
is observed ≈60% of the time between boceprevir and WT and R155K proteases
but drops to 34% in R155K/V36M complex. On the other hand, hydrogen bonds
with R/K155 and A157 (on E2 β-strand) are preserved in the MD simulations
suggesting that these bonds are important enthalpic contributors to the binding
affinity.
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Figure 5.4: Protease-inhibitor hydrogen bonds. (A) Telaprevir (B) boceprevir,
(C) danoprevir. The hydrogen bonds are preserved in complexes of resistant vari-
ants, hence are shown only in wild-type structures. See Table 5.3 for the resistant
variants.
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Table 5.3: Protease-inhibitor hydrogen bonds
Telaprevir Boceprevir Danoprevir
WT R155K
R155K
WT R155K
R155K
WT R155K
R155K
V36M V36M V36M
Crystal structures - Distance between donor and acceptor (A˚)
H57-NE2 OBR 2.6 2.5 2.5 O4 2.6 2.7 2.8 N3 3.1 3.1 3.1
G137-N OBS 2.7 2.7 2.7 O5 2.8 2.8 2.8 O9 2.9 2.9 2.9
G137-N - - - - - - - - O6 3.1 3.1 3.0
S139-N OBS 3.0 3.0 3.0 O5 3.0 3.1 2.9 - - - -
R155-O NAE 3.0 3.1 3.1 N4 3.0 3.1 3.2 N2 3.0 3.0 2.9
A157-O NAC 2.9 2.9 2.8 N2 2.9 2.9 2.9 N1 2.9 2.9 2.9
A157-O - - - - N3 3.0 3.0 2.9 - - - -
A157-N OBT 3.0 2.9 3.0 O1 3.0 3.0 3.0 O3 2.9 2.9 2.9
S159-N OBW 3.0 2.8 2.7 - - - - - - - -
S159-OG OBW 2.9 2.9 2.8 - - - - - - - -
MD simulations - %Time
H57-NE2 OBR 19 2 1 O4 59 60 34 N3 2 1 6
G137-N OBS 74 69 82 O5 61 43 35 O9 16 26 21
G137-N - - - - - - - - O6 47 - 18
S139-N OBS 62 62 46 O5 44 38 45 O4 41 - 7
R155-O NAE 84 81 68 N4 93 94 86 N2 83 91 83
A157-O NAC 90 90 91 N2 48 46 47 N1 74 50 53
A157-O - - - - N3 49 47 50 - - - -
A157-N OBT 87 85 86 O1 71 74 65 O3 88 78 81
S159-N OBW 70 77 77 - - - - - - - -
S159-OG OBW 12 12 12 - - - - N3 57.4 12.2
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5.3.4 Structural Changes in the Protease Backbone
Backbone changes in the crystal structures upon resistance mutations were as-
sessed by computing the differences in the internal Cα-Cα distances between the
resistant and wild-type variants bound to each inhibitor (Figure 5.5). Introducing
V36M mutation to the R155K variant alters the backbone structure more than the
R155K mutation by itself with respect to the wild-type complexes. From single
to double mutant, per-residue average difference in the internal Cα-Cα distances
went up from 0.06 A˚ to 0.08 A˚ for telaprevir, 0.07 A˚ to 0.09 A˚ for boceprevir,
and 0.09 A˚ to 0.14 A˚ for danoprevir. Danoprevir, with almost a 300-fold reduc-
tion in inhibitory activity with R155K/V36M, alters the backbone of the protein
more than the linear telaprevir and boceprevir. Telaprevir is also 220-fold less
potent against R155K/V36M, however the structural changes in the backbone is
less pronounced compared to danoprevir.
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Figure 5.5: Double-difference maps. The differences in internal Cα-Cα dis-
tances were calculated between the R155K-WT, R155K/V36M-WT, and R155K/V36M-
R155K structure pairs for telaprevir, boceprevir, and danoprevir complexes. The
double-difference matrices are colored for each pair with the average double-
difference per residue plotted below. The average double-difference values are
also shown on the structure. The core of the protease is relatively rigid (colored
blue on structure) while backbone structural changes occur around the binding
site and in the loop regions.
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Not only the binding site residues were affected by V36M but also changes
in distal regions were observed (Figure 5.4). More obvious binding site changes
include the loop connecting the β-strands E2-F2 (155 is located on E2), and α2
helix while subtle changes are observed on α1 helix that locates the catalytic H57.
On the other hand, the distal regions with clear backbone changes consist of the
loop connecting A1 (residue 36 is located on A1) and B1 β-strands, N-terminal
region of α0 and C-terminal region of α3. Most of these regions are also flexible
and exhibit differential dynamics upon inhibitor binding (Figure 5.6). The con-
sistency between the crystallographic changes in the backbone structure and the
degree of flexibility in the MD simulations suggests that the regions highlighted in
the double-difference maps are not due to crystal contacts but the conformational
preferences of these regions indeed vary upon mutations.
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Figure 5.6: Changes in the atomic fluctuations in the wild-type NS3/4A.(A)
The RMSFs for the protease in the apo form (gray) and in complex with telaprevir
(blue), boceprevir (red), and danoprevir (green). (B) The RMSFs for the apo and
danoprevir-bound protease are mapped onto the respective crystal structures. (C)
The α2 helix (130-137), which is conformationally stabilized upon inhibitor bind-
ing, is shown on the crystal structures. Consistent with the MD simulations, the
apo crystal structure has two alternate conformations for Y134, which is located
at the α2 helix.
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Characterizing the differential protein dynamics in the bound and unbound
states of a protein can be useful to understand the structural and dynamic mech-
anisms of drug resistance. [128] For HCV NS3/4A, smaller local fluctuations are
observed in inhibitor-bound complexes than the apo protease (Figure 5.6). In the
apo protease, mostly the loop regions are undergoing changes. The core of the
protein is highly stable, also supported by the stable secondary structures over the
trajectories (Supporting Information). An 8 amino acid segment containing the
residues 130-137 that are in close proximity to the binding site loses flexibility
upon inhibitor binding (Figure 5.6), which is consistent with earlier simulation
results reported by Zhu and Briggs. [220] In this segment, I132, L135, K136, and
G137 and to an extent S138 make favorable vdW interactions with the inhibitor
while the backbone amide of G137 hydrogen bonds to the inhibitors. All three
inhibitors stabilize the α2 helix upon binding.
The minimally fluctuating residues, the most rigid Cα’s, in the bound and un-
bound structures of the wild-type protease are not majorly affected by the resis-
tance mutations (Figure 5.7). This suggests that the overall structure of the protein
is vastly stable, which is also consistent with the minimal changes in the secondary
structure throughout the MD simulations (Supporting Figures). Nevertheless, sub-
tle changes upon mutations may be important for the alteration in molecular recog-
nition. The most striking change in atomic fluctuations with V36M mutation is
observed at telaprevir’s A2, B2, and C2 strands, which become significantly more
restrained compared to the wild-type, as evident in the atomic fluctuations (Fig-
ure 5.7). When bound to danoprevir, residues 70-80, which form E1 strand, are
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relatively rigid in the wild-type protease and become mobile in both R155K and
R155K/V36M variants. The other changes in atomic fluctuations are typically at
loop regions. These statistically significant changes in atomic fluctuations upon
mutations may also be significant in the structural mechanism of drug resistance.
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Figure 5.7: Changes in the atomic fluctuations upon resistance mutations.The
RMSFs are plotted for WT (blue), R155K (red), and R155K/V36M (green) pro-
teases in the (A) unbound and (B-D) telaprevir-, boceprevir-, and danoprevir-
bound states. In telaprevir-bound state, the A2 and B2 strands, significantly rigid-
ified in R155K/V36M relative to WT and R155K, are shown in pink on the struc-
ture. The catalytic residues are colored yellow. Telaprevir is shown as sticks.
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5.3.5 Intramolecular Salt Bridges
A key residue determining the electrostatic character of the binding surface is
R155, which can make two salt bridges, one with D81 and the other with D168 in
all inhibitor-bound structures. In the wild-type protease, R155-D168 salt bridge is
more stable than the R155-D81 salt bridge, consistent with the distances observed
in the crystal structures (6.4 A˚ for D81-R155 and 4.8 A˚ for R155-D168). While
danoprevir binding further stabilize R155-D168, the ketoamide inhibitors appear
to optimize the electrostatic network on the binding surface such that both these
salt bridges exist more than ≈80% of the time. However, R155K mutation fa-
vors D81-K155 over K155-D168 in telaprevir and danoprevir complexes but not
in boceprevir. The higher stability of K155-D168 in boceprevir complex is prob-
ably interdependent on the higher stability of the H57-D81 salt bridge, since D81
is no longer available for a salt bridge with K155. This observation combined
with the fact that boceprevir is less susceptible to R155K compared to telaprevir
and danoprevir suggests that the geometry of the catalytic triad is a key factor
stabilizing an inhibitor on the binding surface.
The disruption of the electrostatic network along the binding surface appears
to be predominantly orchestrated by R155K mutation in telaprevir and bocepre-
vir complexes. With danoprevir binding, a slight destabilization of D81-K155 is
observed in the R155K/V36M protease (from %84 to %78).
Another contributor to the electrostatic network along the binding surface is
R123, which is relatively solvent-exposed even in the bound state; therefore the
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side chain conformation may be sensitive to crystal contacts. To test this possibil-
ity, all the potential salt bridges on the protein surface were evaluated (Table 5.4).
Neither inhibitor binding nor mutations in the protease changed the salt bridges
significantly suggesting that the changes observed on the electrostatic network in-
volving H57-D81-R/K155-D168-R123 is due to the mutations in the protease but
not alternate conformations of R123 favored in separate crystals.
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Table 5.4: Salt bridges along the binding site of resistant NS3/4A variants
APO Telaprevir Boceprevir Danoprevir
WT R155K
R155K
WT R155K
R155K
WT R155K
R155K
WT R155K
R155K
V36M V36M V36M V36M
Crystal Structures (Distance between the side chain oxygen and nitrogen in A˚)
H57 D81 3.9 3.9 3.8 3.8 3.9 3.9 3.9 3.9 3.9 3.9
D81 R155 6.4 4.5 - - 4.5 3.7 3.5 - - -
R155 D168 4.8 4.8 4.8 5.2 4.8 - - 3.7 - -
D168 R123 3.6 4.8 4.8 4.3 4.6 3.5 3.6 5.1 3.5 3.5
D25 R11 4.5 4.5 4.4 4.4 4.5 4.5 4.4 4.4 4.4 4.4
E173 E118 5.7 5.7 5.6 5.5 5.5 5.6 5.5 5.4 5.4 5.4
E32 R92a 3.5 - - - 4.1 - 3.3 - - -
E30 R997 4.5 4.7 4.6 4.6 4.8 4.7 4.5 4.9 4.7 4.8
D103 R117 4.5 4.6 4.5 4.5 4.6 4.6 4.6 4.6 4.6 4.7
D121b R118b - - - - - - - 6.7 - -
D112b R130b - - - - - - - - 6.8 6.5
MD Simulations (% of the time the salt bridge criterion was satistifed
H57 D81 100 99.4 99.9 93.9 29.1 34.6 100 100 100 100 22.7 30.5
D81 R155 10.3 12.2 16.4 95.8 89.3 83.3 85.5 2.6 3.9 0 83.9 78.4
R155 D168 98.3 5.6 3.1 86.2 23.8 23.9 79.6 65.0 67.3 100 22.2 21.3
D168 R123 21.7 96.2 99.7 88.5 96.0 95.1 88.7 91.7 84.9 22.3 91.2 90.8
aIn only three structures, unambiguous electron density was observed for R92.
bAll structures had relatively high B-factors for these residues.
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5.3.6 vdW Interactions at the Binding Surface
The drug resistance mutations alter the local packing on the binding surface
reflected in the difference in vdW contacts relative to the wild-type complexes
(Figure 5.8). The most dramatic loss is at danoprevir’s P2 moiety (Figure 5.9)
with the residues R155K, A156 and A157 (Figure 5.8). This interaction loss is
consistent with enhanced flexibility upon R155K (Figure 5.3). Danoprevir also
loses significant interactions at P1′ moiety with F43 on the B1 strand, which is
located close to V36. The gain of interactions at P1 of danoprevir is not enough
to compensate for the lost interactions at P2 and P1′.
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Figure 5.8: vdW interactions at the NS3/4A binding surface. (A) Telaprevir,
(B) boceprevir, (C) danoprevir. On the left, the vdW energies tracked over MD
trajectories were plotted for WT (blue), R155K (green), and R155K/V36M (red)
proteases. On the right, the difference of R155K (blue) and R155K/V36M (red)
variants from the wild-type is shown.
256
Figure 5.8
257
Figure 5.9: vdW interactions of the inhibitor moieties. (A) Telaprevir, (B) bo-
ceprevir, (C) danoprevir. The differences in inhibitor interactions with the R155K
(blue) and R155K/V36M (red) proteases are shown with respect to the wild-type.
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Upon R155K, telaprevir loses favorable vdW interactions mainly with the mu-
tation site K155 and the catalytic H57 at its P2 and P4 positions. On the other
hand, boceprevir, in addition to K155 and H57, loses interactions with K136,
A156 and A157. A156 and A157 are located on the E2 β-strand, which makes up
a significant portion of the binding surface. K136 is located on the α2 helix. This
3-10 helix, spanning residues 130-137, appears to be important in binding events
as it is highly flexible in the apo structure but is restrained significantly upon
inhibitor binding (Figure 5.6). Ordering of this segment can only be achieved by
tight, favorable interactions with the inhibitor. Therefore, losing these interactions
contribute to the loss in the danoprevir affinity upon mutations.
V36M appears to further contribute to the loss of vdW contacts with H57 and
K155. The differences in vdW energies between the R155K and R155K/V36M
variants are small but significant. Danoprevir picks up new interactions with
V158, S159, and T160 of the R155K/V36M protease compared to the WT and
R155K variants. These are sites of more favorable interactions with the natural
substrates than inhibitors (Figure 4.10). While these interactions are not enough to
compensate for the dramatic loss of interactions at D81 and R/K155 for danoprevir
binding, they may have a more pronounced affect on substrate recognition, shift-
ing the equilibrium between substrate recognition and inhibitor binding towards
substrate recognition. A comparison of the vdW energies in the crystal versus
MD structures clearly show that the mutations significantly alter the dynamics of
the protease and only the very obvious change in vdW energy of R155K can be
observed in the crystal structures (Figure 5.8 and 5.10).
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Taken all together, the changes in vdW contacts upon mutations is not limited
to the site of mutation but a structural rearrangement is observed on the binding
surfaces of the mutant proteases.
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Figure 5.10: Crystallographic vdW interactions at the NS3/4A binding sur-
face. (A) Telaprevir, (B) boceprevir, (C) danoprevir. The difference of R155K
(dark gray) and R155K/V36M (light gray) variants from the wild-type is shown.
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5.3.7 Inter-residue Distances in the MD Simulations
To better capture the structural rearrangement in the protease upon resistance
mutations, first the inter-residue distances between V/M36 and F43 was measured
(Figure 5.11). The A1 strand, locating V36, is bridged to the binding site via B1
strand. F43, which directly interacts with the substrates and inhibitors, is located
on B1. In the apo structure, V36M mutation broadens the 36-43 distance distri-
bution while in inhibitor-bound structures the two residues are relatively closer
to each other compared to the wild-type and R155K complexes. The residues
that are affected by the change in V/M36-F43 distance were determined by track-
ing their distances from F43 (Figure 5.12). The four residues, K136 in α2 helix
and R/K155, A156 and A157 on E2 β-strand get closer to F43 with V36M mu-
tation. The fact that E2 and B1 β-strands and the α2 helix are closer to each
other suggests a slight shrinking in the binding site. The loops connecting A1-B1
and E2-F2 strands, which can be thought of as pseudo-flaps in analogy to HIV-1
protease, are also closer to each other in the apo and danoprevir-bound proteases
while the width of the distribution changes in telaprevir-bound state (Figure 5.13).
Because the inhibitors typically protrude beyond the dynamic substrate envelope
(Figure 4.4) this shrinking is expected to impair inhibitor binding more than sub-
strate recognition, hence may contribute to drug resistance.
Structural reorganization in the binding site involving the α2 helix and B1 and
E2 strands also impacts the geometry of the catalytic triad (Figure 5.14). In the
apo protease, S139 gets pulled away from H57 and D81 with V36M in the pres-
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ence of R155K. The distance between S139 and H57/D81 is also significantly
larger in boceprevir and danoprevir complexes. In telaprevir and danoprevir com-
plexes, R155K mutation causes H57 and D81 Cα atoms to get closer to each other
while the side chains are not oriented properly for strong salt bridging (Table 5.4).
On the other hand, the robust H57-D81 salt bridge in boceprevir complexes keep
the residue backbone in place resulting in reasonably overlapping distance distri-
butions for the three mutants.
Finally, the H57-K136 distance decreases in the unbound variants of R155K
and R155K/V36M, with a bimodal distribution in R155K/V36M (Figure 5.15).
Since K136 makes key interactions with the natural substrates, one would expect
that a change in the relative orientation of K136 with respect to the catalytic H57
could alter the balance in the molecular recognition events in favor of substrate
recognition versus inhibitor binding.
The V36M mutation may also interfere with the binding of the cofactor NS4A,
which aids in the proper folding of NS3. Since the A1 strand, at which V36
is located, is in direct contact with the NS4A cofactor in structure (Figure 5.1),
a mutation in A1 may as well affect the interactions with NS4A. In fact, while
subtle shifts are observed in the inhibitor complexes, the distance between the
residues V/M36 in A1 and R28 in NS4A are significantly larger in the apo protease
(Figure 5.16). This shift supports the possibility of an interference of a methionine
side chain in A1 with cofactor binding.
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Figure 5.11: Cα-Cα distance between V/M36 and F43. The distance distribu-
tion is plotted for the WT (blue), R155K (red), and R155K/V36M (green) pro-
teases in unbound and bound states. The residues with underlined labels, I25 and
R28, are in NS4A. The NS3 residues V36 and Q34 are located in A1 β-strand
while E13, one of the most flexible residues with high RMSF values, is located on
α0 helix.
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Figure 5.12: Cα-Cα distance between F43 and K136, R/K155, A156, A157.
The distance distribution is plotted for the WT (blue), R155K (red), and R155K/V36M
(green) proteases in unbound and bound states.
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Figure 5.13: Cα-Cα distance between A39 and R161. The distance distribution
is plotted for the WT (blue), R155K (red), and R155K/V36M (green) proteases
in unbound and bound states. Residues A39 and R161 are located on the loops
(“pseudo-flaps” analogous to HIV-1 protease) connecting A1-B1 and E2-F2, re-
spectively.
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Figure 5.14: Cα-Cα distance within the catalytic triad. The distance distribu-
tion is plotted for the WT (blue), R155K (red), and R155K/V36M (green) pro-
teases in unbound and bound states.
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Figure 5.15: Cα-Cα distance between H57 and K136, A156, and A157. The
distance distribution is plotted for the WT (blue), R155K (red), and R155K/V36M
(green) proteases in unbound and bound states.
274
Figure 5.15
275
Figure 5.16: Cα-Cα distance between NS3 and the cofactor NS4A. The dis-
tance distribution is plotted for the WT (blue), R155K (red), and R155K/V36M
(green) proteases in unbound and bound states.
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5.3.8 Correlation of Equilibrium Fluctuations from Gaussian
Network Model
Equilibrium fluctuations of NS3/4A were evaluated with the Gaussian net-
work model (GNM) to decompose the overall dynamics of the protein into the
more significant modes of motion. Overall conformational dynamics of a protein
is mainly determined by the low frequency slow modes of motions. The cross-
correlations of these motions in the first two slowest modes show that the domain
motions in HIV-1 protease and HCV NS3/4A protease are strikingly similar de-
spite the divergence in sequence and structure (Figure 5.17). The commonality
of the domain motions suggests that the two proteases make use of very similar
mechanistic motions to bind, process, and release their respective substrates inde-
pendent of the substrate or protease sequence, the identity of the catalytic residues
and the chemical mechanism of the actual hydrolysis reaction. In HIV-1 protease,
the differential flap motions and their effect on the inter-residue distances between
monomers has been reported for a highly resistant HIV-1 protease in comparison
to the wild-type. [128] Similarly, in NS3/4A protease, while the active site muta-
tion R155K directly alters the interactions at the binding surface, the distal V36M
mutation may alter the orientation of the two β-barrel domains with respect to
each other as reflected in the internal distances.
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Figure 5.17: The correlation of equilibrium fluctuations in the slowest two
modes from GNM. (A) HCV NS3/4A protease, (B) HIV-1 protease. In the slow-
est mode, the two monomers of HIV-1 protease fluctuate in a negatively correlated
manner where in the second mode, the dimerization interface and the flap fluctu-
ations are negatively correlated. The slow mode motions of NS3/4A protease is
strikingly similar to HIV-1 protease.
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5.4 Conclusion
Molecular basis of drug resistance conferred by V36M in the R55K back-
ground has been investigated using a combination of drug susceptibility assays,
x-ray crystallography, and molecular dynamics simulations. The replicon studies
and binding assays show that the R155K/V36M is more resistant to telaprevir, bo-
ceprevir, and danoprevir than R155K. The impact of the distal V36M mutation on
the crystal structure is subtle but MD simulations suggest that the conformational
dynamics of the protease is altered via two separate mechanisms.
One possible mechanism is that the impact of V36M mutation may be propa-
gated to the binding site through B1 β-strand. V36 is located on the A1 β-strand,
right next to B1. β-strands are stable secondary structural elements that are able to
pass a perturbation along to their spatial neighbors in a protein. The fact that F43,
on B1 β-strand, is also a resistance mutation site supports the plausibility of this
hypothesis. Studying the structural and dynamic effects of mutations at F43 in
comparison to those of V36M variants would result in interesting and potentially
useful insights into the structural adaptability of the protease and the mechanism
of resistance.
The V36M mutation may also interfere with the binding of the cofactor NS4A,
which aids in the proper folding of NS3. Substitution of a valine with a larger side
chain, methionine, alters the local packing. Since the A1 strand containing V36
is in direct contact with NS4A in structure, a mutation in A1 may as well affect
the interactions with NS4A. A hindrance in cofactor binding would also interfere
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with substrate processing efficiency, which may be the reason for the reduced
base-level replicative capacity of V36M and R155K/V36M variants of genotype
1b viruses in the absence of drugs (44% and 76% relative to wild-type). [84]
Because implications for both mechanisms are found in the presented data,
the two mechanisms are probably not mutually exclusive, which makes it an even
more interesting problem. The conventional understanding of allostery is a change
of shape at one site of a protein surface due to the effects of ligand binding to an-
other. However, mutations in regions distant from the binding site can have an
impact on the ligand affinity. This impact clearly shows that allostery does not
have to be brought about by ligand binding but proteins even in the unbound state
can be thought of as a network of residues communicating with each other. The
interdependence of the spatial neighbors in a protein can be characterized rela-
tively easily because of the direct interactions among them; hence rationalizing
the co-occuring mutations in these spatial neighbors is relatively less challenging.
In contrast, elucidating the interdependence of residues that are located distal to
each other is not straightforward. The results of this study show that V36M, in the
context of R155K, significantly decrease the affinity to all three inhibitors. Nev-
ertheless, this mutation does not drastically alter the structure trapped in a crystal
but the conformational dynamics of the protein in solution is affected. In addition,
investigating the conformational ensembles revealed considerable changes in the
internal distances within the unbound bound state of NS3/4A variants. Because
binding is an equilibrium event between the bound and unbound states, further
characterization of the solution dynamics of both states by introducing mutations
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in β-strands A1-B1 and NS4A will aid in elucidation of the complex mechanisms
of allosteric communication in NS3/4A.
5.5 Materials and Methods
5.5.1 Mutagenesis and Gene Information
The HCV genotype 1a NS3/4A protease gene described in a Bristol-Meyers
Squibb patent [221](1) was synthesized by Gen-Script and cloned into the pET28a
expression vector (Novagen). Highly soluble NS3/4A protease domain contains
11 core amino acids of NS4A covalently linked at the N terminus. A similar
protease construct exhibited catalytic activity comparable to that of the authentic
full-length protein. [222] R155K and R155K/V36M protease variants were gen-
erated using the QuikChange Site-Directed Mutagenesis Kit from Stratagene and
sequenced by Genewiz.
5.5.2 Expression and Purification
NS3/4A protease expression and purification were carried out as described
previously. [64, 221] Transformed Escherichia coli BL21(DE3) cells were grown
at 37◦C until OD600 reached 0.6 and induced by adding 1 mM IPTG. Cells were
harvested after overnight expression at 4◦C and pelleted. Cell pellets were resus-
pended in 5 mL/g of resuspension buffer (50 mM phosphate buffer at pH 7.5, 500
mM NaCl, 10% glycerol, 2 mM β-mercaptoethanol [β-ME]), and lysed with a cell
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disruptor. The soluble fraction was applied to a nickel column (Qiagen), washed
with resuspension buffer supplemented with 20 mM imidazole, and eluted with
resuspension buffer supplemented with 200 mM imidazole. The eluant was di-
alyzed overnight (molecular mass cutoff, 10 kDa) against resuspension buffer to
remove the imidazole, thrombin treatment was applied simultaneously to remove
the His tag. The nickel-purified protein was then flash-frozen with liquid nitrogen
and stored at -80◦C for future use.
5.5.3 Crystallization
Danoprevir was prepared in-house using our convergent reaction sequence as
described previously [9]; boceprevir was provided by Merck & Co., Inc; telapre-
vir was purchased from A ChemTek, Inc. (Worcester, MA). For crystallization,
the protein solution was thawed and loaded on a HiLoad Superdex75 16/60 col-
umn equilibrated with gel filtration buffer (25 mM morpholineethanesulfonic acid
[MES] at pH 6.5, 500 mM NaCl, 10% glycerol, 30 µM zinc chloride, and 2 mM
dithiothreitol [DTT]). The protease fractions were pooled and concentrated to 25
mg/mL using an Amicon Ultra-15 10-kDa device (Millipore). The concentrated
samples were incubated 1 h with 2 to 20 molar excess of protease inhibitors. Con-
centrated protein solutions were then mixed with precipitant solution (20 to 26%
polyethylene glycol [PEG] 3350, 0.1 M sodium MES buffer at pH 6.5, and 4% am-
monium sulfate) at a 1:1 ratio in 24-well VDX hanging-drop trays and diffraction-
quality crystals were obtained overnight.
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5.5.4 Data Collection and Structure Solution
Crystals large enough for data collection were flash-frozen in liquid nitro-
gen for storage. Constant cryostream was applied when mounting crystal. X-ray
diffraction data were collected at Advanced Photon Source LS-CAT 21-ID-F and
our in-house Rigaku-Saturn 944 X-ray system. The diffraction intensities were
indexed, integrated, and scaled using the program HKL2000. [223] All structure
solutions were generated using simple isomorphous molecular replacement with
PHASER. [224] The model of viral substrate N-terminal product 5A-5B (PDB ID:
3M5O) [9] was used as the starting model for all structure solutions. Initial refine-
ment was carried out in the absence of modeled ligand, which was subsequently
built in during later stages of refinement. Upon obtaining the correct molecu-
lar replacement solutions, ARP/wARP or Phenix [225] were applied to improve
the phases by building solvent molecules. [226] Crystallographic refinement was
carried out within the CCP4 program suite or PHENIX with iterative rounds of
TLS and restrained refinement until convergence was achieved. [227] The final
structures were evaluated with MolProbity [228]. Five percent of the data was
reserved for the Rfree calculation to prevent model bias throughout the refinement
process. [229] Manual model building and electron density viewing were carried
out using the program COOT. [230]
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5.5.5 Drug Susceptibility and Enzyme Inhibition
For enzyme inhibition experiments, 5 nM of the genotype 1a HCV NS3/4A
protease domain was incubated with increasing boceprevir concentrations for 90
min in 50 mM Tris assay buffer (5% glycerol, 5 mM TCEP, 6 mM LDAO and
4% DMSO, pH 7.5). Proteolysis reactions were initiated by adding 100 nM HCV
NS3/4A substrate [Ac-DE-Dap(QXL520)- EE-Abu-y-[COO]AS-C(5-FAMsp)-NH2]
(AnaSpec) and monitored using the EnVision plate reader (Perkin Elmer) at exci-
tation and emission wavelengths of 485 nm and 530 nm, respectively. The initial
cleavage velocities were determined from sections of the progress curves corre-
sponding to less than 15% substrate cleavage. Apparent inhibition constants (Ki)
were obtained by nonlinear regression fitting to the Morrison equation of initial
velocity versus inhibitor concentration using Prism 5 (GraphPad Software). Data
were generated in triplicate and processed independently to calculate the average
inhibition constant and standard deviation.
5.5.6 Double-Difference Maps
The pair-wise atomic distances between each Cα of a given protease molecule
and every other Cα in the same molecule were calculated. The differences of these
Cα-Cα distances between each pair of protease molecules were then calculated
and contoured as a map for visualization. These maps allow for effective struc-
tural comparisons without the biases associated with superimpositions. Double-
differences in internal distances were then averaged for each protease residue and
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plotted with the standard deviation and shown together with the corresponding
double-difference map. The plots of per-residue averages of double-differences
highlight the most variant regions between the two proteases that are being com-
pared.
5.5.7 Hydrogen Bonds
A hydrogen bond was defined based on the criteria of donor-acceptor distance
of less than 3.5 A˚ and hydrogen-donor-acceptor angle less than 30◦ and calculated
with VMD for both molecular dynamics trajectories and crystal structures. [156]
However, the exact coordinates for hydrogen atoms, even in structures of resolu-
tion as high as 1.5 A˚, cannot be determined with confidence based on the electron
density maps. Therefore, for proper evaluation of potential hydrogen bonds in a
crystal structure, hydrogen atoms were added to the crystal structures such that the
hydrogen bonding network was optimized using Maestro. [231] An energy mini-
mization was also performed on the crystal structures by completely constraining
the non-hydrogen atoms. These structures were then evaluated for the hydrogen
bonds formed between the protease and the inhibitors.
5.5.8 Salt Bridges
Salt bridges were defined as an interaction between a side-chain oxygen atom
of Asp or Glu within 4.0 A˚ of a nitrogen atom of Arg or Lys. The salt bridges in
the molecular dynamics trajectories were tracked using VMD. [156]
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5.5.9 van der Waals Interactions
The protease-inhibitor vdW contact energy was estimated by the simplified
Lennard-Jones potential, the details of which was described in subsection 4.5.6.
For consistency, the vdW parameters,  and σ, were taken from the OPLS2005
forcefield as the OPLS2005 forcefield was also used in the MD simulations. For
the pairs involving two separate atom types, the vdW parameters were geometri-
cally averaged.
5.5.10 MD simulations
Structure preparation and the molecular dynamics simulations were performed
following the energy minimization and molecular dynamics protocol described in
subsection 4.5.3.
5.5.11 Molecular Modeling
Crystal structures for apo R155K and R155K/V36M variants were not avail-
able. These structures were modeled using two separate templates. First, the
inhibitor coordinates were removed from the crystal structures of the danoprevir-
bound R155K (PDB ID: 3SU0) and R155K/V36M variants and the resulting
structure were relaxed using the energy minimization protocol described in sub-
section 4.5.3. Second, the mutations were introduced to the crystal structure of
the wild-type apo protease and the resulting structures were again minimized with
the same protocol. To ensure the equivalence of the independently obtained struc-
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tural models, the energy-minimized structures were then compared with respect to
backbone structural changes, side chain orientations of the mutated amino acids
and the residues that are in direct contact with the sites of mutation.
5.5.12 Gaussian Network Model
Elastic network models, utilizing normal mode analysis, are physically plau-
sible and mathematically tractable tools for characterizing molecular fluctuations
near a given equilibrium state, hence for exploring protein dynamics in the native
state. [232, 233] Among these, Gaussian network model (GNM) is the simplest
to decompose a protein into structural domains, defined as portions of the protein
that move independently. The accuracy of the method was verified for a large set
of proteins and connections with graph theory were indicated. [234] HingeProt
is a web implementation of GNM and its extension ANM (Anisotropic Network
Model). [235] The wild-type apo x-ray structure of HCV NS3/4A protease was
uploaded to HingeProt to calculate the cross-correlations of the low frequency
motions based on GNM with a connectivity cutoff of 10 A˚. For HIV-1 protease,
the substrate CA-p2 was removed from the complex structure (PDB ID: 1F7A).
Because the slowest modes contribute the most to the overall collective motions
of proteins, the cross-correlations of residues in the first two slow modes were
calculated to get an insight on the main domain motions of the enzymes.
Chapter VI
Discussion
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6.1 Robust Drug Design: Hitting Multiple Targets at a
Time
Pharmaceutical industry spends $50 billion to produce only 20 new drugs
annually. [236] Only ≈3% of the drug discovery projects result in a marketed
drug. [144] The reasons for drug failures are diverse and include unclear target
biology, poor potency or selectivity, lack of efficacy, and drug resistance.
Drug resistance negatively impacts millions of patients and costs billions of
dollars. As a result of resistance, new drugs quickly become less effective. [237]
Arguably, the best way to address this problem of productivity in drug develop-
ment is to focus on preclinical stages, which has a 35% success rate in delivering
experimental drugs ready for clinical testing. [144] In the preclinical develop-
ment, the goal of disrupting drug target’s activity is necessary, but not sufficient
for developing a robust drug that can avoid resistance.
To discover robust drugs, first a clear picture of drug target’s native function
should be obtained. Protein structure and dynamics are critical for function; there-
fore initial studies should be focused on these. This seemingly extra investment
will eventually save time, money and lives by increasing the robustness of drugs.
Combating viral diseases, the target is not “a” virus but a viral population
including many variants with various levels of fitness under different conditions.
Thus, integrating evolution into drug discovery is required to come up with long-
lived drugs.
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In addition, at the molecular level, proteins exist as conformational ensembles
but also receptor-drug complexes can be very dynamic. A mutation in the target
enzyme can modulate inhibitor binding by disrupting direct interactions with the
ligand but can also indirectly alter protein dynamics. Therefore, in quickly evolv-
ing diseases, the target is an ensemble in mutational and conformational space.
Structure-based drug design relies on static protein structures despite signifi-
cant evidence for the need to include protein dynamics as a serious consideration.
The traditional approach is to make the compounds bind to a static image of the
wild-type enzyme as tight as possible and hope for the best for the potential mu-
tants. However, mutational and conformational plasticity of the viral enzymes
sets the goal to hitting multiple targets at a time for effective therapies. Simulta-
neous integration of evolution and conformational flexibility into drug discovery
becomes feasible with ever-growing technological innovations in high-throughput
assays, deep sequencing, and computational power.
Designing a robust drug is to hit multiple targets at a time, which is not an
easy goal but certainly is worth the effort.
6.2 Drug Target’s Function and Protein Dynamics
The HIV-1 and HCV NS3/4A proteases both recognize a diverse set of se-
quences as substrates. The recognition motif is not a consensus sequence but a
consensus volume shared by the substrates. Deviations in the binding modes of
existing inhibitors from the natural substrates create opportunities for drug re-
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sistance mutations. According to the substrate envelope hypothesis, the inhibitors
should be designed to mimic the consensus shape of natural substrates to avoid re-
sistance, because a mutation that could potentially reduce inhibitor affinity would
also interfere with substrate recognition, hence that mutant virus would not be
populated under the selective pressure of drug therapy (Figure 6.1A).
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Figure 6.1:Guiding drug design using the dynamic substrate envelope. (A)
The most severe resistance mutations (red) occur at sites contacted by competitive
inhibitors (orange) outside the substrate envelope (blue). (B) Dynamic substrate
envelope can be defined as a probability distribution of the consensus substrate
shape within the binding site by combining molecular dynamics simulations and
three-dimensional grid based volume calculations. (C) Dynamic substrate enve-
lope can be integrated into structure-based design of robust drugs by systemati-
cally optimizing two metrics: (1) Vout: The probabilistic volume of an inhibitor
falling outside the dynamic substrate envelope, (2) Vremanining: The portion of
the dynamic substrate envelope that is not fully occupied and, therefore can be
better-utilized by an inhibitor.
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Figure 6.1
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In my thesis, I reformulated the substrate envelope hypothesis by incorporat-
ing the conformational dynamics of protease-substrate complexes and defined the
dynamic substrate envelope for HIV-1 and HCV NS3/4A proteases (Figure 6.1B).
HIV-1 protease has a mainly hydrophobic binding pocket covered by the flaps
while HCV NS3/4A has a very shallow binding surface. As a result of this fun-
damental difference, the dynamic substrate envelope for HIV-1 protease repro-
duced the essentials of the static substrate envelope based on the crystal struc-
tures, whereas I observed significant deviations in the dynamic substrate enve-
lope of HCV NS3/4A from its static substrate envelope. HIV-1 protease is a very
flexible enzyme in the unbound state with flaps constantly sampling alternative
conformations. Nevertheless, in the bound state with the flaps closed over the
binding pocket, the HIV-1 substrates have less degrees of freedom compared to
the highly exposed substrates of HCV NS34/A on the flat binding surface. As a
result, NS3/4A substrates are freer to move, while HIV-1 substrates are relatively
restrained.
The development and clinical introduction of HIV-1 protease inhibitors is re-
garded as a prime example of structure-based rational drug design. [238] The
conformational restriction on the bound ligands of HIV-1 protease turned these
structure-based drug design efforts into a glorious success story, even though pro-
tein dynamics had not been explicitly considered in the design of these inhibitors.
A good quality structure of a high affinity inhibitor turns out to be a good tem-
plate for optimizing HIV-1 protease inhibitors for better pharmacological proper-
ties and flatter resistance profiles, since the active site is captured in its optimum
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geometry for tight binding and does not undergo extreme conformational changes
in solution. On the other hand, the dynamic substrate envelope of HCV NS3/4A
protease has significant deviations from the static substrate envelope, mainly in P5
and P6 positions. In MD simulations, these two residues are very flexible; hence
their consensus volume is relatively small as opposed to their ordered structure in
crystals.
The local packing, quantified as van der Waals interaction energies, are ex-
tremely important for substrate recognition by the hydrophobic binding pocket of
HIV-1 protease. NS3/4A compensates the lack of a well-defined binding pocket
by stronger and longer ranged electrostatic interactions with P6 acid of substrates.
This electrostatic interaction was identified in crystal structures between P6 and
K165 only, however in the MD simulations, I observed a highly dynamic interac-
tion between acidic P6 and a series of basic residues on the binding surface, R119,
R123, R161, and K165. Substituting the P6 residue in substrates to a non-acidic
side chain completely disrupts substrate binding. Similarly, the activity of the en-
zyme should drop drastically with the substitution of K165 to a non-basic residue
if P6-K165 is the only electrostatic component of substrate recognition. However,
based on my MD simulation data, the K165 mutants would have residual activity
due to the presence of R119, R123, and R161 on the binding surface. The activity
assays coupled with MD simulations, if performed on NS3/4A variants with sin-
gle, double or triple mutations of these four basic residues, will provide insights to
the importance of the electrostatic interactions in substrate recognition in solution.
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6.3 Dynamic Substrate Envelope: Integrating Dynamics
into Drug Discovery while Avoiding Resistance
In this thesis, I introduce the dynamic substrate envelope as a significant im-
provement to the substrate envelope hypothesis to guide the design of robust
NS3/4A inhibitors by systematically assessing the susceptibility to existing and
potential resistance mutations.
The dynamic substrate envelope defines consensus mode of substrate bind-
ing more realistically as a probability distribution. This energetically smoother
function can be added to the existing scoring functions to rank compounds based
on their mimicry of the natural substrate binding (Figure 6.1C). In this process,
new inhibitors should be designed to have an ether-linked quinoxaline or similar
functional groups at P2 moiety that favor tight interactions with the catalytic triad
rather than the resistance mutation sites, R155 and D168. Also compounds with-
out the P2-P4 macrocycle should be designed to avoid D168A mutation. Struc-
tural models of the bound inhibitors can be generated using the crystal structure
of a high-affinity inhibitor as the template. To achieve a fair ranking process,
the conformational plasticity of the inhibitors should also be taken into account
by simulating the bound-state dynamics of the inhibitors. The conformational
ensemble of each inhibitor during the MD simulation can then be compared to
the dynamic substrate envelope. The compounds with a smaller probable vol-
ume falling outside the dynamic substrate envelope (Vout) are ranked as less sus-
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ceptible to resistance. The top-ranked inhibitors can be prioritized in the actual
chemical synthesis. The top-ranked compounds may need further modification to
optimize properties other than affinity and selectivity (i.e. solubility, metabolism,
permeability, or efflux). In that case, Vremaining, the portion of the dynamic sub-
strate envelope that is not fully used by that inhibitor, can guide these modifica-
tions to avoid possible contacts with resistance mutation sites. Other metrics to
avoid resistance can also be easily computed from the MD trajectories such as the
molecular interactions with the catalytic triad and functionally important residues
versus sites of resistance mutations and polymorphisms. Compounds with more
favorable interactions with the evolutionarily conserved residues than the resis-
tance mutation sites should be ranked higher. In addition, the flexibility of the
compounds can be evaluated from the trajectories since flexible P2 moieties are
expected to adapt well to R155K mutation. As an indicator of tight binding, the
stability of the electrostatic network involving the residues H51-D81-R155-D168-
R123 can be assessed. The inhibitors that keep this network intact are expected to
be tighter binders. The design scheme I describe (Figure 6.2) here is completely
feasible as we are currently able to collect about 10 ns/day of simulated molec-
ular dynamics data on explicitly solvated systems containing 25,000 atoms on
average. In addition, the scheme I propose is an iterative process where the syn-
thesized compounds are crystallized and tested against the wild-type and resistant
variants. As more structural and binding data are available, then an ultimate scor-
ing function may be formulated with tuning the weights assigned to each metric.
299
Figure 6.2: A structure-based drug design scheme that incorporates protein
dynamics and potential resistance
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Figure 6.2
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The dynamic substrate envelope-based drug design process can potentially
benefit from further improvements. Currently, no co-crystal structure is available
for the full-length substrates of NS3/4A. Residual catalytic activity of inactive
serine protease, with single, double or triple alanine mutations at the catalytic
triad, still has residual catalytic activity. [239]The N-terminal cleavage products
bind to the protease with higher affinities than C-terminal cleavage products. As
a result, the crystal structures contain electron density only for N-terminal. To
guide drug design, the dynamic substrate envelope defined based on the tight-
binding N-terminal cleavage products is likely as useful as if it was defined based
on the intact substrates. However, full-length substrate co-crystal may add to
our understanding of substrate recognition by NS3/4A and allow more accurate
predictions of substrate co-evolution. Generating molecular models is also an
option in case good quality crystals cannot be obtained.
Another factor that may be important for the balance between substrate recog-
nition and inhibitor binding is the role of water molecules in recognition. [190–
192] Five water molecules are conserved in the substrate co-crystal structures
of HIV-1 protease. [7] These water molecules mediate hydrogen bonding be-
tween the protease and its substrates in the crystal structures. While the NS3/4A
substrates do not have conserved waters in the crystal structures, the inhibitors
danoprevir and vaniprevir have eight crystallographic overlapping water molecules
that are within 4 A˚ of both protease and inhibitor. Characterization of the ther-
modynamic stability of these waters may provide a more complete view of the
differential binding characteristics between the substrates and inhibitors.
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6.4 Predicting Substrate Co-evolution using the
Dynamic Substrate Envelope
Protease-substrate co-evolution contributes to drug resistance in HIV-1. The
HIV-1 protease substrates NC-p1 and p1-p6 has co-evolved with the V82A and
D30N/N88D variants of protease. My molecular models followed by MD simula-
tions show that the substrate envelope is preserved by the compensatory mutations
in the cleavage sites, quantified as increased volume of the cleavage site staying
inside the dynamic substrate envelope. However, the conformational interdepen-
dence of residues within the cleavage site sequences challenges direct prediction
of substrate co-evolution from amino acid sequence or a single structure.
An initial report from the scientists at Vertex Pharmaceuticals, Inc. show that
the four NS3/4A cleavage site sequences were well conserved in most of total 569
patients in response to a treatment regimen containing telaprevir but few changes
in the cleavage site regions were observed in the 159 patients who failed telaprevir
combination treatment, and no statistical evidence of directional selection after the
acquisition of telaprevir resistance was detected. [240] Except for this report, the
co-evolution of NS3/4A substrates with drug resistance has not been investigated
in the HCV field. Based on the high flexibility and poor fit within the dynamic
substrate envelope, I predict the 4A-4B cleavage site to be more sensitive to pro-
tease mutations, hence 4A-4B is more likely to co-evolve with resistant NS3/4A
variants.
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The dynamic substrate envelope can be used more systematically to predict
potential NS3/4A protease-substrate co-evolution. Single mutations need to be
introduced in silico at each position of the substrate. Each variant can be then sub-
jected to energy minimization and short MD simulations to track Vin in the context
of a drug resistance mutation in the protease. Similar to HIV-1, the NS3/4A sub-
strate variants with improved Vin values relative to the mutant protease-wild-type
substrate complex are more likely to compensate for the resistance mutation in the
protease.
Being able to accurately predict the substrate co-evolution can be useful to
reduce the likelihood of drug resistance in drug design. Some inhibitors may pro-
trude beyond the envelope to make favorable contacts with a protease residue with
the purpose of preserving affinity or to improve selectivity, solubility, permeabil-
ity, etc. In those cases, accurately predicting how likely for one or more substrates
to co-evolve with a potential resistance mutation in that particular protease residue
is crucial. The availability of this probabilistic information can be used to decide
at which location an inhibitor’s protrusion beyond the envelope is more affordable
in terms of avoiding the emergence of drug resistance via cleavage site mutations.
6.5 Concluding Remarks
Drug resistance will occur anytime rapid growth and evolution exists under the
selective pressure of drug treatment but the growth is not completely inhibited by
the drug, as it is widespread problem in invasive cancers and pathogenic microbes
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such as bacteria, malaria, fungi, tuberculosis, and viruses. The mechanisms by
which resistance can emerge include point mutations in the target protein. To
overcome drug resistance, resistance should be predicted before it happens and
drugs should be designed accordingly to avoid the accurately predicted resistance
mutations. To achieve this goal, target identification is critical. The enzymes with
multiple substrates that cannot easily tolerate mutations and maintain function
are potentially good candidates. Moreover, all drug targets should be viewed as
evolutionarily dynamic, not static. The inhibitors should be made as evolutionarily
constrained as possible.
The crystal structures are extremely informative to provide insights into the
most probable molecular interactions at the binding sites. But in reality, proteins
are dynamic, they exist in conformational ensembles. Some proteins are inher-
ently more flexible; others are less so. Some inherently flexible proteins may lose
a great deal of flexibility upon inhibitor binding; others may not. Depending on
the protein, ignoring protein dynamics may delay the successful discovery of per-
fect drugs that have high potency, good selectivity, and low toxicity and are also
robust against the evolution of resistance.
Doing so, experimental techniques and computational methods should be used
in concert, each according to its particular strengths. Dynamic substrate envelope
is a useful tool to systematically incorporate the viral protein dynamics and evolu-
tion into structure-based rational drug design. Constant partnering of the dynamic
substrate envelope with multiple disciplines is absolutely necessary to achieve the
goal of discovering robust drugs, such as chemical synthesis, thermodynamics and
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enzyme kinetics, crystallography and NMR, deep sequencing, virology, and many
more.
I hope my work on the structure and dynamics of viral substrate recognition
and drug resistance will serve as a helpful guide for the rational design of future
generation drugs that remain active against diverse populations of drug targets.
Appendices
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Appendix A
Assessing van der Waals Contacts
1.1 A Simplified Lennard-Jones Potential
How a particular ligand (substrate or inhibitor) interacts with a particular pro-
tease variant can be assessed in terms of their detailed molecular interactions; i.e.
hydrogen bonds and van der Waals (vdW) interaction energies. vdW interactions
at a binding surface represent the local packing and can be used to understand the
degree of complementarity between a ligand and receptor. Assessing vdW con-
tacts accurately is a subtle analysis since a simple distance criterion of 4.2 - 5.0 A˚
often does not distribute the energetic contributions accurately.
The vdW contacts in a macromolecular structure are typically evaluated using
the Lennard-Jones 6-12 potential function, a function of the distance between the
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two atoms and the atom types:
V (r) = 4
[(σ
r
)12
−
(σ
r
)6]
(1.1)
where  and σ are the well depth and the collision diameter, respectively, which
depend on the types of interacting atoms (Figure 1.1A). The positive sign in the
first term of Equation 1.1 implies a repulsion, and the minus sign in the second
term implies an attraction. The repulsive part of this potential, was originally
chosen because it can be calculated rapidly by computers using the the square of
r−6. The virtue of this model is that it captures the universal features of a short-
range attraction and even shorter-ranged repulsion and the two parameters  and
σ give enough flexibility for the model to predict experimental data accurately.
While this potential (Equation 1.1) works well in computing the interactions
in a molecular dynamics simulation, the repulsive term is too restrictive in as-
sessing particular interactions of an experimentally determined crystal structure,
where slight changes in position can cause a favorable interaction to be considered
unfavorable.
To overcome this problem and to quantitatively assess vdW contacts, I de-
veloped a ”simplified van der Waals” calculation, where the attractive potential
is retained, but the repulsive potential is removed (Figure 1.1B). Atoms that are
”much” too close are flagged for the crystallographer to check. This approach
allows the vdW potentials to be calculated and compared for each ligand (sub-
strate or inhibitor) in complex with the wild-type or mutated protease. Also the
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distribution of the vdW is shown for a ligand on a residue-by-residue basis. This
the contacts can be quantitatively compared for a series of structures, such as
a particular inhibitor with a series of protease variants, or a series of different
inhibitors with the same protease. In addition, the role of a particular amino
acid residue can be compared for a series of inhibitors. I have applied this tech-
nique to the analysis of various HIV-1 protease and HCV NS3/4A protease struc-
tures. [46, 90, 165, 187, 189, 241, 242]
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Figure 1.1: The Original and Simplified Lennard-Jones 6-12 Potential Func-
tions. (A) Lennard-Jones 6-12 potential function. (B) The Lennard-Jones 6-12
potential function simplified to consider only the attractive forces.
311
Figure 1.1
312
1.2 Forcefield
For macroscopic system like biological macromolecules, the total van der
Waals force is often estimated as the sum over all interacting pairs. To get the
van der Waals interaction energy of X-Y atom pair,  and σ are obtained by arith-
metically or geometrically averaging the parameters of the individual atoms, i.e.,
The values of the  and σ parameters were taken from the CNS forcefield for
HIV-1 protease-substrate interactions (chapter II, and III):
σXY =
1
2
(σXX + σY Y )
XY =
√
XXY Y (1.2)
For the interactions of NS3/4A protease with its substrates and small-molecule
inhibitors, the  and σ parameters were taken from the OPLS2005 forcefield
(chapter IV, and V):
σXY =
1
2
(σXX + σY Y )
XY =
1
2
(XX + Y Y ) (1.3)
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1.3 Limitations
The van der Waals contact potential of the atoms that have alternate confor-
mations in a crystal structure was calculated based on the weighted averaged co-
ordinates of those atoms. The alternate conformations were weighted by the oc-
cupancy factor of each conformer. To determine the contact potential of each
alternate conformation separately, one should modify the input PDB file to keep
the desired conformation and delete all others and alter the occupancy factors to
one.
The sole purpose of this calculation is to get a quantitative picture of the fa-
vorable local packing at an interaction surface. The calculated contact potential
values DO NOT intend to replicate the binding free energies or DO NOT NEC-
ESSARILY follow a similar trend with the binding free energies for a series of
compounds bound to the same drug target. The change in free energy upon bind-
ing is dependent on a variety of components, only one of which is the van der
Waals contact potential.
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